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ABSTRACT OF DISSERTATION 
THE METABOLOMIC EFFECTS OF METFORMIN ON COLON CANCER 
Metformin is an oral biguanide that is prescribed to over 120 million people 
worldwide for the treatment of conditions including type II diabetes mellitus, 
polycystic ovarian syndrome, and gestational diabetes. This hypoglycemic agent 
is rapidly emerging as a potential cost-effective anti-oncogenic agent. Over the 
past decade multiple epidemiologic studies have consistently associated 
metformin with decreased cancer incidence and cancer-related mortality. More 
recently numerous preclinical and clinical studies have demonstrated anti-cancer 
effects of metformin, leading to the proposal of numerous clinical trials to better 
understand this drug and its mechanisms of action. 
Previously experts believed metformin primarily targeted AMP-activated 
protein kinase (AMPK), a crucial cellular energy sensor, but more recent data 
suggest the impact of metformin has a multi-faceted impact on various metabolic 
pathways. Current understanding of the potential anti-cancer effects of metformin 
raises the intriguing possibility of a duality of action, suggesting that metformin 
has the ability to act directly on a tumor while also indirectly lowering insulin 
levels in the host. This complexity creates challenges in determining the true 
impact of this drug in the clinical and translational setting. 
Despite an increase in investment, only one in every 10 new molecular 
therapeutic agents that enters clinical development receives approval from the 
Food and Drug Administration. This warrants a demand for better designed 
clinical trials with more elegant and robust analyses of relevant primary endpoints 
to determine which targeted therapies are cost-effective, and more importantly 
which agents will provide the best care for our patients. Stable isotope resolved 
metabolomics (SIRM) is a powerful tool capable of robust analyses that can 
address these questions. Using these capabilities we have determined that 
metformin does significantly impact cellular metabolism by shifting colon cancer 
cells into glycolytic overdrive, ultimately leading to decreased proliferation and 
protein synthesis in cancer cells. This study contributes to the literature and 
implores that we continue to elucidate the full potential of this drug, especially in 
the setting of personalized medicine where select patients may receive maximal 
benefit from this agent. 
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CHAPTER ONE: INTRODUCTION 
1.1 Colon Cancer 
Colon and rectal cancers are the second leading cause of cancer related 
death in the United States with an estimated 150,000 new diagnoses to occur in 
2015. Colon cancer is an insidious, ruthless process that takes advantage of our 
own genetic and cellular pathways and wreaks havoc to create an environment 
conducive to tumor growth and development. Colonic mucosa is deemed to be at 
risk for the development of malignancy in the setting of genetic instability which 
sets the stage for a precursor lesion (1). Cell proliferation increases due to 
altered metabolism, decreased apoptosis, and unlimited replication which leads 
to a cancer in situ and more developed adenomas. Later activated protease 
systems, immune modulation, and angiogenesis or blood vessel development to 
supply these tumors, leads to all the requirements for the development of an 
invasive disease and ultimately a metastatic cancer (2). Risk factors for the 
development of colon cancer include genetic predisposition, dietary factors such 
as a diet high in red meat and animal fat, low-fiber diets, and low overall intake of 
fruits and vegetables. Obesity and lifestyle choices such as cigarette smoking, 
alcohol consumption, and sedentary habits have also been associated with 
increased risk for colorectal cancer (3-5).  
1.1.2 Development and Diagnosis of Colon Cancer 
Initial symptoms of colon cancer frequently include abdominal and or 
pelvic pain, blood in the stools, unintentional weight loss, and eventually sepsis if 
obstruction and/or perforation of the intestine occur (6). Diagnosis of is often 
made prior to the development of severe symptoms based on screening and 
surveillance, especially in high risk populations. It is estimated that full 
implementation of screening guidelines could cut mortality rate from colorectal 
cancer in the United States by an estimated additional 50% (7). Other studies 
such as fecal occult blood testing, carcinogenic embryogenic antigen (CEA), and 
tissue biopsy aid in the initial diagnosis of colon cancer. Patients may also be 
evaluated for the presence of metastatic disease, or spread of cancer to distant 
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organ sites, using computer tomography (CT) imaging of the chest, abdomen, 
and pelvis, and positron emission tomography (PET) scanning to assess for 
distant hypermetabolic disease processes.  
1.1.3 Staging and Current Treatments of Colon Cancer 
Five year survival rates for colon cancer are largely dependent on the 
stage of disease at the time of diagnosis and treatment. Stages of colon cancer 
are classified as Stage I-IV. These stages are developed based on the disease 
burden present in the primary tumor (T), lymph nodes (N), and metastasis (M), 
which is referred to as TNM staging (8). Stage I disease is defined as T1 (tumor 
invades submucosa) or T2 (tumor invades muscularis propria), without evidence 
of nodal or metastatic disease. Stage II is defined as tumors described as T3, 
(Stage IIA- tumor extends through the muscularis propria), T4a (Stage IIB- tumor 
penetrates to the surface of the visceral peritoneum), or T4b (Stage IIC-tumor 
directly invades or is adherent to local organs or structures), but still does not 
have disease burden in the lymph nodes or at distant organ sites. Stage III is 
defined as cancer that has spread to the lymph nodes and Stage IV describes 
metastatic disease that has spread to a single distant organ (Stage IVA, M1a), or 
is present in multiple different organs and/or the peritoneum (Stage IVB, M1b) 
(9).  
Patients diagnosed with Stage I disease have an average survival of over 
90%, whereas patients diagnosed with Stage IV disease have a more dismal 
prognosis with five year survival rates of around 5% (10). When considering the 
prognosis for all-comers with this disease, which includes patients with Stages I, 
II, III, and IV colon cancer, the five year survival rate is 65.9% with an estimated 
50,000 deaths to occur this year (11). When broken down by stage at 
presentation and year survival rates, the prognosis actually sounds much more 
dismal. 39% of patients present with localized disease which has that higher 90% 
survival rate previously mentioned, while 36% of present with regionally 
progressive disease with a 5 year survival rate of 70.8%. With consideration to 
patients with distal disease, which compromises 20% of this population, survival 
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drops to 13.1% at five years (12).  
Current recommendations for the treatment of colon cancer include 
surgery and chemotherapy. Depending on the location and extent of the primary 
tumor, surgical options include right colectomy, extended right colectomy, left 
colectomy, sigmoid colectomy, and total abdominal colectomy with ileorectal 
anastomosis (13). These procedures may be performed with a minimally invasive 
approach (i.e. laparoscopic or robotic) in select patients (14, 15). Patients with 
stage IV disease limited to the liver and/or lung may benefit from resection of 
these distant metastatic tumors (16, 17). Patients with residual disease or 
advanced stage colon cancers are treated with chemotherapy adjuvantly 
(postoperative) which commonly include 5-fluorouracil (5-FU) with leucovorin or 
capecitabine, either alone or in combination with oxaliplatin (18, 19). Advances in 
targeted therapies and personalized medicine has prompted treatment with 
biologic agents such as Bevacizumab (Avastin), Cetuximab (Erbitux) (20-22). 
These agents are effective at reducing tumor burden and increasing both disease 
free and overall survival, but frequently have significant side effects such as 
severe nausea, vomiting, weight loss, and risk of infectious complications due to 
immunosuppression. 
Recent studies have suggested using off label agents in combination with 
traditional chemotherapy and biologic agents (23, 24). Metformin, which is an 
oral hypoglycemic agent traditionally used to treated Type II diabetes mellitus, 
offers an alternative that will allow decrease doses, and therefore toxicity, of 
aggressive traditional chemotherapy. We also speculate using this drug during 
the pre-surgical and immediate post-surgical interval when no other therapeutic 
intervention such as chemotherapy can safely be offered could potentially lead to 
decreased micro-metastatic disease which results in later recurrences. 
Furthermore, patients who cannot tolerate aggressive chemotherapy due to age 
or other medical conditions could significantly benefit from this safe and less toxic 
alternative.  
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1.2 The History and Development of Metformin 
Metformin was first described in the scientific literature in 1919, by Emil 
Werner and James Bell, as a product in the synthesis of N,N-dimethylguanidine, 
however it had been in use since medieval times in Europe (1). In the 17th 
century a English botanist determined the extracts of Galega officinalis, also 
known as French lilac or goat’s rue, could be used to treat polyurea (i.e. 
increased frequency of urination) associated with the development of diabetes 
mellitus (2). The active ingredient in the French lilac that produced the lowering of 
blood glucose was shown to be galegine or isoamylene guanidine, but 
guanidines alone are too toxic for routine use at high doses (3). The 
development of biguanides (two linked guanidine rings) were effective and safer 
than traditional botanicals. Metformin and other oral biguanides such as 
phenformin and buformin gained popularity in the early 1920’s as effect oral 
hypoglycemics used to treat diabetes mellitus. Within a decade the use of these 
agents was discouraged due to ready availability of subcutaneous insulin which 
was fast- acting and easier to titrate, as well as the increased risk of renal and/or 
liver failure with increasing doses of biguanides (4-7). Renewed interest in oral 
biguanides emerged in the 1950’s when scientists began studying the 
pharmacokinetic effects of the drug and determined previous studies were flawed 
based on a misunderstanding of the mechanisms and dosing of biguanides (1). 
Unfortunately as a number of lactic acidosis and cardiac related deaths 
increased, phenformin was removed from the market in the United States (US) in 
1977. Despite concerns in the US, endocrinologists in France and Scotland felt 
comfortable continuing to use it cautiously. In 1995 the benefits of metformin 
were rediscovered in Europe during the United Kingdom (UK) Prospective 
Diabetes Study which was a randomized, multicenter clinical trial that followed 
3867 patients over 10 years (8). Independently of blood glucose control, 
metformin reduced the risks of myocardial infarction and mortality of all causes 
and is considered to be safer than other biguanides because it is less lipophilic 
due to its structure containing two methyl substitutes as opposed to a large 
phenylethyl side chain, which is seen in phenformin (3, 9) (Figure 1.1).  
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Figure 1.1. Metformin is less lipophilic because it has two methyl side 
groups.  
Metformin is less lipophilic than because of the two methyl substituents on 
metformin compared to the larger phenylethyl side chain in phenformin. 
  
 6 
Metformin was approved by the Food and Drug Administration (FDA) in 1994 
and Glucophage (i.e. “glucose eater”) was the first branded formulation 
marketed by Bristol-Meyers Squibb (10). It is now prescribed to over at least 120 
million people worldwide and is the most commonly used drug for type II 
diabetes (11). 
Since then metformin has also been approved to treat polycystic ovarian 
disease, non-alcoholic fatty liver disease, and gestational diabetes (12-15). In 
1924, the Nobel laureate Otto Heinrich Warburg first hypothesized the existence 
of a connection between cellular metabolism and malignancy (16). In 1971, 
Dilman et al. suggested that oral biguanides hold promising potential as potent 
anti-aging and anti-oncogenic agents (17). Over the past three decades 
substantial data has surfaced suggesting that metformin may exert cancer and 
chemopreventive effects by suppressing the transformative and 
hyperproliferative processes that initiate carcinogenesis (18). Metformin has 
been shown to have anti-proliferative and anti-metabolic effects against cancer 
in many different types of cancer including breast, prostate, lung, colon, liver, 
and ovarian, but there is scarce data describing the specific mechanism 
metformin utilizes to target these oncogenic cells, notably colon cancer cells (19-
24). Furthermore, although metformin has been studied as a molecular inhibitor, 
there currently is scant literature describing specifically which patients may 
benefit most from this therapy (25, 26). These issues highlight the need for 
further of the precise mechanism of this drug and which patients may receive the 
most benefit from, specifically those with colon cancers. 
1.3 Metformin: Mechanisms of Action 
Metformin is considered to be a hypoglycemic agent because it lowers 
blood glucose concentrations in patients with type II diabetes without causing 
physiologically overwhelming hypoglycemia. Metformin is also frequently 
described as an insulin sensitizer leading to reduction in insulin resistance and 
significant reduction of plasma fasting insulin level (27). Metformin is also 
responsible for inhibiting hepatic gluconeogenesis, however multiple 
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mechanisms including enzymatic variations in glucose-6-phosphatase (G6P), 
pyruvate carboxylase-phosphoenolpyruvate carboxykinase (PC-PEPCK), and 
inhibition of mitochondrial glycerophosphate dehydrogenase (28-31). Metformin 
also increases anaerobic glucose metabolism in the intestine and decreases 
gluconeogenesis, glycogenolysis, and fatty acid oxidation in the liver. It is 
responsible for insulin-mediated glucose uptake, decreases glycogenesis, and 
decreases fatty acid oxidation in skeletal muscle (11) (Figure 1.2). Central to the 
understanding of the molecular mechanisms of metformin is the traditionally 
accepted target 5' adenosine monophosphate-activated protein kinase (AMPK) 
(Figure 1.3). 
AMPK is a crucial cellular energy sensor because it promotes adenosine 
triphosphate production (ATP) by increasing the expression of catabolic proteins 
while conserving ATP by switching off biosynthetic pathways (32). AMPK is 
activated by increases in AMP:ATP or ADP:ATP ratios, which occur when cellular 
energy status has been compromised. This frequently occurs in response to 
metabolic stresses, such as oncogenesis, that either interfere with ATP 
production or that accelerate ATP consumption. AMPK and its orthologues exist 
universally as heterotrimeric complexes comprising a catalytic α-subunit and 
regulatory β- and γ-subunit (33). The function of the catalytic subunits of AMPK 
is very important to its relationship with tumor biology. For many decades AMPK 
has been thought to be the main target of Metformin in both its direct and indirect 
metabolic functions. It consists of three protein subunits that together make a 
functional enzyme, conserved from yeast to humans. Triggering the activation of 
AMPK can be carried out when the γ subunit of AMPK undergoes a 
conformational change so as to expose the active site (Thr-172) on the α subunit. 
AMPK is activated by increases in AMP and ADP as the cellular concentrations 
of ATP, ADP and AMP change. In the basal state, sites 1 and 3 in the γ-subunit 
are occupied by ATP. Replacement of ATP by ADP or AMP at site 3 during 
moderate stress promotes phosphorylation of Thr172. Replacement of ATP by 
AMP at site 1 during more severe stress causes a further tenfold allosteric  
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Figure 1.2. Metformin impacts metabolism in the intestine, liver, and 
skeletal muscle.  
Metformin increases anaerobic glucose metabolism in the intestine and 
decreases gluconeogenesis, glycogenolysis, and fatty acid oxidation in the liver. 
It also increases insulin-mediated glucose uptake, decreases glycogenesis, and 
decreases fatty acid oxidation in skeletal muscle. All of this results in systemic 
hypoglycemia (Adapted from Bailey, Diab Vasc Dis Res, 2009). 
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Figure 1.3. 5' adenosine monophosphate-activated protein kinase (AMPK) 
is an enzyme that plays a role in cellular energy homeostasis.  
Triggering the activation of AMPK can be carried out when the γ subunit of 
AMPK undergoes a conformational change so as to expose the active site (Thr-
172) on the α subunit. AMPK is activated by increases in AMP and ADP as the 
cellular concentrations of ATP, ADP and AMP change (Hardie et al. Nat Rev Mol 
Cell Biol 2012;13:251-262; used with permission). 
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activation. As cellular energy status returns to normal, AMP at site 1 and ADP or 
AMP at site 3 are progressively replaced by ATP. This promotes the 
dephosphorylation of Thr172 and a return to the basal state (33). The major 
upstream kinases of AMPK are the LKB1–STRAD–MO25 complex and the 
Ca2+/calmodulin-activated protein kinase kinases (34, 35). The LKB1–STRAD–
MO25 complex provides a high basal level of phosphorylation at Thr172 that is 
modulated by the binding of AMP to the AMPK γ-subunit, which promotes 
phosphorylation and inhibits dephosphorylation. In tumor cells that have lost the 
tumor suppressor LKB1 owing to somatic mutations, treatments that increase 
AMP and ADP levels do not normally activate AMPK because basal activity is too 
low for the effects of nucleotide binding on phosphorylation status to become 
evident. This emphasizes that the effects of AMP and/or ADP on Thr172 
phosphorylation status are a result of their binding to AMPK, and such effects are 
independent of the upstream kinases and phosphatases that phosphorylate or 
dephosphorylate Thr172 (32). 
Although metformin activates AMPK, this may not explain all of the 
therapeutic effects of the drug. Metformin, at least in part, does exert its 
therapeutic effects by activating the AMPK. However, the site of its action, as 
well as the mechanism to activate AMPK, remains elusive. Other mechanisms of 
action have been proposed for metformin such as inhibition of mitochondrial 
complex I, inhibition of glucagon-induced elevation of cyclic adenosine 
monophosphate (cAMP), and consequent activation of protein kinase A (PKA), 
inhibition of mitochondrial glycerophosphate dehydrogenase (31, 36, 37). The 
exact mechanism of metformin has not been fully elucidated and warrants further 
review. 
1.3.1 Indirect Mechanisms of Action 
The indirect insulin-dependent effects of metformin are mediated by its 
ability to activate 5' adenosine monophosphate-activated protein kinase AMPK 
and inhibit gluconeogenesis in the liver and stimulate glucose uptake in muscle. 
The resulting reduction in circulating insulin alleviates activation of 
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PI3K/AKT/mTOR pathway signaling in cancer cells. The indirect effects of 
metformin are due to decreased blood glucose primarily by suppressing glucose 
production by the liver, or hepatic gluconeogenesis (Figure 1.4). The direct 
effects of metformin include increased insulin sensitivity, enhances peripheral 
glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor), 
decreases insulin-induced suppression of fatty acid oxidation, and decreases 
absorption of glucose from the gastrointestinal tract (38, 39). Increased 
peripheral use of glucose may be due to improved insulin binding to insulin 
receptors, but this theory also applies to its role as an anti-cancer agent (40, 41). 
Metformin diminishes hepatic glucose output leading to lower systemic glucose 
and insulin levels, which could impair malignant growth indirectly without 
requiring accumulation of metformin in the tumor. High insulin levels associated 
with obesity, insulin resistance and type 2 diabetes may promote tumorigenesis. 
Insulin-like growth factors, insulin, IGF-1 and IGF-2, secreted by visceral or 
mammary adipose tissue have significant paracrine and endocrine effects. These 
effects can be exacerbated by increased steroid hormone production (41). The 
insulin receptor lies upstream of a number of growth-promoting pathways 
including the PI3K/AKT/mTOR signaling network which are implicated in 
oncogenesis (42, 43). 
1.3.2 Direct Mechanisms of Action 
The direct insulin-independent effects of metformin are mediated by 
activation of AMPK and a reduction in mammalian target of rapamycin (mTOR) 
signaling and protein synthesis in cancer cells (44). The tumor suppressors liver 
kinase B1 (LKB1) and TSC2 are important in mediating the effects of metformin 
on AMPK and mTOR respectively; however, metformin may also inhibit mTOR 
independently of LKB1, AMPK and TSC2 (45). Metformin can act directly on 
cancer cells by inhibiting cell progression by suppressing mTOR signaling, 
mitochondrial glucose oxidation, and/or reducing stability of hypoxia inducing 
factor (HIF) under hypoxic conditions. 
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Figure 1.4. Metformin has direct and indirect effects on cellular and 
molecular signaling.  
The indirect effects of metformin are due to decreased blood glucose primarily by 
suppressing glucose production by the liver, or hepatic gluconeogenesis. The 
direct effects of metformin include increased insulin sensitivity, enhances 
peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer 
factor), decreases insulin-induced suppression of fatty acid oxidation, and 
decreases absorption of glucose from the gastrointestinal tract (Adapted from 
Luengo et al. BMC Biol 2014;12:82). 
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1.4 Metformin’s Impact as an Anti-Cancer Agent 
Insufficient activity of AMPK allows uncontrolled cell growth, despite the 
conditions of cellular stress such as those occurring during tumorigenesis, 
making AMPK an attractive target for anti-cancer therapy. Although numerous 
AMPK-activating drugs have been described, only metformin is widely used 
clinically and available in cost-effective generic formulations. Other AMPK 
activators are currently less suitable for routine clinical use due to the higher 
rates of lactic acidosis (phenformin) or low specificity and potency (5- 
aminoimidaz-ole-4-carboxamide ribonucleoside). Novel, more specific AMPK 
activators are still in preclinical development (46). A rapidly increasing body of 
preclinical and clinical evidence argues for the use of metformin as an anti- 
oncogenic agent. 
1.4.1 Molecular and Cellular Signaling Targets of Metformin 
Protein synthesis is one of the most energy-consuming processes in the 
cell and, as such, is a major target of AMPK signalling under conditions of 
cellular energy stress. Upon activation by metformin, AMPK phosphorylates 
TSC2, stimulating its GTPase-activating protein (GAP) activity towards the small 
GTPase RHEB, which causes a reduction in mTOR signaling. mTOR controls 
protein synthesis by regulating the phosphorylation of key proteins involved in 
mRNA translation, such as the 4E-BPs and S6Ks (Figure 1.5). Inhibition of 
mTOR signaling leads to a reduction in phosphorylation of downstream effectors 
like 4E-BPs and S6Ks, therefore resulting in decreased protein synthesis and 
subsequent cancer cell proliferation (47). As indicated earlier, LKB1 is the 
immediate AMPK activator in response to cellular energy stress and 
phosphorylates a key AMPK residue (Thr172) obligate for catalytic activity (22, 
33, 48). Cells lacking LKB1 exhibit decreased AMPK activation and elevated 
mTOR signaling even under conditions of cellular energy stress or treatment with 
AMPK agonists (49). LKB1 is also required for metformin-mediated AMPK 
activation. A variety of cells lacking LKB1, are resistant to the growth inhibitory  
  
 14 
 
Figure 1.5. Multiple molecular mechanisms have been proposed to explain 
how metformin decreases cell metabolism and proliferation.  
Although AMPK is thought to be the main mediator of the potential anti- 
carcinogenic effects of metformin, the molecular mechanism of metformin is 
incompletely understood: metabolic inhibition of the mitochondrial respiratory 
chain (complex I) results in increased glycolysis and acetyl-CoA carboxylase 
(ACC) activation results in decreased lipid synthesis and increased oxidation. 
Activation of AMPK is also thought to result in decreased proliferation by cell 
cycle arrest and protein synthesis inhibition via decrease of CD1/CDK and 
inhibition of mTOR complex I, respectively (Habibollahi et al. J Nucl Med 
2013;54:252-258). 
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effects of metformin in vitro LKB1 and TSC2 represent key factors in determining 
tumor sensitivity to the effects of metformin (22). 
AMPK phosphorylates p53, a tumor suppressor responsible for regulating 
cell cycle arrest (50, 51). AMPK activation induces phosphorylation of p53 on 
serine 15, and this phosphorylation is required to initiate AMPK-dependent cell- 
cycle arrest. AMPK-induced p53 activation promotes cellular survival in response 
to glucose deprivation, and cells that have undergone a p53-dependent 
metabolic arrest can rapidly reenter the cell cycle upon glucose restoration. 
However, persistent activation of AMPK leads to accelerated p53-dependent 
cellular senescence. Thus, AMPK is a cell-intrinsic regulator of the cell cycle that 
coordinates cellular proliferation with carbon source availability (52). 
Metformin also exerts its downstream therapeutic effects such as 
regulating lipid synthesis by inhibiting Acetyl-CoA carboxylase (ACC) and 
regulating mTOR signaling by activating TSC2 (38, 53). Uptake of fatty acids into 
mitochondria, which seems to be the rate-limiting step in β-oxidation, is promoted 
by AMPK via phosphorylation and in activation of the ACC2 isoform of ACC (33). 
This results in a drop in concentration of the ACC product, malonyl CoA, an 
inhibitor of fatty acid entry into mitochondria mediated by the carnitine O - 
palmitoyltransferase 1 (CPT1) system (54, 55). Malonyl-CoA is a critical bi-
functional molecule, i.e., a substrate of fatty acid synthase (FASN) for acyl chain 
elongation (fatty acid synthesis) (56). Since ACC is a rate-limiting enzymes in de 
novo fatty acid synthesis as it catalyzes ATP-dependent carboxylation of acetyl- 
CoA to form malonyl-CoA. Loubiere et al. determined metformin does not alter 
the concentration of malonyl-CoA and that the inhibitory effect of metformin on 
lipogenesis in prostate cancer cell lines is primarily due to a cellular energy 
deficit (57). Furthermore, they determined metformin decreases ATP in a dose-
dependent manner, and this diminution is significantly correlated with the 
inhibition of lipogenesis. 
1.4.2 Metabolic and Bioenergetic Changes Initiated by Metformin 
Altered cellular metabolism is a hallmark of cancer cells (16, 58). Tumor 
 16 
cells adapt their metabolism to provide the necessary substrates to continue to 
immortally proliferate (59, 60). Sensitivity to the anti-tumoral effects of metformin 
may also be governed by expression levels of the organic cation transporters 
(OCT1). Metformin enters the cell by OCT1, where it then accumulates in the 
mitochondria (Figure 1.6). There, metformin inhibits complex I of the electron 
transport chain and mGDP, resulting in decreased NADH oxidation. One of the 
best described mechanisms of metformin is by inhibition of complex I, the first 
component of the mitochondrial electron transport chain (58). Complex I 
inhibition by metformin interrupts mitochondrial respiration and decreases 
proton-driven synthesis of ATP, causing cellular energetic stress and elevation 
of the AMP:ATP ratio. Decreased electron chain activity suppresses tricarboxylic 
acid (TCA) cycle flux and decreases mitochondrial ATP synthesis, and these 
actions result in increased AMPK signaling, decreased cAMP/PKA signaling, 
decreased gluconeogenesis and increased glycolysis (28). 
Madiraju et al. determined metformin non-competitively inhibits the redox 
shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an 
altered hepatocellular redox state, reduced conversion of lactate and glycerol to 
glucose, and decreased hepatic gluconeogenesis by using whole- body 
mitochondrial glycerophosphate dehydrogenase knockout mice (31). Acute and 
chronic low-dose metformin treatment effectively reduced endogenous glucose 
production, while increasing cytosolic redox and decreasing mitochondrial redox 
states. mGPD transports cytosolic reducing equivalents from NADH into the 
mitochondria via the glycerol-phosphate shuttle. Interestingly, inhibition of mGPD 
and complex I both compromise the ability of mitochondria to oxidize cytosolic 
NADH and decrease the entry of these reducing equivalents into the electron. 
Mitochondria are highly sensitive to stress and are susceptible to oxidative 
damage which accompanies inflammation and subsequently an ideal 
environment for tumor establishment and proliferation (61). The sensitivity of 
measuring mitochondrial stress may offer novel insight into translational 
questions regarding mitochondria as an energy sensor and targeted molecular 
therapies for cancer like metformin (26) (Figure 1.7). 
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Figure 1.6. Metformin inhibits mitochondrial metabolism.  
Metformin enters the cell by organic cation transporter 1 (OCT1), where it then 
accumulates in the mitochondria. There, metformin inhibits complex I of the 
electron transport chain and mGDP, resulting in decreased NADH oxidation. 
Decreased electron chain activity suppresses tricarboxylic acid (TCA) cycle flux 
and decreases mitochondrial ATP synthesis. These actions result in increased 
AMPK signaling, decreased cAMP/PKA signaling, decreased gluconeogenesis 
and increased glycolysis (Luengo et al. BMC Biol 2014;12:82). 
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Figure 1.7 XF Extracellular Flux Analysis can be used to determine the 
bioenergetic health index.  
The specific metabolic downstream effects Metformin causes by mitochondrial 
inhibition can be determined by performing a mitochondrial stress test using 
measurements of cellular oxygen consumption rate (OCR) (Chacko et al., Clin 
Sci (Lond) 2014;127:367-373). 
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1.4.3 Epidemiologic Evidence of Metformin as an Anti-Cancer Agent in Colon 
Cancer 
Evans et al. were the first to report a potential association of metformin 
use with reduced cancer incidence. In diabetics receiving metformin (as opposed 
to other therapies), overall cancer incidence was lowered (odds ratio (OR) 0.86 
and 95% confidence interval (95% CI) (0.73–1.02) and there was evidence of a 
dose response in relation to the total duration of use or number of prescriptions 
dispensed (62). Landman et al. showed that metformin use was associated with 
lower cancer mortality compared to no metformin use (hazard ratio 0.23–0.80) 
and that the effect was dose dependent (63). Specifically to colon cancer, Cho et 
al. recently reported that in patients taking metformin independently associated 
with decreased adenoma incidence (OR=0.738, 95% CI=0.554-0.983, P=0.03) 
(64). Table 1.1 reviews epidemiologic studies specific to colon cancers. 
Although epidemiological studies have fairly consistently reported reduced 
cancer incidence and/or mortality in diabetic patients who receive metformin in 
standard clinical doses (1500–2250 mg/day in adults), these studies have 
important methodological limitations. Most were conducted retrospectively and 
many sampled their cases from hospital or clinical registries rather than 
population-based registries, thereby limiting external validity and introducing 
potential selection biases (62, 64). Inclusion criteria varied (65). Some studies did 
not exclude individuals with prior diagnosis of cancer, thus introducing a possible 
reverse causation bias (65). Many studies included patients exposed to a variety 
of treatments for diabetes complicating the analysis of metformin associations 
(62, 65-67). However, despite the flaws in the epidemiologic data there is valid 
evidence to support that this drug potentially has anti-oncogenic capabilities. 
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Table 1.1. Recent epidemiologic studies evaluating metformin colon 
cancer. 
Study type Outcome Sample 
size 
Comparison Results 
(HR/OR/RR, 
95% CI) 
Reference 
Retrospective 
cohort 
Incidence 62,809 Sulfonurea HR-1.8 
(1.29-2.53) 
Currie et 
al. (2009) 
   Metformin + 
sulfonurea 
HR-1.43 
(1.05-1.94) 
 
Prospective 
cohort 
Incidence 480,984 Any vs. no 
metformin 
HR-0.36 
(0.13-0.98) 
Lee et al. 
(2011) 
Retrospective 
cohort 
Mortality 595 Any vs. no 
metformin 
HR-1.45 
(1.08-1.93) 
Lee et al. 
(2012) 
Retrospective 
cohort 
Incidence 995,843 Any vs. no 
metformin 
RR-0.643 
(0.490- 
0.845) 
Tseng 
(2012) 
Retrospective 
cohort 
Adenoma 
incidence 
12,186 Any vs. no 
metformin 
OR-0.738 
(0.554- 
0.983) 
Cho 
(2014) 
 
Abbreviations: Hazard ratio (HR), Odds ratio (OR), Confidence Interval (CI). 
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1.4.4 Pre-clinical Evidence of Metformin as an Anti-Cancer Agent in Colon 
Cancer 
Despite extensive funding in research and development to cure colon 
cancer, few agents pass preclinical trials to demonstrate efficacy in humans. 
These advancements most often rely on murine models to screen for efficacy 
before progressing to clinical trials. Previously there has been little focus on the 
validation of these models, even in the era of targeted therapy where 
understanding the genetic signatures of tumors under study is critical. Table 1.2 
represents recent animal models used to evaluate metformin in colon cancer. 
Each of these models provides valuable information regarding metformin. 
Li et al. determined with either vitamin D3 or metformin alone, combined use of 
vitamin D3 and metformin showed more pronounced effect in reducing the 
numbers of aberrant crypt foci (ACF) and tumor in the colon and was associated 
with downregulation of S6P expression, via the AMPK (IGFI)/mTOR pathway 
(68). 
Algire et al. determined administration of metformin led to the activation of 
AMPK, the inhibitory phosphorylation of ACC and increased apoptosis as 
estimated by poly (ADP-ribose) polymerase (PARP) cleavage in mice fed a high- 
energy diet on growth of an in vivo colon cancer model in mice injected with 
MC38 colon carcinoma cells (23). Zafaar et al. evaluated the effects of induced 
diabetes with metformin treatment in combination with or without oxaliplatin and 
determined that metformin did have anti-proliferative effects with this murine 
model (69). Buzzai et al. determined that metformin is selectively toxic to p53 
deficient cells. They used paired isogenic colon cancer cell lines HCT116 
p53(+/+) and HCT116 p53(-/-) treatment with metformin selectively suppressed 
the tumor growth of HCT116 p53(-/-) xenografts (50). Hosono et al. used an 
azoxymethane (AOM) model with a 6 week intraperitoneal injection of metformin 
(250mg/kg/d) and determined that metformin suppresses colonic epithelial 
proliferation via the inhibition of the mTOR pathway through the activation of 
AMPK (70).  
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Table 1.2. Recent murine models using metformin to study colon cancer. 
Gender Animal Model Dose Route Effect on 
pathways 
Reference 
Male Wister rat DSS 120 
mg/kg/d 
i.p. decrease 
PI3K/mTOR 
Li, 2015 
Male C57BL/6 5×105 
MC38 
s.c. 
50 mg/kg d.w. decrease 
FASN, Akt 
Algire, 
2010 
Male p53 WT 
vs KO 
HCT116 
s.c. 
250mg/kg i.p. p53(-/-) less 
autophagy 
Buzzai, 
2007 
Male Swiss 
albino 
DMH 100 or 
200 
mg/kg 
d.w. decrease 
angiogenesis 
Zafaar, 
2014 
Male BALB/c AOM (250 
mg/kg/d) 
i.p. aberrant crypt 
foci 
Hosono, 
2010 
 
Abbreviations: DMH-dextran sodium sulfate (DSS), azoxymethane (AOM), 
intraperitoneal (i.p.), drinking water (d.w.), subcutaneous (s.c.), mTOR 
mammalian target of rapamycin, fatty acid synthase (FASN), 1,2- 
dimethylhydrazine (DMH). 
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Although each of these recent models contributes to the literature, 
collectively there is such a profound variety in available models with regard to 
cancer induction model, delivery of treatment, doses of treatment, and varieties 
and combinations of treatments it is difficult to draw substantial conclusions 
which would warrant proceeding with performing a clinical trial. The need for 
translational data prompts researchers to seek more clinically applicable models 
by reviewing human data obtained through clinical and translational programs. 
1.4.5 Clinical Evidence of Metformin as an Anti-Cancer Agent in Colon Cancer 
Gaining access to human and clinical specimens is a priority to better 
understand the true mechanisms of metformin and other molecular inhibitors that 
act in a multi-faceted manner. Baba et al. used immunohistochemistry data to 
determine that phosphorylated AMPK expression in colorectal cancer is 
associated with superior prognosis among p-MAPK3/1-positive cases, 
suggesting a possible interaction between the AMPK and MAPK pathways 
influencing tumor behavior (71). Julien et al. obtained and implanted 54 human 
colorectal tumors in immunodeficient mice and rats, representing 35 primary 
tumors, 5 peritoneal cancers and 14 metastases (72). Furthermore, they 
determined through extensive in vivo analysis they were able to compare the 
molecular profile with the drug sensitivity of each tumor mode and found that the 
key role of KRAS mutation in cetuximab resistance. Using patient derived 
xenografts (PDX) Nunes et al. IGF2 upregulation (16%), which was mutually 
exclusive with IRS2, PIK3CA, PTEN, and INPP4B alterations, supporting IGF2 
as a potential drug target (73). Development of targeted therapeutics required 
translationally relevant preclinical models with well-characterized cancer genome 
alterations. Colorectal PDXs are appropriate tools to identify both new targets 
and predictive biomarkers of response/resistance to targeted therapies. 
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1.5 The Challenges of Moving Metformin from the Bench to the Bedside for 
Cancer Treatment 
1.5.1 Review of Previous Clinical Trials Using Metformin as an Anti-Cancer 
Agent in Colon Cancer 
Prospective randomized clinical trials designed to use metformin for the 
treatment of breast and prostate cancers are just now reaching accrual and/or 
offering relevant data regarding the efficacy of using this treatment as a 
molecular inhibitor to target cancer (74-76). Most of the breast cancer trials that 
have met accrual and finished data collection or have evaluated initial data 
determined there was no difference in mortality or proliferative biomarkers when 
comparing their treatment groups (77-80). A couple of recently performed trials 
did show significant decreases in proliferative markers such as Ki67 (81, 82). 
Interestingly in their recent randomized placebo controlled trial Bonanni et al. 
determined that the metformin effect on Ki-67 change relative to placebo was not 
statistically significant, with a mean proportional increase of 4.0% (95% CI, - 
5.6% to 14.4%) 4 weeks apart, but did show significantly different effects 
according to insulin resistance, particularly in luminal B tumors (19). Kalinsky et 
al. determined that although there was no reduction in ln(ki-67) after metformin 
(p=0.98) or compared to controls (p = 0.47) that there was a significant reduction 
in BMI, cholesterol, and leptin (83). 
Thus far there is little data regarding completed clinical trials observing the 
effect of metformin on colon cancer. Table 1.3 offers a brief overview of the 
current clinical trials on available on the National Cancer Institute (NCI) site 
(www.clinicaltrials.gov). Multiple trials are currently ongoing while others had 
difficulty reaching accrual. Hosono et al. performed a prospectively randomized 
trial on 26 nondiabetic patients with aberrant crypt foci to treatment with 
metformin (250 mg/d, n = 12) or no treatment (control, n = 14) (84). They 
examined proliferative activity in colonic epithelium (via proliferating cell nuclear 
antigen labeling index) and apoptotic activity (via terminal deoxynucleotidyl  
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Table 1.3 Recent and ongoing clinical trials using metformin for colon 
cancer. 
Trial 
number 
Institute Design Trial Arms Inclusi
on 
Criteria 
Primary 
End 
Point 
NCT0192
6769* 
Gachon 
University 
Non-
random-
ized 
1. FOLFOX6 + 
Metformin 
2. FOFIRI + 
Metformin 
Advan-
ced 
CRC 
DFS, OS 
NCT0193
0864+ 
Barretos 
Cancer 
Hospital, 
Gil Medical 
Center 
Non-
random-
ized 
1. Irinotecan 
350mg/m² q21d 
+ metformin up 
to 2500mg/d 
2. Irinotecan 
alone 
Refrac-
tory to 
oxali-
platin, 
5-FU, 
iritoe-
can 
Non-
progres-
sion 
at 12 
weeks 
NCT0163
2020# 
University 
of 
Arkansas 
(Slow 
accrual) 
Random-
ized, 
double-
blinded 
placebo  
1. Metformin 
850mg PO BID 
14-21 days 
2. Control 
StageI-
IV colon 
or rectal 
cancer 
Prolifer-
ation 
status of 
CRC 
tumor 
and 
adjacent 
normal 
tissue 
following 
Metfor-
min 
therapy 
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NCT0181
6659# 
M.D. 
Anderson 
Cancer 
Center 
(Slow 
accrual) 
Random-
ized, 
double-
blinded 
placebo  
1. Metformin 
850mg PO BID 
14-21 days 
2. Control 
Stage I-
IV colon 
or rectal 
cancer 
Compare 
Ki67 
biopsy vs. 
surgery  
NCT0172
5490* 
Yonsei 
University 
Random-
ized, 
double- 
blinded 
placebo 
1. Metformin 
500mg PO 
Qday 
2. Metformin 
1500mg PO 
Qday 
3. Control 
FAP Speci-
men 
number 
and size 
of polyps 
NCT0220
1381! 
Health 
Clinics 
Limited 
(Pending 
discus-
sions with 
regulatory 
ethical 
bodies 
Pro-
spective 
(QOL 
measure / 
form) 
1. Atorvastatin 
80mg Qday 
2. Metformin up 
to 1000mg once 
a day 
3. Doxycycline 
100mg day for 1 
Qday month 
4. Mebendazole 
100mg Qday 
Stage 
IV 
PFS 
NCT0131
2467© 
National 
Cancer 
Institute 
(NCI) 
Single arm 1. Metformin 
500mg PO 
Qday 
Colon 
cancer, 
Colon 
adeno-
ma, 
Obesity 
Change 
in 
activated 
S6serine
235 over 
12 weeks 
 
Abbreviations: Disease free survival (DFS), Overall survival (OS), Colorectal 
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cancer (CRC), per oral (PO), twice daily (BID), Familial Adenomatous Polyposis 
(FAP), every day, (Qday), Quality of life (QOL).  
*Recruiting +Not recruiting #Terminated !Suspended ©Completed. 
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transferase dUTP nick-end labeling). At 1 month, the metformin group had a 
significant decrease in the mean number of ACF per patient (8.78 +/- 6.45 before 
treatment versus 5.11 +/- 4.99 at 1 month, P = 0.007), whereas the mean ACF 
number did not change significantly in the control group (7.23 +/- 6.65 versus 
7.56 +/- 6.75, P = 0.609). To date this is the first reported trial of metformin for 
inhibiting colorectal carcinogenesis in humans provides preliminary evidence that 
metformin suppresses colonic epithelial proliferation and rectal aberrant crypt foci 
formation in humans, suggesting its promise for the chemoprevention of 
colorectal cancer. 
1.5.2 Elucidation of the Metabolomic Impact of Metformin in Colon Cancer 
Most of the clinical trials that have been completed thus far must combine 
different tumor biology, patients with variable health backgrounds, and off-target 
primary outcomes in order to meet accrual and continue to secure funding (85- 
87). Evaluating molecular end points can be hindered by difficulties in procuring 
tumor tissue before and after drug administration and by heterogeneity in 
previous exposure to cancer therapies. 
To determine the true effects of metformin on colon cancer cells will 
require differentiation of the relative importance of indirect (insulin-mediated) and 
direct (insulin-independent) effects. The currently accepted mechanisms of action 
give rise to a broad range of therapeutic targets, leading to a large number of 
potential clinical markers of metformin benefit, so clinical and translational 
scientists must choose wisely and aim well when choosing which drugs to use 
and which molecular pathways to target (88). Recently developed high- 
throughput experimental technologies, summarized by the terms genomics, 
transcriptomics, proteomics and metabolomics provide for the first time ever the 
means to comprehensively monitor the molecular level of disease processes 
(89). These advances can characterize a drug target's physiology and improving 
the overall efficiency of pharmaceutical research processes. Fendt et al. used 
treated prostate cancer cell lines with metformin and performed labeled 13C- 
glucose and 13C-glutamine to measure the incorporation of labeled carbon from 
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either nutrient into the tricarboxylic acid cycle metabolite α-ketoglutarate by gas 
chromatography - mass spectrometry (90). They determined that metformin 
Inhibition of glutamine anaplerosis in the presence of metformin further 
attenuated proliferation while increasing glutamine metabolism rescued the 
proliferative defect induced by metformin (Figure 1.8). 
The Warburg effect describes the biochemical anomaly that occurs when 
a shift in glucose metabolism occurs from mitochondrial oxidative 
phosphorylation to glycolysis, therefore the tumor is phenotypically exhibiting the 
effects of anaerobic metabolism (i.e. increased lactate production) (91). These 
metabolic hallmarks can be readily assessed either in vitro or in vivo by 
metabolic technologies to monitor responsiveness and resistance to novel 
targeted drugs. 
1.5.2a Stable Isotope-Resolved Metabolomics (SIRM) 
Metabolomics can be defined as a “systemic interrogation of the 
metabolome in terms of metabolite concentration, structure, and transformation 
of pathways” (92). One of the most reliable methods of measuring the complexity 
of oncogenic metabolomic abnormalities, namely of glucose metabolism and 
phospholipid turnover, is by SIRM (93). Isotopes are different forms of a 
respective element. The atoms have the same number of protons, but different 
numbers of neutrons. For example, when considering the isotopes of carbon, the 
“most common” carbon is 12C, as it is stable and quite abundant in the 
environment (98.89%). It is important to point out that 12C is balanced in the 
sense that it has 6 protons and 6 neutrons, therefore the term “isotope” has no 
impact on the nuclear stability. Similarly 13C, which has 6 protons and 7 
neutrons, is a staple isotope, is not radioactive, but is much less abundant 
(1.11%) than 12C. 13C, if it has 6 protons and 8 neutrons, is a radioisotope and is 
not considered to be a stable isotope; however, this isotope is extremely rare. 
Although stable isotopes do have the potential to become unbalanced, 
and therefore unstable, this generally does not happen as the difference  
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Figure 1.8 Metformin specifically blocks glutamine from contributing to 
glycolytic metabolism in prostate cancer cells.  
Previous authors determined that metformin attenuates proliferation in prostate 
cancer cells by inhibiting complex I of the respiratory chain and that metformin 
increases the dependency of the prostate cancer cell lines on reductive 
glutamine anaplerosis of the tricarboxylic acid (TCA) or Kreb’s cycle Therefore 
they suggest a combination therapy between metformin and inhibitors of the 
glutamine pathway might have a therapeutic benefit in prostate cancer (Fendt et 
al. Cancer Res. 2013; 73:4429-4438; used with permission).  
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between 12C and 13C is very small and it does not have the ability to participate 
in the bond- breaking step in the metabolic sequence (94). Finally, isotopomers 
should not be confused with isotopes. Isotopomers are compounds of identical 
chemical structure but are different in isotopic composition at individual atoms 
(92). This important concept is how different structures can be identified once 
they are labeled (Figure 1.9). 
Sample Processing 
From a clinical and translational, as well as ethical, standpoint it is 
imperative to note that 13C is naturally occurring in the environment and does not 
pose a health risk to animals or humans (95). Animal or human tissues may be 
labeled by various methodologies. In vivo labeling generally requires access to 
either a intravascular compartment (intravenous) or a body compartment 
(intraperitoneal, subcutaneous) so the 13C may be ultimately absorbed and 
circulated throughout the body in order to effectively label the tissues. Once the 
tissues are adequately labeled the clinical and translational scientist must take 
extreme caution to produce excellent precision and accuracy during sample 
collection and processing to ensure high quality, structured data (96). The 
ultimate goals of excellent sample processing are as follows: 1) to maintain 
biochemical integrity during sampling; 2) to efficiently and reproducibly recover 
metabolites from biospecimens with high throughput; 3) to increase the coverage 
of the metabolome on limited quantities of biospecimens; 4) to determine trace 
level and/or labile metabolites in the presence of stable and abundant species, 
with high throughput; 5) to enable large-scale metabolite identification and 
automation of metabolite assignment; 6) to identify de novo or obtain crucial 
structural information of unknowns, with or without the use of metabolite; 
databases; 7) to facilitate metabolite quantification without the need for authentic 
standards (93). 
Briefly, sample processing involves sample homogenization and sample 
extraction. During homogenization samples must be broken into very fine 
particles (i.e. <10µm) without compromising their biochemical integrity (96). 
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Figure 1.9 13C-6 Glucose labeling identifies specific components of the 
citric acid cycle.  
Stable Isotope-Resolved Metabolomics (SIRM) refers to the labeling of stable 
isotopes which are different forms of a respective element (i.e. 13C versus 12C). 
The atoms have the same number of protons, but different numbers of neutrons. 
An isotopomer is a compound of identical chemical structure but differs in 
isotopic composition at individual atoms which allows for the analysis and editing 
of different metabolites after SIRM (Image courtesy of Teresa Fan, PhD).  
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Typical homogenization techniques may include manual grinding with a pestal 
(liquid N2 compatible) or mechanical liquid N2 homogenizers. For very small 
samples (i.e. biopsy samples, small ex vivo labeled tissues), in order to maximize 
the amount of sample retrieved, it may be necessary to homogenize these 
samples with glass beads using a micro ball mill directly in solvents that denature 
and precipitate the proteins without affecting their biochemical integrity. 
Sample extraction includes separation of the polar fraction metabolites 
from the lipid fraction and protein fractions using acids or solvents. Lyophilization 
should be employed after polar extraction in order to remove water, 
trichloroacetic acid (TCA), and ammonium bicarbonate. Sixty percent acetonitrile, 
acetone, or chloroform/methanol/water are ideal solvents for extraction because 
they are compatible with acid-labile metabolites (i.e. fructose-2,6-bisphosphate, 
UDP-N-acetylglucosamine) and the solvent extraction method can be integrated 
with the solvent quenching steps (96). Of note, TCA extraction is an excellent is 
superior with regard to sample throughput because the removal of the volatile 
TCA can be done with lyophilization, but it can lead do degradation of some 
metabolites like glutamine. 
One of the benefits of metabolomic analysis is that a robust amount of 
data can be gained from careful attention to ensure quality labeling and precision 
sample preparation, however if this standard is not respected then 13C labeling 
will not occur on all of the appropriate positions and the sample will be 
compromised. This error will likely require re-analysis or re-extraction, and will 
not yield the robust statistical analysis that is standard when samples are 
prepared with care and precision. 
1.5.2b Nuclear Magnetic Resonance (NMR) 
NMR is a powerful tool that can be used to identify and quantify 
metabolites in an unfractionated mixture like serum or media samples or crude 
cell/tissue extracts (97). When SIRM is used, NMR can determine the positional 
isotopomer distributions of metabolites derived from a precursor enriched in 
stable isotopes such as 13C and 15N via metabolic transformations. NMR readily 
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determines each positional isotopomer as a distinct species without the need for 
fragmentation, however one disadvantage of NMR is its relatively low sensitivity 
(97). With regard to 2D experiments, as 13C is a magnetic nucleus, whereas 12C 
is not, a 13C NMR experiment recorded at natural abundance with proton 
decoupling will consist of a series of singlets (i.e. one for each carbon atom), but 
if a molecule is enriched with 13C, adjacent carbons will couple and also “split” 
like what is seen in the 1H spectrum observed in homonuclear scalar 
experiments. For screening purposes 1 D HSQC (heteronuclear single quantum 
coherence) can help select metabolites that are 13C enriched, but sometimes this 
is an overestimation of labeling since also takes into account additional 13C 
atoms (98). When combined with mass spectrometry, NMR provides a very 
accurate measurement of complementary information. 
1.6 Purposes and Aims of Studies 
Although the exact mechanisms of metformin are not entirely understood, 
there is robust literature that defines the hallmarks of cellular and molecular 
signaling in colon cancer cell lines with regards to protein synthesis, fatty acid 
oxidation, and cell cycle arrest (23, 51, 99). Approaching this project, the primary 
research questions is what exactly are the metabolomic effects of metformin on 
colon cancer cells, especially since this has already been determined in other 
cancers such as breast and prostate (90, 100)? Furthermore, additional 
questions stem from the tremendous phenotypic and genotypic variability seen 
when comparing individuals within our patient population. How can we expect 
one drug to work exactly the same way as a molecular inhibitor for every 
patient? The world of metabolomics opens amazing opportunities to analyze 
each patient’s cancer and potentially find personalized targeted therapies for 
responders and potentially elucidate more beneficial therapies through pathway 
discovery for non-responders (74, 92, 101) (Figure 1.10). 
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Figure 1.10 Specific impact of metformin on the citric acid cycle in colon 
cancer cells.  
Previous data suggests that metformin does decrease colon cancer cell 
proliferation and metabolism, especially when used in combination with 
chemotherapeutic agents. However, the current literature lacks information 
regarding exactly how and where metformin impacts colon cancer metabolism in 
vitro patient derived cell lines, patient derived xenografts in murine models, and 
in ex vivo human tissues studies. The aim of our multi-faceted study is to 
determine the specific glycolytic mechanisms of how metformin impacts human 
colon cancers and to determine if certain molecular inhibitors may be more 
beneficial than other for select patients. 
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The hypothesis is that each colon cancer cell line and collected human 
tissue will have its own unique metabolic profile. I also hypothesize that a newly 
created colon cancer cell line from a PDX that was originated from a locally 
invasive cancer will be less responsive to metformin treatment and provide a 
more realistic concept of human patient tumor biology. I anticipate there will be 
notable changes through the citric acid cycle, and it is very likely that metformin 
will increase lactate production since it forces most cells into a more glycolytic 
form of metabolism. Furthermore, we anticipate that a newly created PDX will 
provide an excellent and reproducible background on which we can treat 
samples with in vivo murine models for future drug discovery models. 
 
 37 
CHAPTER TWO: MATERIALS AND METHODS 
2.1 Cell lines 
Colon cancer cell lines SW480, KM20, HT29, and HCT116 were 
authenticated November 2011 (Genetica DNA Laboratories, Cincinnati, OH). 
Cancer cell line PDX was created from human tissues collected (Appendix A) at 
the University of Kentucky after three generations of tumor implantation into 
(severe combined immunodeficiency SCID) mice (Appendix B). Table 2.1 
contains specific information for cell lines. 
2.2 Animal studies 
All animals were housed in a specific pathogen-free animal facility (060- 
immunodeficient animal room) at the University of Kentucky BioPharmacy 
Complex with 12 hour light-dark cycle. Animals received water and chow ad lib. 
All animal procedures were reviewed and approved by the University of Kentucky 
IACUC (Appendix B). 
2.2.1 Implantation of PDX 
SCID mice underwent implantation of human derived tissues obtained 
from consenting patients with colon cancer undergoing surgical resection at the 
University of Kentucky. Interaction with these patients and the collection of these 
tissues was approved by the University of Kentucky IRB (Appendix A). 
The general procedure for the subcutaneous implantation of involves 
preparation of the tumor by washing it with 2% Penicillin/Streptozosin/Fungizone 
in phosphate buffered saline (PBS) at least three times for all colon samples. 
Original patient derived tissue is flash frozen in liquid nitrogen (LN2) for protein 
analysis and additional tissue is placed in 10% formalin for 24 hours, the 70% 
ethanol to later be paraffin blocked and prepared for immunohistochemistry 
(IHC). Next the tumor is cut into very small pieces (i.e. tumor slurry) and a portion 
is placed in 100µL of Matrigel (Corning, Bedford, MA) and remains on ice while 
transported to the animal facility for implantation. 
  
 38 
Table 2.1. Colon cancer cell line properties. 
 SW480 KM20 HT29 HCT116 PDX 
Culture 
media 
DMEM+10% 
FBS 
EMEM + 
additives* 
McCoy's 
5A+10% 
FBS 
McCoy's 
5A+10% 
FBS 
DMEM+10% 
FBS 
Organism Human Human Human Human Human 
Tissue Colon Colon Colon Colon Colon 
Morpho-
logy 
Epithelial Epithelial Epithelial Epithelial Epithelial 
Culture 
proper-
ties 
Adherent Adherent Adherent Adherent Adherent 
Disease Duke's B, 
adeno-
carcinoma 
Stage IV Stage I, 
well-
differen-
tiated 
Colon 
adeno-
carcinoma 
Colon 
adenocarCA 
Age 50 N/A 44 Adult 63 
Gender Male N/A Female Male Male 
Ethnicity Caucasian N/A N/A N/A Caucasian 
Genetic 
infor-
mation 
mutation 
codon-12; 
Chemo-
resistant 
CEA CEA increased 
MSI 
 ras proto-
oncogene 
Gemcitabine, 
5-FU 
expression expression KRAS 
negative 
 c-myc, K-
ras, H-ras, 
N-ras 
  TGF-1, 
TGF-2 
*recurrent 
cancer 
 myb, sis, fos 
oncogenes 
    
 
 39 
Abbreviations: (DMEM), (FBS), carcinoembryonic antigen (CEA), transforming 
growth factor (TGF), cancer (CA). 
Additives: sodium pyruvate, non-essential amino acids, multivitamins 
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The animal facility is reserved and sterile equipment is prepared and 
covered to ensure sterility. The animal is anesthetized with isofluorane and 
oxygen at 2L/min. The skin is prepped with betadine and alcohol and covered 
with sterile towels. The skin is incised with an 11” scalpel and a subcutaneous 
flank pocket is developed using an 18” gauge blunt needle. The tumor slurry is 
pipetted into the pocket, ensuring there is no spillage of contents. The skin is 
gently grasped while a buried subcuticular stitch using 5-0 absorbable suture 
(Ethicon, Somerville, NJ) to approximate the skin edges. The skin is cleaned with 
alcohol and the animal is allowed to gently wake up. Further details regarding 
this procedure can be found in Appendix B. 
2.2.2 Randomized trial of intraperitoneal metformin injection 
Ten 8-week old SCID mice, all weighing over 25.0 grams were implanted 
with a single third generation PDX as described above. All implanted tumor 
volumes were from an equally divided second generation PDX and mixed with 
1.5mL of Matrigel (Corning, Bedford, MA). Each mouse received 100µL of the 
3rd generation tumor/Matrigel slurry delivered subcutaneously to the left flank by 
strict sterile technique. After 22 days all ten mice developed subcutaneous 
tumors. Mice were randomized into two groups. They were weighed and tumors 
were measured on days 1, 7, and 14. The control group received a daily 
intraperitoneal injection of 30µL of sterile normal saline for 14-16 days of 
treatment. The metformin group received a daily injection 30µL of Metformin 
(200mg/kg/day) for 14-16 days. The mice received water and regular chow ad lib. 
2.2.3 13C-glucose tissue and plasma labeling 
Prior to sacrifice, in order to achieve 13C-glucose tissue and plasma 
labeling a 20% solution of 13C -Glc in PBS (1.075 M) was sterile-filtered and 100 
µL of this solution (i.e. 20 mg of 13C -Glc) were injected into the lateral tail vein 
while the mouse was under intermittent anesthesia. Mice were injected with three 
sequential injections of 100 ul of 20 % glucose 15 minutes part (i.e. at 0, 15, 30, 
with sampling at 45 minutes post injection). Approximately 50 µL of blood 
samples were taken intraorbitally at timed intervals, chilled on ice 5 minutes after 
 41 
standing at room temperature and separated into plasma and blood cells by 
centrifugation at 4°C at 3,500 g for 15 minutes. Plasma was immediately flash- 
frozen in liquid N2 for storage prior to metabolite extraction. 
2.2.4 Tissue harvest 
Mice were sacrificed humanely by cervical dislocation at different times 
post 13C -Glc injection, and the following xenograft was resected. Dissected 
tissue was blotted, washed with water, blotted and flash-frozen in liquid N2 
within 3 minutes of euthanasia. Additional tissues were flash frozen and placed 
in 10% formalin for 24 hours followed by 70% ethanol for Western blotting and 
paraffin blocking prior to sectioning for immunohistochemical staining. 
Mice were sacrificed over the course of three days. The mice were 
“evenly” sacrificed (sacrifice day 1- 1 control, 1 metformin; sacrifice day 2- 2 
control, 2 metformin; sacrifice day 3- 1 control, 1 metformin). 
2.3 Collection of human tissues 
The clinical and translational scientist is responsible for identifying and 
contacting potential patients for the gastrointestinal tissue protocol which 
received IRB approval in November 2013 (Appendix A). If the patient agrees to 
participate in the study the clinical and translational scientist obtains consent 
which is secured in locked cabinet and all electronic patient identifiers are 
maintained in a password and firewall protected secure file. The biospecimen 
core and/or operating room circulator is requested to call or page when the 
specimen is available. The clinical and translational scientist retrieves tissues 
with ice and distributes and stores the tissues accordingly to other lab personnel. 
2.4 Ex vivo tissue labeling/incubation 
Tissues intended for labeling were collected and glucose-free DMEM + 
0.45% 13C 6 –Glucose + 10% dialyzed FBS +antibiotics was prepared. Tissues 
were washed with antibiotic/antifungal PBS x 3 and then resuspended tissue 
pieces were placed in 5-10 mL of freshly made and pre-warmed tracer medium in 
a T25 flask. Next, 0.2 mL of aliquot of tracer medium was removed from the flask 
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and stored in a 1.5 mL microfuge tube and flash-frozen and store at -80C. The 
T25 flask was placed on shaker x 24 hours in 37C, 5% CO2 incubator. At the end 
of the tracer treatment, it was removed from shaker and record the weight of the 
flask. Next the medium was transferred into a 15 mL centrifuge tube and 
centrifuge at 3500xg or higher speed for 10 minutes at 4C. Immediately after 
medium removal, transfer the tissue pieces to a microcentrifuge tube. Wash the 
tissue pieces on ice with ice-cold PBS 3 times. Remove supernatant and place 
tube in LN2. 
2.5 Cellular and molecular signaling 
2.5.1 Proliferation analysis 
All cell lines (Table 2.1) were plated in a 6 well dish at 1.0x106 cell 
number and allowed to seed for 12 hours. Conditions were treatment control, 
1mM metformin, and 5 mM metformin at time points of 24 hours, 48 hours, and 
72 hours. At each time point the cells were washed with PBS and 500µL of the 
crystal violet staining solution (0.5% crystal violet in 20% methanol) to the cells in 
the 6-well dish. These cells were fixed and stained for 20 minutes at room 
temperature. Next plate was generously rinsed and allowed to dry overnight. The 
next day the dried and stained cells were stained with 500 µL of 1% SDS and 
placed on a shaker for 20 minutes to dissolve the stain. The 200 µL of SDS/cell 
solution was added into a 96 well plate and measured at an absorbance of 
570nm. 
2.5.2 Western blotting analysis 
All cell lines (Table 2.1) were plated in a 6 well dish at 5.0x106 and 
allowed to seed for 12 hours. Then the cells were treated with varying doses of 
metformin (control, 1mM, 5mM) for 24 hours. The cells were then collected and 
lysed with TNN buffer [50 mM Tris-HCI (pH 7.5), 150 mM NaCl, 0.5 mM NP40, 
50 mM NaF, 1 mM sodium orthovanadate, 1 mM DTT, 1 mM 
phenylmethylsulfonyl fluoride, and 25 µg/ml each of aprotinin, leupeptin, and 
pepstatin A] at 4°C for 30 min. Lysates were clarified by centrifugation (10,000 × 
g for 30 min at 4°C), and protein concentrations were determined using the 
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Bradford method (102). Briefly, total protein (100 µg) was resolved on a 10% 
polyacrylamide gel and transferred to Immobilon-P nylon membranes. Filters 
were incubated overnight at 4°C in a blocking solution (Tris-buffered saline 
containing 5% nonfat dried milk and 0.1% Tween 20), followed by a 1-hour 
incubation with primary antibodies. Primary antibodies analyzed were p-ACC 
(Cell Signaling #11818) ACC (Cell Signaling #3676), p-AMPK (Cell Signaling 
#2535), AMPK (Cell Signaling #5831, p-S6 (Cell Signaling #2217) and β-actin. 
Filters were washed three times in a blocking solution and incubated with 
horseradish peroxidase-conjugated second antibodies for 1 h. After three 
additional washes, the immune complexes were visualized by the enhanced 
chemiluminescence detection system. 
2.5.3 Immunohistochemistry 
All 10 animals from the randomized trial of intraperitoneal metformin 
injection and all collected human tissues (immediate post resection and ex vivo 
incubated) were analyzed for expression of proliferation marker Ki67 (Cell 
Signaling #9027) and apoptotic marker cleaved caspase-3 (Cell Signaling 
#9661). Aperioscope digital imaging was used to determine a quantitative score 
for nuclear staining (Ki67) and positive pixel count (cleaved caspase-3). The 
extent of expression score was assessed on a scale of 0 to 3 the intensity score 
was also measured on a scale of 0 to 3 (negative = 0, weak = 1, moderate = 2, 
strong = 3). Multiplication of the values for intensity and extent of expression 
provided a score for immunoreactivity. 
2.6 Metabolic studies 
2.6.1 Seahorse analysis 
Cellular OCR was used to measure basal respiration, non-mitochondrial 
respiration, ATP-linked respiration, and proton leak. ECAR was used to monitor 
glycolysis. Each cell line was plated in specialized XF96 plates (Seahorse 
Bioscience, North Billerica, MA). Each cell line was plated at a concentration of 
3.0x104 cells/well. Twelve hours after seeding cells were treated with control 
(ddH20) or 1mM of metformin (Sigma-Aldrich, St. Louis, MO). Plated cells were 
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maintained for 24 hours in a 37°C/5% CO2 incubator. One hour prior to assay, 
cells were equilibrated with bicarbonate-free low buffered DMEM medium without 
any supplement, or supplemented with glucose or glutamine as indicated, in a 
37°C non-CO2 incubator. Reagents required for the experimental protocol were 
prepared in assay medium, loaded into reservoirs and automatically injected into 
plates as required for each assay. 
2.6.1a Oxygen consumption rate (OCR) 
Experimental design followed the protocol provided by Seahorse 
Bioscience. Briefly, cells were metabolically perturbed by the addition of three 
different compounds in succession and the OCR was measured prior to and after 
injection of each compound. First, cells were injected with oligomycin (1 µM 
working concentration), which inhibits ATP synthesis and identifies the 
percentage of OCR devoted to ATP synthesis. The second compound, carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) (0.6 µM working 
concentration), an uncoupling agent, collapses the mitochondrial membrane 
potential; a rapid consumption of energy and oxygen without ATP generation 
follows. FCCP was used to calculate the maximum and spare respiratory 
capacity of cells. Finally, cells were exposed to a combination of rotenone, a 
complex I inhibitor, and antimycin A, a complex III inhibitor (1 µM working 
concentration). This combination inhibits mitochondrial respiration and allows 
calculation of the mitochondrial and non-mitochondrial fractions contributing to 
respiration. 
2.6.1b Extracellular acidification rate (ECAR) 
For the first ECAR assessment, non-glycolytic acidification was obtained 
in the absence of extracellular glucose and pyruvate. Next, cells were exposed to 
three compounds, with measurements after each injection. The first injection, a 
saturating concentration of glucose (10 mM), causes an increase in ECAR and 
defines the rate of glycolysis under basal conditions. The second injection, 
oligomycin (1 µM working concentration), inhibits mitochondrial respiration and 
shifts energy production toward glycolysis, revealing the maximum glycolytic 
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capacity of the cells. The final injection, 2-deoxy-D-glucose (2-DG; 100 mM), a 
glucose analog, inhibits glycolysis. The difference between glycolytic capacity 
(Measurement 2) and glycolysis (Measurement 1) defines the glycolytic reserve. 
2.6.2 Metabolomic analysis 
2.6.2a Cell and media experiments 
SW480 and PDX cells were plated at 60-70% confluency in 10 cm dishes. 
The conditions for both cell lines were as follows: unlabeled control, unlabeled 
treated with 1mM metformin, 13C-glucose labeled control, 13C-glucose labeled 
treated with 1mM metformin. Prior to placing labeled medium on the cells all cell 
lines were was twice with PBS. Each plate was weighed before and after 
extracting 100µL of media (0 hour time point) which was immediately flash 
frozen. Cells were allowed to incubate in 37C/C02 for 24 hours. Each plate was 
weighed before and after extraction of 100 µL of media (24 hour time point) and 
this was also flash frozen. The remaining media was transferred into a 15 ml 
conical tube and centrifuged at 3,500xg for 20 minutes at 4C. Supernatant was 
removed and 100 µl was aliquoted in a 2 ml screw top tube (USA Scientific 1420- 
8700) for metabolite extraction. 5 mL of cold non-sterile PBS buffer was added 
onto the plate, and gently rotated on the plate to wash all surface of the plate 
prior to being suctioned off. Remove PBS by vacuum-suction and repeat. 
2.6.2b Cell quenching and collection 
1 mL of cold acetonitrile was added to cover the whole plate and allowed 
to stand for 5 minutes. Next 0.55 mL of nanopure water + 0.2 ml 0.2 mM Tris- 
HCl pH 8 was added as an internal standard for NMR to the plate. Then the cells 
were scraped and placed into a 15mL tube for a final acetonitrile to water ratio of 
2:1.5 (v/v). 
2.6.2c Cell and media experiments using acetone extraction 
One lyophilized NMR aliquot of the polar fraction resulting from CH3CN- 
H2O-CHCl3 extraction of tissue sample on ice and the sample is dissolved in 
100 µL of nanopure water and mixed. Then 400 µL of ice cold 100% acetone was 
 46 
added to perform protein precipitation and vortexes prior to being placed in -80C 
for 30 minutes to after a second centrifugation for 20 minutes @ 14,000 rpm in 
4C the supernatant may be transferred to a 2mL screw top tube and the protein 
pellet is further extracted with 100 µL of 60% acetonitrile and repeated to 
preserve as much sample as possible. The samples are flash frozen and then 
transferred to the lyophilizer. Then the dry samples are dissolved in 55 µL of 50% 
D2O with 50 nmoles DSS (With EDTA) per 0.1 mL and vortex to mix the buffer 
with the extract and centrifuge for 20 minutes @ 14,000 rpm, 4C before loading 
into 1.7 mm NMR tubes to attain a minimum column height of 36 mm. 
2.6.2d Tissue extraction for animal and human samples 
Frozen tissues were ground in liquid N2 to < 10 µm particles in a 6750 
Freezer/Mill (Retsch, Inc., Newtown, PA) and extracted simultaneously for 
soluble and lipidic metabolites as follows. Up to 20 mg of frozen tissue powder in 
15 ml polypropylene conical centrifuge tube (Sarstedt, Newton, NC) containing 
three 3 mm diameter glass beads was vigorously shaken in 2 mL of cold 
acetonitrile (mass spectrometry grade, stored at -20 C) to denature proteins, 
followed by addition of 1.5 mL nanopure water, and 1 ml HPLC-grade chloroform 
(Fisher Scientific). The mixture was shaken vigorously until achieving a milky 
consistency followed by centrifugation at 3,000 g for 20 minutes at 4 C to 
separate the polar (top), lipidic (bottom), and tissue debris layers (interface). The 
polar and lipidic layers were recovered sequentially and the remaining tissue 
debris (mainly denatured proteins) was extracted again with 0.5 ml 
chloroform:methanol:butylated hydroxytoluene (BHT) (2:1:1 mM) and centrifuged 
at 4C, 22,000xg for 20 min to separate the three phases again. The residual 
polar and lipid fractions were pooled with respective main fractions. All three 
fractions were vacuum-dried in a speedvac device (Vacufuge, Eppendorf, New 
York, NY) and/or by lyophylization. The dry weight of tissue debris was obtained 
for normalization of metabolite content. The polar extracts were redissolved in 
100 % D2O containing 30 nmol perdeuterated DSS (2,2’-dimethyl-2-silapentane- 
5-sulfonate, Cambridge Isotope Laboratories, Andover, MA) as internal chemical 
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shift and concentration reference for NMR measurement. 
2.6.2e NMR Spectroscopy 
NMR spectra were recorded at 14.1 T on a Varian Inova spectrometer 
equipped with a 5 mm inverse triple resonance cold probe, at 20 °C. 1-D 1H 
NMR spectra were recorded with an acquisition time of 2 s and a recycle time of 
5 s to minimize peak saturation. 1-D 1H Spectra were typically processed with 
zero filling to 131 k points, and apodized with an unshifted Gaussian and a 0.5 
Hz line broadening exponential. Concentrations of metabolites and 13C 
incorporation were determined by peak integration of the 1H NMR spectra 
referenced to the intensity of DSS methyl groups, with correction for differential 
relaxation, as previously described (103-105).  
13C profiling was achieved using 1-D 1H-(106) HSQC experiments 
recorded with a recycle time of 1.5 s and 13C GARP decoupling during the 
proton acquisition time of 0.15 s. 1-D HSQC spectra were processed with zero-
filling to 16 k points and apodized using an unshifted Gaussian function and 6 Hz 
line broadening.  
TOCSY and HSQC-TOCSY spectra were recorded with an isotropic 
mixing time of 50 ms, a B1 field strength of 8 kHz, and acquisition times of 0.341 
s in t2 and 0.05 s in t1. The free induction decays were zero-filled once in t2, and 
linear predicted and zero filled to 4096 points in t1. The data were apodized 
using an unshifted Gaussian and a 1 Hz line broadening exponential in both 
dimensions. Positional 13C incorporation into labeled metabolites was quantified 
as previously described (104, 107). 
2.7 Statistical analysis 
Proliferation data was normally distributed and was therefore compared 
with a paired two-tailed t-test comparing the control condition to each of the 
treatment conditions within the respective time point. Statistical analyses were 
performed with SAS 9.3 (Cary, NC) and a p-value of <0.05 was the standard for 
statistical significance. Seahorse data was analyzed using a Wilcoxon signed 
 48 
rank test because the data was not normally distributed and required statistical 
analysis with a non-parametric test to ensure statistical significance was valid 
when present. Paired tests using the Wilcoxon signed rank test were employed 
to assess differential expression of ordinal biomarker immunoreactivity scores 
between matched normal versus tumor and normal versus metastatic tissues as 
this data did not appear to be normally distributed based on histogram and 
required analysis with a non-parametric test. The correlations between 
biomarkers were measured using Spearman’s correlation coefficient non- 
normally distributed data. All results are expressed as mean ± SE. 
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CHAPTER THREE: RESULTS 
Introduction 
Reprogrammed energy metabolism is a hallmark of cancer cells and is 
rapidly emerging as a potential target for therapeutic intervention (108). To 
overcome metabolic stress, cancer cells activate several pro-survival pathways. 
Activation of AMPK, an established metabolic stress sensor, occurs with even 
modest decreases in ATP production. This activation promotes enhanced activity 
of catabolic pathways that generate more ATP and inhibits anabolic pathways 
(32). AMPK is certainly implicated in the decreased proliferation, lipid synthesis, 
and protein synthesis observed in human colon cancers, but alone it cannot 
explain why colon cancer cells exhibit such a significant increase in glycolysis 
when under metabolic stress. 
Madiraju et al. demonstrated that non-competitively inhibits the redox 
shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an 
altered hepatocellular redox state, reduced conversion of lactate and glycerol to 
glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose 
metformin treatment effectively reduced endogenous glucose production, while 
increasing cytosolic redox and decreasing mitochondrial redox states (31). While 
this novel mechanism certainly contributes to the effect of metformin on whole 
body energy metabolism, it is likely one of many mechanisms that contributes to 
metformin’s actions as an anti-cancer agent. 
Fendt et al. determined that metformin decreased glucose oxidation and 
increased dependency on reductive glutamine metabolism in both cancer cell 
lines and in a mouse model of prostate cancer. Inhibition of glutamine 
anaplerosis in the presence of metformin further attenuated proliferation, 
whereas increasing glutamine metabolism rescued the proliferative defect 
induced by metformin. These data suggest that interfering with glutamine may 
synergize with metformin to improve outcomes in patients with prostate cancer 
(90). Corominas-Faja et al. showed that certain breast cancer cells treated with 
metformin had an accumulation of 5-formimino-tetrahydrofolate, one of the one-
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carbon units responsible for de novo synthesis of purines and pyrimidines (100). 
We hypothesized that since metformin has similar anti-cancer effects on colon 
cancer cells that it has in breast and prostate cancer cells that there are novel 
mechanisms relevant to colon cancer that can be determined with metabolomic 
analysis. This study focuses on the effects cellular and molecular, as well as 
metabolic changes seen with the use of metformin on four well-establish colon 
cancer cell lines and a new, yet aggressive colon cancer cell line. Furthermore, 
we suggest that metabolomic analysis of colon cancer cells treated with 
metformin can determine if the drug has effects that can be seen with SIRM and 
if not can identify where and how certain cancer cell lines and/or human tissues 
are resistant. 
Results 
3.1 Cellular and molecular signaling 
Metformin decreases colon cancer cell proliferation and increases p-
AMPK and p-ACC while decreasing p-S6 
3.2 In vitro cellular and molecular signaling 
Treatment with metformin results in decreased proliferation and in all cell 
lines at 5mM for 24 hours, but only in cell lines HT29 and HCT116 was there an 
effect prior to 72 hours or at a lower dose than 5 mM. Both of these cell lines are 
less aggressive than S480, KM20, or PDX and the both of these cell lines had 
virtually no expression of p-S6 with the 5mM dose. SW480 cell line did have a 
notable decrease in expression of p-S6 and a moderate increase of p-AMPK and 
p-ACC on Western blot (Figure 3.1A). Only at the 5mM dose of metformin after 
72 hours of treatment did metformin significantly affect the proliferation of SW480 
cells (Figure 3.1B). 
The pattern of response seen in KM20 cells is very to the behavior that is 
exhibited by SW480 cells. Both have a notable increase in p-S6 with the 5mM  
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Figure 3.1A Western blot analysis identifies that metformin increases p-
ACC and p-AMPK, and decreases p-S6 in SW480 cells.  
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours 
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount 
of p-S6. 
Figure 3.1B Metformin decreases cell proliferation in SW480 cells.  
Metformin only significantly decreases proliferation at doses of 5mM after 72 
hours of treatment in SW480 cells (p=0.002). 
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dose (Figure 3.2A). However, both of these metastatic cell lined do not 
experience anti-proliferative effects with metformin treatment unless they have 
been treated with 5mM for at least 72 hours (Figure 3.2B). The HT29 cell line 
originated from a woman with grade I well-differentiated colon adenocarcinoma in 
the 1970s. It does not have any very notable genetic mutations and only 
expresses carcinoembryonic antigen (CEA). The notable difference over 24 
hours between the control cell, 1mM, and 5mM is marked (Figure 3.3A). It is 
also notable that metformin has an anti-proliferative effect on these cells a day 
earlier than other three more aggressive colon cancer cell lines (5mM 48 hours 
p=0.005, 5mM 72 hours p=0.002) (Figure 3.4B). 
Interestingly, although metformin has a much more dramatic impact on 
proliferation in HCT116 cells, the increase in p-AMPK and p-ACC and the 
decrease in p-S6 in HT29 cells compared to the expression seen by Western 
blotting with the HCT116 cell line suggests that metformin has more of an impact 
on the pathways that regulate glycolysis, fatty acid synthesis metabolism, and a 
decrease in protein synthesis (Figure 3.4A). The HCT116 cell line probably has 
the most impressive response to the anti-proliferative properties of metformin 
because it has a marked dose dependent response at 48 hours (5mM p=0.003), 
but at 72 hours even the 1mM doses significantly decreases cancer cell 
proliferation in HCT 116 cells (72 hours 1 mM p=0.007, 5mM p=0.001) (Figure 
3.4B). Not surprisingly, the PDX cell line had virtually no response to treatment 
with metformin at 24 hours (Figure 3.5A) and displayed decreased cell 
proliferation only after 72 hours of in vitro treatment (Figure 3.5B). 
PDX in from patients with colon cancer maintains histologic integrity 
despite many generations. This is a very aggressive cell line that originated 
this year after our lab performed implanted this aggressive locally advanced 
stage IV adenocarcinoma into a SCID mouse (Figure 3.6). 
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Figure 3.2A Western blot analysis identifies that metformin increases p- 
ACC and p-AMPK, and decreases p-S6 in KM20 cells.  
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours 
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount 
of p-S6. There is a significant decrease in the cells treated with the 5mM dose 
(p=0.010). 
Figure 3.2B Metformin decreases cell proliferation in KM20 cells.  
Metformin only significantly decreases proliferation at doses of 5mM after 72 
hours of treatment in KM20 cells. 
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Figure 3.3A Western blot analysis identifies that metformin increases p- 
ACC and p-AMPK, and decreases p-S6 in HT29 cells.  
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours markedly 
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount 
of p-S6 suggesting that in this cell line is an increase in glycolysis, decrease in 
fatty acid synthesis, and a decrease in protein synthesis and cell proliferation. 
Figure 3.3B Metformin decreases cell proliferation in HT29 cells.  
Metformin significantly decreases proliferation at the 5mM dose after 48 hours 
(p=0.005) and even more so at 72 hours (p=0.002) in HT29 cells. This data 
suggests that colon cancers with tumor characteristics similar to the HT29 cell 
line may be more responsive to metformin as an anti-cancer agent. 
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Figure 3.4A Western blot analysis identifies that metformin increases p- 
ACC and p-AMPK, and decreases p-S6 in HCT116 cells.  
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours 
increases the phosphorylation of p-ACC and p-AMPK and decreases the amount 
of p-S6. This cell line is more responsive than the metastatic cell lines in the 
study, but it is not as responsive as the HT29 cells. 
Figure 3.4B Metformin decreases cell proliferation in HCT116 cells.  
Metformin significantly decreases proliferation at the 5mM dose after 48 hours 
(p=0.003) and even more so at 72 hours (p<0.001) in HCT 116 cells. Most 
importantly, this cell line also demonstrates a significant decrease in cell 
proliferation when treated for 72 hours with 1mM of the study drug (p=0.007). 
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Figure 3.5A Western blot analysis identifies that metformin has less impact 
on p-ACC and p-AMPK, and p-S6 when PDX is compared to other 
commonly used colon cancer cell lines.  
Increasing doses of Metformin (1mM and 5mM) for a period of 24 hours show 
little impact on the phosphorylation of p- ACC and p-AMPK, nor does it seem to 
decrease the amount of p-S6. 
Figure 3.5B High doses of metformin decreases cell proliferation in PDX 
cells after 72 hours.  
Although little change is seen at 24 hours of treatment and there actually seems 
to be an initial increase in metabolism at 24 hours in cells treated with metformin, 
the drug does decrease proliferation at 48 hours (although not significantly, 
p=0.444). 
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Figure 3.6. Example of patient derived tissue implantation (A-D) and 
resulting patient derived xenograft (PDX) (E-H).  
A small pocket is created with an 11” blade scalpel (A). Next the subcutaneous 
pocket is developed with a blunt 18”gauge needed and the matrigel/tumor slurry 
is deposited into the subcutaneous pocket (B,C). The wound is closed with 5-0 
absorbable suture. After one month of allowing the tumor to develop, a 
subcutaneous PDX will form (E). The skin is incised and gently dissected away 
from the tumor (F). The tumor is removed, cleansed, and sectioned (G). The 
tumor is then implanted into another mouse (steps A-D) to create the next 
generation of the PDX (H). 
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Patients who undergo gastrointestinal cancer surgery at the University of 
Kentucky are offered the option to participate in clinical research. Table 3.1 is a 
deidentified record of patients whose tissues have evolved into xenografts 
researchers can use to explore novel cancer therapies and molecular 
mechanisms. For the most part these tumors maintain their histological integrity 
after multiple generations through SCID mice, therefore these tissues are clinical 
relevant and represent a translational science advance (Figure 3.7). 
3.3 In vivo cellular and molecular signaling 
Ten SCID mice were implanted with third generation tumor from patient 93 
as was described in the previous methods section. Approximately three weeks 
after their initial implantation all ten mice began to uniformly develop tumors. 
There was no significant difference (p=0.39) when comparing the two 
randomized groups (Figure 3.8) (Table 3.2). 
The two groups started the trial at roughly the same weight, however the 
treatment group was notably leaner than the control group after the first week 
(Figure 3.9) (Table 3.3). The mice did gain weight over the course of the next 
week. Although their tumor size was no different when compared to their 
counterparts, it is hard to know if this weight gain was due to increased tumor 
size or metabolic adaptation to metformin. Weight loss is a side effect of 
metformin so the initial weight loss was not shocking. While these mice were 
smaller than the control group on their respective days of sacrifice, this difference 
was not statistically significant (p=0.051). 
Metformin has little impact on pS6, p-AMPK, or p-ACC in SCID mice 
carrying the aggressive PDX from the initial tumor of patient 93 (Figure 3.10). 
However, observing the IHC staining reveals a decrease in Ki67 therefore 
suggesting that metformin does indeed impact tumor proliferation in vivo (Figure 
3.11). There is no significant difference between the metformin group and the 
control group when evaluating the apoptotic marker cleaved caspase-3. These 
findings suggest that an aggressive human tumor may not respond to short  
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Table 3.1. Deidentified record of tumors progressing to successful patient 
derived xenograft (PDX). 
Patient 93 109 130 
Age/ Gender 63/Male 79/Male 63/Male 
Surgery Resection of 
metastasis 
Sigmoid 
colectomy/en bloc 
bladder 
extended right 
colectomy/ileocolic anas. 
Tumor size .5cm (one 
abdominal wall 
deposit) 
2.9x2.8x2.5cm 2.5x1.8x1.8cm 
Tumor grade Poorly 
differentiated 
Invasive poorly 
differentiated 
invasive moderately 
differentiated 
Tumor type AdenoCa- 
medullary 
subtype 
adenocarcinoma adenocarcinoma 
Stage T3Nb1 T4N2 T3N*M1a(liver) 
Number +LN 2 out of 23 4 out of 20 0 out of 14 
Extramural 
invasion 
No No Yes 
Intramural 
invasion 
No Yes No 
Lymphvascul
ar invasi 
No No Yes 
Perineural 
invasion 
No No Yes 
Tumor inf. 
Lymphs 
>3 HPF <3 moderate 
Mutations increased MSI, 
KRAS negative 
loss of nuclear 
expression of 
MLH1 and PMS2 
loss of MLH1 and PMS2, 
+BRAFV600E 
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Outcome to 
date 
No disease to 
date (April 2015) 
<1 year PFS Died 6 days post op; 
sepsis/cardiac failure 
Notes: Recurrent right 
colon CA; 1st 
surgery 2012 
Palliative with 
Xeloda and 
Bevacizumab 
Sigmoid colectomy-CA 
1976; Left colon polyp 
1991; Met to liver- treated 
with Folfox; Avastin 
neoadjuvantly 
Abbreviations: lymph node (LN), CA (cancer), high power field (HPF), 
microsatellite instability (MSI), progression free survival (PFS), anastomosis 
(anas). 
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Figure 3.7. Hemotoxylin and Eosin staining of patient derived xenografts 
(PDX) through subsequent generations.  
Three patients (patient 93, 109, and 130) provided tissues that have maintained 
their histological integrity. This resource offers a tremendous opportunity to 
pursue translational cancer questions with human derived tissues that provide a 
more realistic structure in which to study tumor microenvironment. 
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Figure 3.8. Severe combined immunodeficiency (SCID) tumor volume over 
the study period.  
There was no significant difference with respect to tumor size when comparing 
the control group to the metformin group (p=0.39). 
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Table 3.2. Severe combined immunodeficiency (SCID) mice metformin trial 
tumor size. 
This table corresponds to the raw data used to generate Figure 3.8. 
 
Ear 
tag 
no. 
Treat-
ment 
Group 
Day 1 Day 7 Day 14-16 
L W H L W H L W H 
610 Control 0.5 0.5 0.2 1.51 1.1 0.3 1.51 1.1 0.5 
613 Control 0.4 0.2 0.3 2.21 1.2 0.5 2.21 1.2 1 
616 Control 0.3 0.4 0.1 2.15 1.53 0.4 2.15 1.53 0.7 
620 Control 0.5 0.3 0.2 1.25 1.91 0.2 1.25 1.91 0.4 
627 Control 0.4 0.3 0.05 2.11 1.85 0.3 2.11 1.85 0.5 
611 Met 0.5 0.4 0.1 2.02 1.61 0.5 2.02 1.61 1 
612 Met 0.3 0.4 0.1 2.3 1.34 0.3 2.3 1.34 0.6 
615 Met 0.4 0.3 0.05 1.92 1.38 0.2 1.92 1.38 0.5 
618 Met 0.5 0.5 0.2 1.92 1.21 0.4 1.92 1.21 0.6 
626 Met 0.3 0.5 0.2 1.89 1.48 0.3 1.89 1.48 0.7 
 
Abbreviations: L, length (cm); W, width (cm), H, height (cm), Met, Metformin 
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Figure 3.9. Severe combined immunodeficiency (SCID) weight over the 
study period.  
The treatment group initially lost weight which is likely due common side effects 
from metformin, however this weight loss did not prove to be a significant factor 
by the end of the murine trial (p=0.051). 
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Table 3.3. Severe combined immunodeficiency (SCID) mice metformin trial 
weights. 
This table corresponds to the raw data used to generate Figure 3.9. 
Ear tag 
number 
Treatment 
group 
Day 1 
(gm) 
Day 7 
(gm) 
Day 14-16 
(gm) 
610 Control 30.2 30.1 31.4 
613 Control 33.1 33.2 33.5 
616 Control 31.9 32 32.3 
620 Control 28.8 29 29.6 
627 Control 30.5 30.9 31.2 
611 Metformin 30.4 30.1 31 
612 Metformin 31 30.8 30.9 
615 Metformin 32 30.5 31.1 
618 Metformin 31 31 31.2 
626 Metformin 27.8 27.7 28.3 
 
  
 66 
 
Figure 3.10. Western blotting analysis of PDX tumors from control and 
metformin treated mice show minimal differences in p-ACC, p-AMPK, and 
p-S6.  
Ten severe combined immunodeficiency (SCID) mice received left 
subcutaneous flank implanted with third generation tumor from a third generation 
PDX. Based on cell signaling patterns there is a slight increase in p-ACC and p- 
AMPK expression and a decrease in p-S6 expression in the treatment group 
suggesting that metformin does cause some downstream changes in glycolysis, 
lipid metabolism, and protein metabolism in mice harboring PDX. 
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Figure 3.11. Immunohistochemistry (IHC) staining of patient derived 
xenograft (PDX) tumors from control and metformin treated mice show a 
decrease in Ki67 in the treatment group, but no significant difference in 
cleaved caspase-3.  
Ten severe combined immunodeficiency (SCID) mice received left 
subcutaneous flank implanted with third generation tumor from PDX. Tumors 
were allowed to grow to 0.5x0.5 cm and then were randomized into two 
treatment groups. The control group (n=5) received a 30 uL IP injection of saline 
each day for 14 days and the treatment group (n=5) received a 30uL (200mg/kg) 
intraperitoneal injection Metformin for 14-16 days. 
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course (i.e. 1 to 3 days) of in vitro treatment with a molecular inhibitor, but over a 
course of time exposed to both the direct and indirect effects of the drug in vivo, 
researchers may be able to elucidate more information regarding an 
individualized tumor in a relatively controlled environment. 
3.4 Ex vivo tissue labeling 
Ex vivo tissue labeling offers a relatively simple technique to elegantly 
observe human tissues and cancers in an environment that is at least applicable 
to the human tumor microenvironment that previously accommodated the 
respective neoplasm. During the same time we performed 13C6 labeling of 
freshly resected tissues from patients we also incubated tissue for IHC analysis 
to evaluate for sample quality. We determined that specimens maintain their 
tissue structure and integrity despite 24 hours of being gently shaken in labeling 
media (Figures 3.12). We also determined that larger tumors may be sectioned 
and a PDX can be performed utilized as well. We were able to compare one 
patient’s tissues both as a fresh primary sample and then later after one 
generation through a SCID mouse (Figure 3.13). In the era of personalized 
medicine, this strategy offers a safe, relatively easy, and cost-efficient way to 
“trial” multiple different therapies on one patient without any worries for side 
effects or subsequent therapy related morbidity or mortality to the patient. 
3.5 In vitro metabolic data 
After determining that different colon cancer cell lines had varying 
metabolic responses to metformin based on their baseline phenotype using 
various molecular markers such p-AMPK, p-ACC, p-S6, Ki67, and cleaved 
caspase-3 and direct proliferation studies of cells, we then sought to probe 
further into the metabolic profiles of all five cell lines to determine if the varied 
responses to a single molecular inhibitor, metformin, could be elucidated by 
mitochondrial stress tests and measurements of glycolytic energy responses. 
Collectively the metabolic impact of metformin significantly decreases 
mitochondrial respiration while increasing glycolysis. But this did not fully explain  
  
 69 
 
Figure 3.12. (Patient 109) Ex vivo labeled tissues are evaluated using 
immunohistochemistry (IHC) staining to observe for markers of cell 
proliferation (Ki67) and apoptosis (cleaved caspase 3).  
Ex vivo labeled tissues are being used to determine the direct effects of tumor 
microenvironment in a controlled environment. There was no difference in the 
markers evaluated within these respective samples. 
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Figure 3.13 (Patient 130) Another example of ex vivo labeled tissues are 
evaluated using immunohistochemistry (IHC) staining to observe for 
markers of cell proliferation (Ki67) and apoptosis (cleaved caspase 3).  
Ex vivo labeled tissues are being used to determine the direct effects of tumor 
microenvironment in a controlled environment. There was no difference in the 
markers evaluated within these respective samples. 
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why certain cell lines, namely SW480 and PDX, could also increase glycolysis 
and decrease mitochondrial respiration in an effort to more efficiently metabolism 
energy substrates, but have such little change to their overall metabolic 
phenotype. This prompted us to use SIRM to evaluate SW480 and PDX cells 
and their medial, in addition to murine in vivo labeled tissues and human ex vivo 
labeled tissues to determine the specific impact metformin has on glycolysis 
occurs by increasing 13C-6 Lactate and decreasing 13C-6 Alanine. However we 
also found that in these two particular cell lines there appears to be a “recycled” 
pathway that allows for continued metabolism despite a stressed environment 
which normally forces cells into a more conservative and energy saving 
phenotype. 
3.6 Seahorse analysis of OCR and ECAR 
Cellular OCR was used to measure basal respiration, non-mitochondrial 
respiration, ATP-linked respiration, and proton leak and ECAR was used to 
monitor glycolysis, glycolytic reserve, and glycolytic capacity. 
Upon evaluating OCR in our five cell lines of interest we determined 
certain patterns applied to each cell line. For example, we determined earlier that 
the two cell lines that were not as phenotypically aggressive (i.e. HT29 and 
HCT116) had more phosphorylation changes of factors associated with energy 
balance (p-AMPK), fatty acid oxidation (p-ACC), and protein synthesis (p-S6), as 
well as decreased proliferation measured by cell count. Also, we determined that 
the three more aggressive and/or metastatic cell lines (SW480,KM20, and PDX) 
were less responsive to metformin when evaluate with markers of cellular and 
molecular metabolism. 
However, upon evaluating the mitochondrial respiration, with the exception 
of HCT116 and HT29 and non-mitochondrial respiration, each cell line has a 
significant decreases in maximal respiration, non-mitochondrial respiration, ATP- 
linked respiration, and proton leak (Figures 3.14-3.18). Briefly, a decrease in 
non-mitochondrial respiration suggests mitochondrial respiration is dysfunctional  
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Figure 3.14. SW480 Oxygen consumption rate (OCR).  
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in 
OCR. B. The overall phenotype of the cell changes from an energetic to a more 
glycolytic state form of metabolism when observing both OCR and extracellular 
acidification rate (ECAR).  C. Both basal respiration and non-mitochondrial 
respiration are significantly decreased with metformin treatment, suggesting 
mitochondrial respiration has peaked and other energy pathways are being 
utilized.  D. ATP-linked respiration is significantly decreased with metformin 
treatment, suggesting a decrease in the respiration used to drive mitochondrial 
ATP synthesis. E. Maximal respiration is significantly decreased with metformin 
treatment, suggesting substrate oxidation and respiratory chain activity increase 
in an attempt to maintain mitochondrial membrane potential. F. Proton leak is 
significantly decreased suggesting oxidation phosphorylation is incompletely 
coupled. 
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Figure 3.15. KM20 Oxygen consumption rate (OCR).  
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in 
OCR. B. The overall phenotype of the cell changes to a more glycolytic strategy 
of metabolism. The phenotypic change in this cell line is more marked compared 
to SW480, HT29, HCT116, and UKPDX cells. C. Both basal respiration and non-
mitochondrial respiration are significantly decreased with metformin treatment, 
suggesting mitochondrial respiration has peaked and other energy pathways are 
being utilized. D. ATP-linked respiration is significantly decreased with metformin 
treatment, suggesting a decrease in the respiration used to drive mitochondrial 
ATP synthesis. E. Maximal respiration is significantly decreased with metformin 
treatment, suggesting substrate oxidation and respiratory chain activity increase 
in an attempt to maintain mitochondrial membrane potential. F. Proton leak is 
significantly decreased suggesting oxidation phosphorylation is incompletely 
coupled. 
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Figure 3.16. HT29 Oxygen consumption rate (OCR).  
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in 
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of 
cellular metabolism, but this is not as marked as seen in other cell lines. C. Basal 
respiration is significantly decreased with metformin treatment, but non- 
mitochondrial respiration is not. Overall this cell line responds more to metformin 
treatment and this is because mitochondrial inhibition of complex I is increased in 
this particular cell line, thus further sensitizing colon cancers with this phenotype 
to metformin treatment. D. ATP-linked respiration is significantly decreased with 
metformin treatment, suggesting a decrease in the respiration used to drive 
mitochondrial ATP synthesis. E. Maximal respiration is significantly decreased 
with metformin treatment, suggesting substrate oxidation and respiratory chain 
activity increase in an attempt to maintain mitochondrial membrane potential. F. 
Proton leak is significantly decreased suggesting oxidation phosphorylation is 
incompletely coupled and mitochondrial respiration is significantly decreased, 
likely through inhibition of complex I. 
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Figure 3.17. HCT116 Oxygen consumption rate (OCR).  
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in 
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of 
metabolism. C. Basal respiration is significantly decreased with metformin 
treatment, but non- mitochondrial respiration is not. Overall this cell line 
responds more to metformin treatment and this is because mitochondrial 
inhibition of complex I is increased in this particular cell line, thus further 
sensitizing colon cancers with this phenotype to metformin treatment. This 
pattern is similar to HT29 cells, which also had a significant response to 24 hours 
of treatment with 1mM Metformin. D. ATP-linked respiration is significantly 
decreased with metformin treatment, suggesting a decrease in the respiration 
used to drive mitochondrial ATP synthesis. E. Maximal respiration is significantly 
decreased with metformin treatment, suggesting substrate oxidation and 
respiratory chain activity increase in an attempt to maintain mitochondrial 
membrane potential. F. Proton leak is significantly decreased suggesting 
oxidation phosphorylation is incompletely coupled and mitochondrial respiration 
is significantly decreased, likely through inhibition of complex I. 
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Figure 3.18. PDX Oxygen consumption rate (OCR).  
A. 24 hours of 1mM treatment with Metformin results in a significant decrease in 
OCR. B. The overall phenotype of the cell changes to a more glycolytic form of 
metabolism. C. Basal respiration is significantly decreased with metformin 
treatment, but non- mitochondrial respiration is not. Overall this cell line 
responds more to metformin treatment and this is because mitochondrial 
inhibition of complex I is increased in this particular cell line, thus further 
sensitizing colon cancers with this phenotype to metformin treatment. D. ATP-
linked respiration is significantly decreased with metformin treatment, suggesting 
a decrease in the respiration used to drive mitochondrial ATP synthesis. E. 
Maximal respiration is significantly decreased with metformin treatment, 
suggesting substrate oxidation and respiratory chain activity increase in an 
attempt to maintain mitochondrial membrane potential. F. Proton leak is 
significantly decreased suggesting oxidation phosphorylation is incompletely 
coupled and mitochondrial respiration is significantly decreased. 
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because of an overload or inhibition of complex I and complex III (109). 
Therefore, HT29 and HCT116 (Figures 3.16 and 3.17), both of which are cell 
lines that are quite responsive to metformin based on the fact that cellular and 
molecular signaling is “maxed out” with regard to metformin’s inhibition of 
respiratory complex I, a well-known mediator of metformin efficacy (58). The 
three more aggressive cell lines have respective OCRs that are profoundly 
affected by metformin, therefore they must be getting energy substrates from 
another source. By observing the phenotypic changes in KM20 (Figure 3.15), it 
seems that this cell line, which is metastatic and extremely chemo-resistant, 
nearly exhausts its glycolytic pathways (Figure 3.20) by significantly increasing 
glycolysis (p=0.040) and eventually limiting glycolytic reserve (p<0.001) in order 
to deal with metformin’s metabolic assault. Unfortunately SW480 and PDX do not 
follow this pattern, and in fact, although PDX does increase its glycolytic function, 
it is the only cell line that does not have an significant increase in glycolysis 
(p=0.304) (Figures 3.19-23). SW480 significantly increases its glycolysis levels, 
but not as markedly as KM20. Furthermore, by taking a closer look at glycolytic 
reserve in these three aggressive cell lines (Figures 3.20, 3.21, 3.23) a pattern 
emerges that KM20 makes glycolysis its energy back-up plan and has a 
significantly reduced glycolytic reserve as a trade-off. In contrast, SW480, which 
also significantly increases its glycolytic levels, has a significant, yet more modest 
decrease in glycolytic reserve. Surprisingly, PDX has a significant decrease in 
glycolytic reserve without the significant increase in glycolysis (Figure 3.23). 
Therefore, a more sensitive metabolic test is required to determine what the 
back-up system these two aggressive cell lines (i.e. SW480 and PDX) use to 
evade the inhibitory effects of metformin as an anti-cancer agent. 
3.7 13C-NMR and 1H analysis of SW480 and PDX cells and media  
Given that we hypothesized that certain more aggressive cell lines had an 
alternate source of energy substrates to allow its evasion from metformin as a 
targeted therapy we sought a more elegant way to answer this question. If there 
are significant changes then SIRM labeling would allow us to see if and where in   
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Figure 3.19. SW480 Extracellular acidification rate (ECAR).  
A. Overall there are significant differences in ECAR in SW480 cells treated with 
metformin versus those that are not for 24 hours, although these changes in 
base levels and glycolytic capacity are not significantly different (B, D). There are 
significant changes in both glycolysis (C) and glycolytic reserve (E), suggesting 
that metformin does force the cells into a more glycolytic form of metabolism in 
order to continue proliferation and metabolism of energy substrates while 
decreasing reserve and later potentially exhausting this form of metabolism. 
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Figure 3.20. KM20 Extracellular acidification rate (ECAR).  
A. Overall there are significant differences in ECAR in KM20 cells treated with 
metformin versus those that are not for 24 hours although the decreases in basal 
levels and glycolytic capacity are not significantly different (B, D). There are 
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting 
that metformin induces an increase in glycolysis and forces cells into a more 
glycolytic strategy of energy metabolism while also decreasing amount of 
glycolytic reserve remaining to continue this source of metabolism. 
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Figure 3.21. HT 29 Extracellular acidification rate (ECAR).  
A. Overall there are significant differences in ECAR in HT29 cells treated with 
metformin versus those that are not for 24 hours. Similar to other cell lines there 
is little if no changes in both base levels and glycolytic capacity. There are 
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting 
that metformin does glycolysis and forces cells into a more glycolytic strategy of 
energy metabolism while also decreasing amount of glycolytic reserve remaining 
to continue this source of metabolism. Most notably, these changes are more 
profound in this cell line which mirrors the cell signaling and proliferation data, 
again suggesting that patients with tumor phenotypes similar to this cancer cell 
line may exhibit a more positive response to metformin as an anti-cancer agent. 
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Figure 3.22. HCT116 Extracellular acidification rate (ECAR).  
A. Overall there are significant differences in ECAR in HCT116 cells treated with 
metformin versus those that are not for 24 hours. Similar to other cell lines there 
is little if no changes in both base levels and glycolytic capacity. There are 
significant changes in both glycolysis (C) and glycolytic reserve (E) suggesting 
that metformin does glycolysis and forces cells into a more glycolytic strategy of 
energy metabolism while also decreasing amount of glycolytic reserve remaining 
to continue this source of metabolism. Most notably, these changes are more 
profound in this cell line which mirrors the cell signaling and proliferation data, 
again suggesting that patients with tumor phenotypes similar to this cancer cell 
line may exhibit a more positive response to metformin as an anti-cancer agent. 
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Figure 3.23. PDX Extracellular acidification rate (ECAR).  
A. Overall there are significant differences in ECAR in UKPDX cells treated with 
metformin versus those that are not for 24 hours. Similar to other cell lines there 
is little if no changes in both base levels and glycolytic capacity. Surprisingly, 
glycolysis is increased in this aggressive and novel cell line, but there is not a 
statistically significant difference between the treatment and control groups 
(p=0.304). Glycolytic reserve is significantly decreased (p<0.001) (E) suggesting 
in more aggressive colon adenocarcinomas metformin may cause cells to start 
using an alternate energy source prior to completely exhausting their glycolytic 
reserve. 
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glycolysis these aggressive cell lines were able to evade molecular inhibitors that 
normally induce a metabolic stress state by increasing glycolysis. The 
interrogation of the metabolome to answer complex molecular questions focuses 
on human disease by metabolite profiling for biomarker discovery, as well as 
pharmacology and therapeutics. Recent advances in stable isotope tracer-based 
metabolomic approaches enable unambiguous tracking of individual atoms 
through compartmentalized metabolic networks directly in human subjects, which 
made this resource an ideal tool to elucidate the complexities of the direct and 
indirect actions of metformin, especially in its relationship with aggressive 
molecularly evasive cancers. 
The metabolomic analysis of the SW480 cells and PDX cells as well as 
their respective media samples gave tremendous insight into our question and 
hypothesis and confirmed that there is an alternate energy source that is being 
utilized in addition to glycolysis during cellular metabolism when cells are treated 
with metformin. Given the labeled stable isotopes identified during the 13C6-
glucose HSQC and 13C6-glucose, 1H analysis were namely 13C-lactate and small 
peaks in 13C-alanine. Also, notably there are decreases in 13C-4-glutamine 
suggesting that metformin may preferentially increase mitochondrial oxidation 
therefore shunting glutamine into the system and forcing the cell to use this high 
energy substrate as its best resource in a high stress system. The qualitative 
data available through analysis of the media also suggested that metformin 
causes cells to preferentially use alanine and secrete lactate as a waste product, 
and that perhaps the alanine is being ”recycled” through another pathway to 
ensure there is always a pyruvate pool available with ample energy substrates. 
In Figure 3.24 NMR analysis with 13C6-Glc HSQC determined that SW480 
cells treated with metformin versus those that were not treated with metformin 
exhibit peaks in 13C-lactate and decreases in the peaks expressing evidence of 
13C- alanine metabolism. Also, notably there are decreases in 13C-4-glutamine, 
13C-4-glucose-total glutathione, and 13C-3-aspartate, as well as a slight increase 
in 13C-G1-uridine diphosphate glucose. These findings indicate a decrease in 
nucleotide synthesis in cells treated with Metformin. Figure 3.25 shows similar  
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Figure 3.24 SW480 colon cancer cells 13C6-Glc HSQC.  
NMR analysis with 13C6-Glc HSQC determined that SW480 cells treated with 
metformin versus those that are not exhibit peaks in 13C-lactate and small peaks 
in 13C- alanine. Also, notably there are decreases in 13C-4-Gln, 13C-4-Glu-
GSH+GSSG, and 13C-3-Asp, as well as a slight increase in 13C-G1-UDPG. 
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Figure 3.25. SW480 colon cancer cells 13C6-Glc, 1H.  
NMR analysis with 13C6-Glc, 1H determined that SW480 cells treated with 
metformin versus those that are not exhibit peaks in 13C-lactate and decrease in 
13C- alanine. Also, notably there are decreases in 13C-4-Gln, 13C-4-Glu-
GSH+GSSG, and 13C-3-Asp. 
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peaks with a different 1H chemical shift (0.81-2.89 ppm) which also determined 
that SW480 cells treated with metformin versus those that are not exhibit peaks 
in 13C -lactate and small peaks in 13C - alanine, as well as the corresponding 
changes in nucleotide synthesis.  Figure 3.26 represents 1H shift between 5.14-
6.56 ppm for SW480 colon cancer cells that are not labeled with 13C-glucose.  
Analysis of unlabeled SW480 cells also revealed that the control groups had 
peaks in the 12C -G1-Glycogen, 12C -G1-uridine diphosphate N -
acetylglucosamine, 12C -G1- uridine diphosphate N -acetylglucosamine, 12C 
-1’-UXP (uracil nucleotide) suggesting they may use fructose 6-phosphate and 
glutamine as an alternate energy sources. Figure 3.27 represents the 1H shift 
analysis (0.81-2.89 ppm) of SW480 colon cancer cell medium associated with 
cell treatment with 13C6-Glucose. Interestingly the media also had notable 13C-3-
Lactate peaks suggesting that the cells preferentially use glutamine and alanine 
as their “primary” back-up energy sources and create a more acidic surrounding 
environment by releasing more lactate into the surrounding media. 
We observed similar results when we analyzed the metabolic changes 
seen in PDX 93 cells treated with Metformin versus those treated with the control 
media. Figure 3.28 represents the 13C6-Glucose HSQC analysis of PDX colon 
cancer cells treated with metformin versus those that were not treated with 
metformin. Here, were also noted that our PDX colon cancer cells also exhibit 
primarily increased peaks in 13C-lactate and small peaks in 13C- alanine, again 
suggesting that these cells get there additional energy source from additional 
pyruvate pools.  Figure 3.29 demonstrates that the 1H shift (0.81-2.89 ppm) for 
PDX colon cancer cells also shows an increase in 13C-lactate. Figure 3.30 shows 
that results of 1H shift (0.81-2.89 ppm) in unlabeled PDX colon cancer cells. 
These results mirror those seen in the preexisting SW480 cell line and suggest 
the control groups had peaks in the 12C -G1-Glycogen, 12C -G1-uridine 
diphosphate N -acetylglucosamine, 12C -G1- uridine diphosphate N -
acetylglucosamine, 12C -1’-UXP (uracil nucleotide) suggesting they may use 
fructose 6-phosphate and glutamine as an alternate energy sources. Figure 
3.31 demonstrates that effects of metformin on the medium of PDX colon cancer 
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cells with and without metformin. The 13C6-glucose analysis of the 1H shift (0.81-
2.89 ppm), although not as pronounced due to the decreased amounts of protein, 
that the PDX cells also demonstrate increases in 13C-lactate suggesting that 
metformin causes these cells to use alternate energy pathways, although they 
are not purely glycolytic. 
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Figure 3.26. SW480 colon cancer cells unlabeled, 1H.  
Unlabeled SW480 cells revealed the control groups had peaks in the 12C -G1-
Glycogen, 12C -G1-UDPGlcNAc, 12C -G1-UDPGalNAc, 12C -1’-UXP (uracil 
nucleotide) suggesting they may use fructose 6-phosphate and glutamine as an 
alternate energy sources. 
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Figure 3.27. SW480 colon cancer cell medium 13C6-Glc, 1H.  
Interestingly the media also had notable 13C-3-Lac peaks suggesting that the 
cells preferentially use glutamine and alanine as their “primary” back-up energy 
sources and create a more acidic surrounding environment by releasing more 
lactate into the surrounding media. 
  
 90 
 
Figure 3.28. PDX colon cancer cells 13C6-Glc HSQC.  
PDX colon cancer cells also exhibit primarily increased peaks in 13C-lactate and 
small peaks in 13C- alanine, again suggesting that these cells get there additional 
energy source from additional pyruvate pools. 
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Figure 3.29. PDX colon cancer cells 13C6-Glc, 1H.  
This sample also shows an increase in 13C-lactate and small peaks in 13C-
alanine, but the peaks are somewhat less clear with this example because there 
is likely a low level of protein and possible issues with the sample causing the 
data to be less precise. 
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Figure 3.30. PDX cells colon cancer cells unlabeled, 1H.  
Similarly to SW480 cells the unlabeled PDX cells showed increases in unlabeled 
SW480 cells revealed increased uptake at 12C -G1-Glycogen, 12C -G1-
UDPGlcNAc, 12C -G1-UDPGalNAc, 12C -1’-UXP suggesting they may use 
fructose 6-phosphate and glutamine as an alternate energy source and may be 
a precursor to downstream lipid metabolism. 
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Figure 3.31. PDX colon cancer cell medium 13C6-Glc, 1H.  
Although not as pronounced due to the decreased amounts of protein, the PDX 
cells also demonstrate increases in 13C-lactate suggesting that metformin 
causes these cells to use alternate energy pathways, although they are not 
purely glycolytic. 
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CHAPTER FOUR: CLINICAL TRIAL DESIGN 
4.1 Objectives 
Primary Objectives 
To estimate the percent increase of AMPK phosphorylation, by 
immunohistochemistry, in patients receiving a minimum of 14-days of Metformin 
given preoperatively, in stage I-IV colon cancer patients. 
Secondary Objectives 
1. To examine the difference in proliferative expression of Ki-67 using 
immunohistochemistry comparing the two treatment populations. 
2. To determine the expression of liver kinase B1 (LKB1), p-mTOR Phospho- 
S6K, and acetyl CoA using Western blotting in this population of subjects. 
3. Post-hoc genetic analysis of surgical specimens to determine presence of K-
ras, hereditary nonpolyposis colon cancer (HNPCC), phosphoinositide- 3-
kinase gene (PI3KCA), and mismatch repair (MMR). 
4. To delineate the effect of Metformin on glycolysis and downstream tumor 
metabolism in human colon cancer tissues through the use of nuclear 
magnetic resonance imaging (NMR) and mass spectrometry (MS) 
metabolomics analysis. 
4.2 Background 
Study Disease(s): Colon Cancer 
Colon cancer is the third leading cause of cancer mortality worldwide, has 
become increasingly prevalent in Western populations, and is associated with 
both obesity and Type II diabetes mellitus (DMII) (110, 111). Colon cancer is 
increasingly prevalent in Appalachia, and our cancer center serves a large 
number of colon cancer victims from this area (112). Metformin is an oral 
antidiabetic drug in the biguanide class and is FDA approved as the first line drug 
of choice for the treatment of DMII, but has also been shown to have potential 
anti-cancer effects (11, 113).Our central hypothesis is that the predominant role 
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of Metformin in colon cancer cells is to activate AMPK which has downstream 
impacts on decreasing protein metabolism through the its effect Akt/mTOR 
pathway, and decreasing fatty acid metabolism through decreasing ACC and its 
targeted impact on fatty acid metabolism. Moreover, we speculate that 
Metformin’s impact on these molecular growth factors will inhibit colon cancer cell 
growth, proliferation, and tumor metabolism during the time interval after 
diagnosis and prior to surgery, and may even offer a therapeutic option for 
patients whom cannot tolerate aggressive traditional chemotherapy agents. 
Study Drug: Metformin 
Metformin is an oral antidiabetic drug in the biguanide class and is FDA 
approved as the first line drug of choice for the treatment of DMII, but has also 
been shown to have potential anti-cancer effects (11, 112). The primary anti-
tumor molecular target of Metformin is AMP-activated protein kinase (AMPK), 
which is a serine/threonine protein kinase (39). AMPK plays a crucial role in 
monitoring systemic and cellular energy status and which protects crucial cellular 
functions under energy-restricted conditions such as metabolic stress, i.e. tumor 
development (45). Specific downstream metabolic mechanisms proposed to be 
affected by Metformin’s action on AMPK in colon cancers are i)protein 
metabolism and translation by the mammalian target of rapamycin (mTOR) 
pathway and ii) acetyl co-enzyme A (ACC) pathway in lipid metabolism (18, 114, 
115). 
In addition to its function as a gluconeogenesis suppressor, Metformin has 
recently been shown to possess strong anti-cancer properties. It has been shown 
to reduce proliferation, induce apoptosis, cause cell cycle arrest, and improve 
response to breast tumor xenografts in pre-clinical studies (18, 51, 99, 116-118). 
Pre-clinical studies of the impact of Metformin on lung, prostate, colon, and 
pancreatic cancer have been explored (20, 22, 24, 69). Metformin is a safe 
therapeutic agent that has been previously used in many cancer clinical trials 
studying breast cancer (19, 81, 82). For pre-clinical treatment studies similar to 
the study we propose, safe doses range from 500mg two times per day up to 
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1,700 mg per day (19, 82, 119). Recent pharmacokinetic data shows that 
effective metformin induced inhibition of hepatic gluconeogenesis can be 
achieved with bi-daily dosing of metformin to achieve 74-100 µM peak average 
values of serum concentrations (31).  
Metformin’s most common side effects are gastrointestinal, and these 
symptoms are often resolve spontaneously and can often be avoided by gradual 
escalation of dosage. We do not plan to escalate the dose of metformin in this 
study, but similarly to previously performed studies in breast cancer and other 
ongoing trials exploring colon cancer, we intend to give two to three week trials 
of clinically accepted levels of this agent. Metformin treatment has not been 
associated with hypoglycemia unless used in conjunction with other glucose-
lowering medicines (sulfonylureas or insulin). In U.S. clinical trials, about 4% of 
participants were unable to continue metformin due to adverse effects. Serious 
adverse events are infrequent and generally limited to lactic acidosis, which 
occurs only in persons with renal or hepatic insufficiency or other 
contraindications (120). 
Contraindications to this drug include CHF, metabolic acidosis with or 
without coma, DKA, renal disease (serum creatinine >1.5 mg/dL in males or 
>1.4mg/dL in females), abnormal creatinine clearance resulting from shock, 
septicemia, or myocardial infarction, radiologic contrast study for 48 hr after, and 
current lactation (9). Metformin has a bioavailability of 50-60% and the peak 
plasma time of the regular release form is 2-3 hours. It is eliminated by the 
kidneys (90% by tubular secretion) at 450-540 ml/min with a t1/2 of 4-9 hours 
(121). 
Rationale 
Colon cancer is a devastating disease that is increasing in incidence 
regionally, nationally, and worldwide. Colon cancer is strongly associated with 
obesity, now considered an epidemic in the United States. Our surrounding 
Appalachian population has the highest rates of both obesity and colon cancer in 
the country, and could benefit significantly from our proposed pilot study. Our 
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proposed project using Metformin as a safe, low cost, targeted therapy offers an 
agent which can affect the correlated conditions of colon cancer and obesity. 
Current recommendations for the treatment of colon cancer include surgery and 
chemotherapy. Metformin offers an alternative that will allow decrease doses, 
and therefore toxicity, of aggressive traditional chemotherapy. We also speculate 
using this drug during the pre-surgical and immediate post-surgical interval when 
no other therapeutic intervention such as chemotherapy can safely be offered 
could potentially lead to decreased micro-metastatic disease which results in 
later recurrences. Furthermore, patients who cannot tolerate aggressive 
chemotherapy due to age or other medical conditions could significantly benefit 
from this safe and less toxic alternative. 
Epidemiologic data in human colon cancers suggests patients taking 
Metformin for the treatment of diabetes have better outcomes than their non- 
diabetic counterparts, which seems counterintuitive as these patients often have 
other comorbidities such as obesity which contribute to less optimal outcomes 
(67, 121). Both in vitro and in vivo animal data in colon cancer also suggest 
Metformin does have an anti-tumor effect, but the direct metabolic implications of 
the drug have yet to be determined (122, 123). Previous studies have shown the 
anti-tumor effects of Metformin in breast, prostate, gastric, and pancreatic 
cancers (83, 124-126). However, a randomized trial studying the specific 
metabolic effects of Metformin in human colon cancer has yet to be performed. 
We therefore propose to explore a novel, innovative approach studying the 
metabolic effects of Metformin in human colon cancer tissues using a 
prospective, double-blinded, randomized control pilot study at the University of 
Kentucky Markey Cancer Center. We intend to determine the metabolic impact of 
Metformin treatment in patients with colon cancer by examining the role of 
Metformin on protein metabolism and tumor cell proliferation in colon cancer 
tissues, as well as delineating the effect of Metformin on fatty acid metabolism in 
human colon cancer tissues. 
 98 
Correlative Studies Background 
AMPK analysis by IHC staining 
We plan to analyze both the pre and post treatment specimens to 
determine phosphorylation changes of AMPK in the Metformin treated 
specimens. IHC staining is an established and well characterized technique to 
identify and analyze AMPK in both pre-clinical and clinical studies (71, 127, 128). 
AMPK is an enzyme that plays a role in cellular energy homeostasis. It is also 
acts as an effector of metformin action on glucose uptake in cellular processes 
(129). Since Metformin targets AMPK we intend to use it as a primary biomarker 
in our study. We anticipate that Metformin treated tissues will show increased 
phosphorylation changes in AMPK when compared to specimens not treated 
with Metformin. We plan to prepare and stain these tissues in our laboratory at 
the Markey Cancer Center and have the resources and equipment to carry out 
all procedures. We plan to quantify and compare differences in AMPK 
phosphorylation with Aperioscope imaging and quantification. 
Ki67 analysis by IHC staining 
We plan to analyze both the pre and post treatment specimens to 
determine the proliferative changes present by comparing and quantifying the 
positive staining of Ki67 in the tissues. Ki67 is a nuclear protein that is associated 
with and may be necessary for cellular proliferation, and it is also associated with 
ribosomal RNA protein transcription (130, 131). There are multiple pre-clinical 
and clinical studies supporting the evaluation of Ki67 as a proliferative marker in 
tumor biology studies and that it can be accurately quantified and used as a 
reliable marker (131). We anticipate that tumor specimens which have not been 
exposed to the study drug will have an increased observance of the staining of 
Ki67, thus indicating an increase of proliferation in tissues not exposed to 
Metformin. We plan to stain all tissues for this biomarker by the same protocol to 
maintain consistency and we plan to quantify and compare differences in Ki67 
staining with Aperioscope imaging and quantification. 
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LKB1 analysis by Western blotting 
LKB1 is a primary upstream kinase of AMPK and exerts its growth 
suppressing effects by activating a group of ~14 other kinases, comprising AMPK 
and AMPK-related kinases (48). Activation of AMPK by LKB1 suppresses growth 
and proliferation when energy and nutrient levels are scarce. Activation of AMPK- 
related kinases by LKB1 plays vital roles maintaining cell polarity thereby 
inhibiting inappropriate expansion of tumor cells (34). LKB1 leads to 
disorganization of cell polarity and facilitates tumor growth under energetically 
unfavorable conditions (132). We plan to analyze both the pre and post treatment 
specimens to determine the presence of LKB1. We anticipate an increase in 
LKB1 in the tissues not exposed to Metformin as this kinase which is upstream of 
the anticipated target biomarker as it is allows tumor growth in settings of cellular 
stress. Western blotting analysis will allow us to study qualitative data of protein 
expression related to LKB1. 
p-mTOR and phospho-S6K analysis by Western blotting 
mTOR and phospho-S6K are both effectors of cell growth and proliferation 
via the regulation of protein synthesis in tumor cell growth and metabolism we 
intend to analyze with Western blotting. mTOR is a phylogenetically conserved 
serine/threonine kinase which is phosphorylated and activated by Akt, but can 
also auto phosphorylate when experiencing metabolic stress (133). mTOR 
regulates protein synthesis through the phosphorylation and inactivation of the 
repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein (4E- 
BP1), and through the phosphorylation and activation of S6 kinase (S6K1) (53). 
Pre-clinical studies have shown that metformin potentiates the effects of 
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and 
modulation of the mTOR pathway and clinical studies in human tumor xenografts 
show that Metformin treatment results in a downregulation of mTOR and 
downstream effectors such as pS6K (42, 134). We intend to use Western blotting 
analysis to study qualitative data of protein expression related to the mTOR and 
pS6K inhibition we expect to observe in Metformin treated tissue specimens. 
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acetyl CoA analysis by Western blotting 
Acetyl-CoA is produced during the second step of aerobic cellular 
respiration, pyruvate decarboxylation, which occurs in the matrix of the 
mitochondria and its main function is to convey the carbon atoms within the 
acetyl group to the citric acid cycle to be oxidized for energy production. This 
metabolic molecule is extremely important in the understanding of cellular 
metabolism and for this reason we would like to include it in our qualitative 
Western blotting analysis studies. Preclinical data shows that fatty acid oxidation 
is increased in the presence of Metformin and downstream effectors involved in 
fatty acid metabolism such as acetyl CoA and fatty acid synthase (FASN) are 
increased in models of cellular stress (23, 106, 135). We anticipate that the 
Metformin treated tissues will show an increase in the protein expression of 
acetyl CoA using Western blotting analysis. 
Genetic studies of surgical specimens 
Genetic analysis of all tumor specimens is important as we need to 
understand the implications of any genetic differences we find in comparing the 
pre and post treatment specimens. We intend to observe mutations for K-ras, 
PI3KCA, HNPCC, and MMR, all of which are important genetic mutations in 
colon cancer known to effect tumor biology (136-139). It is currently unknown if 
or how Metformin treatment changes expression of any of these genetic profiles. 
Unfortunately adequate tumor biopsy tissue will not be available in quantity or in 
a timely manner in order to stratify patient to a respective treatment arm based 
on genetic information, however a post-hoc analysis to determine if there is a 
relationship between Metformin and any of these mutations will present novel 
and interesting data. 
Metabolomic analysis of specimens with NMR and MS 
Metabolomic analysis is a new and exciting high throughput analysis 
which will allow for rapid progress that will significantly advance the fields of 
colon cancer physiology, endocrinology, and metabolism. Ultimately, our findings 
will provide insight into the specific mechanisms by which Metformin acts on 
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human colon cancer tissues could provide other insights into other novel 
avenues of research for drug development in the treatment and control of this 
devastating disease. This technology has been utilized by other groups to study 
the pharmacokinetics of Metformin and suggest its effect in in vitro studies, but 
has yet to be used to study Metformin and/or colon cancer in human tissue 
studies (100, 106, 140). Fan et al. has shown that human tissue studies in lung 
cancers can be performed using both NMR and MS (92, 94, 97). We anticipate 
that tissues treated with Metformin will show decrease levels of glycolysis and 
downstream effects of tumor metabolism, but these secondary outcomes will 
involve drug and pathway discovery in Metformin and its relationship to colon 
cancer. 
4.3 Patient Selection 
Eligibility Criteria 
• Patients must have histologically or cytologically confirmed colon cancer 
stage I-IV. 
• Patients must have surgically resectable disease 
• Age ≥18 years and < 90 years of age. Because no dosing or adverse event 
data are currently available on the use of metformin in patients <18 years of 
age, children are excluded from this study, but will be eligible for future 
pediatric trials. 
• ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). 
• Life expectancy of greater than 3 months. 
• Patients must have normal hepatic and renal function as defined below: 
• AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal 
• creatinine < 1.5 mg/dL 
• The effects of metformin on the developing human fetus are unknown. For 
this reason and because biguanide agents are known to be teratogenic 
(Category B), women of child-bearing potential and men must agree to use 
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adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or 
her partner is participating in this study, she should inform her treating 
physician immediately. Men treated or enrolled on this protocol must also 
agree to use adequate contraception prior to the study, for the duration of 
study participation, and 4 months after completion of metformin 
administration. 
• Ability to understand and the willingness to sign a written informed consent 
document. 
Exclusion Criteria 
• Patients who are not able to undergo surgical resection of their colorectal 
cancer 
• Stage 0 (carcinoma in situ) and suspected but not biopsy proven colon cancer 
• Surgical intervention at another institution for treatment of colorectal cancer 
prior to being treated at University of Kentucky 
• Subjects with a history of previous malignancy treated with chemotherapy or 
radiation within the last 6 months. 
• Current pregnancy or breast feeding. If patient becomes pregnant during their 
time in the study they will be removed from the study. 
• Pre-operative testing that includes any of the following: 
o Creatinine level (renal function test)- > 1.5 mg/dL 
o AST/ALT > 2.5 ULN 
o Glucose testing that reveals persistent (> 3 laboratory measurements) 
hypoglycemia without patient being in fasting state. 
• Patients with known brain metastases should be excluded from this clinical 
trial because of their poor prognosis and because they often develop 
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progressive neurologic dysfunction that would confound the evaluation of 
neurologic and other adverse events. 
History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to metformin. 
Uncontrolled intercurrent illness including, but not limited to, ongoing or 
active infection, symptomatic congestive heart failure, unstable angina pectoris, 
cardiac arrhythmia, or psychiatric illness/social situations that would limit 
compliance with study requirements. 
Pregnant women are excluded from this study because metformin is an 
agent with the potential for teratogenic or abortifacient effects (Category B). 
Because there is an unknown but potential risk for adverse events in nursing 
infants secondary to treatment of the mother with metformin, breastfeeding 
should be discontinued if the mother is treated with metformin. 
HIV-positive patients on combination antiretroviral therapy are ineligible 
because of the potential for pharmacokinetic interactions with metformin. 
Inclusion of Women and Minorities 
• Both men and women of all races and ethnic groups are eligible for this 
trial. 
• We shall enroll 50% women in this study as previous census and patient 
population data show that this is an appropriate representation of the 
state, region, and disease demographic. 
• At least 10% of the sample we include we will recruit will comprise minority 
participants. We also plan to enroll at least 40% of our population from 
native Appalachians. 
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4.4 Registration Procedures 
Protocol Review and Monitoring Committee and Institutional Review Board 
Review 
Before implementing this study, the protocol, the proposed informed 
consent form and other information to subjects, must be reviewed by the Markey 
Cancer Center’s Protocol Review and Monitoring Committee and the University 
of Kentucky Institutional Review Board (IRB). A signed and dated statement that 
the protocol and informed consent have been approved by the IRB must be 
maintained in the Markey Cancer Center Clinical Research Office (MCC CRO) 
regulatory binder. Any amendments to the protocol, other than administrative 
ones, must be approved by the study sponsor and the UK IRB. 
Enrollment Guidelines 
Eligible patients will be identified by the principal investigator and co- 
investigators of this study. Potentially eligible patients will be screened in the 
University of Kentucky Markey Cancer Center clinics by the investigators, study 
personnel, and the Principal Investigator (PI). Upon obtaining proper consent, 
patients will be enrolled into the study. 
Informed Consent 
The goal of the informed consent process is to provide people with 
sufficient information so they can make informed choices about whether to begin 
or continue participation in clinical research. The process involves a dynamic 
and continuing exchange of information between the research team and the 
participant throughout the research experience. It includes discussion of the 
study’s purpose, research procedures, risks and potential benefits, and the 
voluntary nature of participation. 
The informed consent document provides a summary of the clinical study 
and the individual’s rights as a research participant. The document acts as a 
starting point for the necessary exchange of information between the investigator 
and potential research participant. Also, research participants and their families 
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may use the consent document as an information resource and reference 
throughout participation in the trial. The informed consent document is often 
considered the foundation of the informed consent process; it does not, however, 
represent the entirety of the process. Nor is the informed consent document a 
risk-management tool for the investigator and/or institution. 
The investigator must explain to each subject (or legally authorized 
representative) the nature of the study, its purpose, the procedures involved, the 
expected duration, the potential risks and benefits involved and any discomfort it 
may entail. Each subject must be informed that participation in the study is 
voluntary and that he/she may withdraw from the study at any time and that 
withdrawal of consent will not affect his/her subsequent medical treatment or 
relationship with the treating physician. 
This informed consent should be given by means of a standard written 
statement, written in non-technical language. The subject should read and 
consider the statement before signing and dating it, and should be given a copy 
of the signed document. If the subject cannot read or sign the documents, oral 
presentation may be made or signature given by the subject’s legally appointed 
representative, if witnessed by a person not involved in the study, mentioning 
that the patient could not read or sign the documents. No patient can enter the 
study before his/her informed consent has been obtained. The informed consent 
form is considered to be part of the protocol, and must be submitted by the 
investigator with the protocol at the time of IRB review. 
Compliance with Laws and Regulations 
The study will be conducted in accordance with U.S. Food and Drug 
Administration (FDA) and International Conference on Harmonization (ICH) 
Guidelines for Good Clinical Practice (GCP), the Declaration of Helsinki, any 
applicable local health authority, and IRB requirements. The PI or designee will 
be responsible for obtaining continuing and not less than annual IRB re-approval 
throughout the duration of the study. Copies of the Investigator’s annual report to 
the IRB and copies of the IRB continuance of approval must maintained by the 
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MCC CRO. The PI or designee is also responsible for notifying the Data and 
Safety Monitoring Committee of the MCC and the UK IRB of any significant 
adverse events that are serious and/or unexpected, as per SOP’s of those 
entities.  
4.5 Treatment Plan 
Enrollment and Screening Process 
Prior to any study-required tests, subjects must first provide written 
informed consent to participate in this study. All lab tests and radiographic 
studies should be completed within 1 week prior to registration/initiation of 
treatment. These studies will include, but are not limited to the following: 
Complete history, physical examination, and evaluation of Zubrod Performance 
Status. Pathological biopsy or cytologically proven colon cancer. CT of the 
abdomen and pelvis with contrast or PET/CT Bone scan, only if the patient has 
bone pain and/or elevated alkaline phosphatase. CBC; serum chemistry tests to 
include alkaline phosphatase, glucose, creatinine, electrolytes, AST (SGOT), and 
total bilirubin. All radiographic studies should be completed within 1 week prior to 
registration/initiation of treatment. 
Agent Administration 
Treatment will be administered on an outpatient basis. Reported adverse 
events and potential risks are described in Section 7. The patient will discontinue 
the study if they experience adverse events during the 14-21 days of treatment 
with the research drug. No investigational or commercial agents or therapies 
other than those described below may be administered with the intent to treat the 
patient’s malignancy. The patients will receive a reminder of their choice (i.e. text 
messaging, email, phone call) from the research coordinator. We will also 
request that the patient keep either an electronic or hard copy medication diary 
to be given to research staff on the day of their scheduled operation. Plasma 
obtained in the pre-operative holding area prior to surgery will be analyzed for 
presence of Metformin in the patient’s circulatory system. Any patient having a 
plasma sample without evidence of the study drug will be excluded from the 
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study. 
Metformin 
Metformin will be supplied by the IDS pharmacy and will be given at a 
dose of 850 mg BID for a minimum of 14 days and a maximum of 21 days prior 
to surgery. Patients will not receive any prophylactic or supportive care regimens 
during the use of this study drug. We will ensure all patients have not had 
imaging with contrast studies within one week of starting study drug as this could 
significantly impair renal function. 
General Concomitant Medication and Supportive Care Guidelines 
Metformin is metabolized via hepatic and intestinal CYP3A1/2 and is 
renally excreted. Therefore, we anticipate there will be little interaction with 
medications that are metabolized by the cytochrome P450 system, but we will 
take care to protect patients from drugs with increased renal elimination, most 
notably patients undergoing radiographic imaging with renally cleared contrast 
dyes. Because there is a potential for interaction of metformin with other 
concomitantly administered drugs eliminated through renal secretion, the case 
report form must capture the concurrent use of all other drugs, over-the-counter 
medications, or alternative therapies. The Principal Investigator should be 
alerted if the patient is taking any agent known to affect or with the potential to 
affect renal function. 
Duration of Therapy 
In the absence of treatment delays due to adverse event(s), treatment will 
consist of a single 14-21 day period of oral metformin ingestion, followed by 
surgical resection of the subject’s colon cancer per institutional standards, or until 
one of the following criteria applies: 
• Disease progression 
• Intercurrent illness that prevents further administration of treatment, 
• Unacceptable adverse event(s), 
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• Patient decides to withdraw from the study, or 
• General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
Duration of Follow Up 
Patients will be followed for 4 weeks after removal from study or until 
death, whichever occurs first. Patients removed from study for unacceptable 
adverse event(s) will be followed until resolution or stabilization of the adverse 
event. 
Criteria for Removal from Study 
Patients will be removed from study when any of the criteria listed in 
Section 5.5 applies. The reason for study removal and the date the patient was 
removed must be documented in the Case Report Form. 
4.6 Dosing Delays/Dose Modifications 
Below are dose modification tables for the following adverse events: 
nausea, vomiting, diarrhea, hypoglycemia, renal dysfunction, and hepatic 
dysfunction. 
Nausea or 
Vomiting 
Management/Next Dose for Metformin 
≤ Grade 1 No change in dose 
Grade 2 Hold until ≤ Grade 1. Resume at same dose level. 
Grade 3 Off protocol therapy 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks should go off protocol therapy. 
**Patients requiring > two dose reductions should go off protocol therapy. 
Recommended management: antiemetics. 
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Diarrhea Management/Next Dose for Metformin 
≤ Grade 1 No change in dose 
Grade 2 Hold until ≤ Grade 1. Resume at same dose level. 
Grade 3 Off protocol therapy 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks should go off protocol therapy. 
**Patients requiring > two dose reductions should go off protocol therapy. 
Recommended management: Loperamide antidiarrheal therapy 
Dosage schedule: 4 mg at first onset, followed by 2 mg with each loose motion 
until diarrhea-free for 12 hours (maximum dosage: 16 mg/24 hours) 
 
 
Diarrhea Management/Next Dose for Metformin 
Adjunct anti-diarrheal therapy is permitted and should be recorded when used. 
 
 
Renal 
dysfunction 
Management/Next Dose for Metformin 
≤ Grade 1 No change in dose 
Grade 2 Hold until ≤ Grade 1. Resume at same dose level. 
Grade 3 Off protocol therapy. 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks should go off protocol therapy. 
**Patients requiring > two dose reductions should go off protocol therapy. 
Recommended management: Per NCCN guidelines 
 
  
 110 
Hepatic 
dysfunction 
Management/Next Dose for Metformin 
≤ Grade 1 No change in dose 
Grade 2 Hold until ≤ Grade 1. Resume at same dose level. 
Grade 3 Hold* until < Grade 2. Resume at one dose level lower, if 
indicated.** 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks should go off protocol therapy. 
 
 
Hepatic 
dysfunction 
Management/Next Dose for Metformin 
**Patients requiring > two dose reductions should go off protocol therapy. 
Insert any recommended management guidelines, if appropriate. 
 
 
Hypoglycemia Management/Next Dose for Metformin 
≤ Grade 1 No change in dose 
Grade 2 Hold until ≤ Grade 1. Resume at same dose level. 
Grade 3 Off protocol therapy. 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks should go off protocol therapy. 
**Patients requiring > two dose reductions should go off protocol therapy. 
Recommended management: antiemetics. 
Insert any recommended management guidelines, if appropriate. 
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4.7 Adverse Events: List and Reporting Requirements 
Adverse event (AE) monitoring and reporting is a routine part of every 
clinical trial.  
Expected Toxicities 
Adverse Events List 
Adverse Event List(s) for Metformin 
More common 
• Abdominal or stomach discomfort 
• cough or hoarseness 
• decreased appetite 
• diarrhea 
• fast or shallow breathing 
• fever or chills 
• general feeling of discomfort 
• lower back or side pain 
• muscle pain or cramping 
• painful or difficult urination 
• sleepiness 
Less common 
• Anxiety 
• blurred vision 
• chest discomfort 
• cold sweats 
• coma 
• confusion 
• cool, pale skin 
• depression 
• difficult or labored breathing 
• dizziness 
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• fast, irregular, pounding, or racing heartbeat or pulse 
• feeling of warmth 
• headache 
• increased hunger 
• increased sweating 
• nausea 
• nervousness 
• nightmares 
• redness of the face, neck, arms, and occasionally, upper chest 
• seizures 
• shakiness 
• shortness of breath 
• slurred speech 
• tightness in the chest 
• unusual tiredness or weakness 
• wheezing 
Rare 
• Behavior change similar to being drunk 
• difficulty with concentrating 
• drowsiness 
• lack or loss of strength 
• restless sleep 
• unusual sleepiness 
Serious side effects include the following: 
• Renal failure most common in patients with impaired CrCl 
• Lactic acidosis most common in patients with diabetic ketoacidosis or 
pre- existing metabolic derangement 
 
Adverse Event List(s) for Other Agent(s) Oral Glucose Tablet? 
• Hyperglycemia 
• Excitability 
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Adverse Event Characteristics 
• CTCAE term (AE description) and grade: The descriptions and grading 
scales found in the revised NCI Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0 will be utilized for AE reporting. All appropriate 
treatment areas should have access to a copy of the CTCAE version 4.0. A 
copy of the CTCAE version 4.0 can be downloaded from the CTEP web site: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.ht. 
• For expedited reporting purposes only: 
o aEs for the agent(s) that are listed above should be reported only if the 
adverse event varies in nature, intensity or frequency from the expected 
toxicity information which is provided. 
o Other Aes for the protocol that do not require expedited reporting are 
outlined in the next section (Expedited Adverse Event Reporting) under 
the sub-heading of Protocol-Specific Expedited Adverse Event Reporting 
Exclusions. 
§ Attribution of the AE: 
- Definite – The AE is clearly related to the study treatment. 
- Probable – The AE is likely related to the study treatment. 
- Possible – The AE may be related to the study treatment. 
- Unlikely – The AE is doubtfully related to the study treatment. 
- Unrelated – The AE is clearly NOT related to the study treatment. 
• Expedited Adverse Event Reporting 
For MCC Investigator-Initiated Trials (IITs), investigators must report to 
the Overall PI any serious adverse event (SAE) that occurs after the initial dose 
of study treatment, during treatment, or within 30 days of the last dose of 
treatment on the local institutional SAE form. This applies to the following 
categories: 
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• Grade 3 (severe) Medical Events – Only events that are Unexpected and 
Possibly, Probably or Definitely Related / Associated with the Intervention. 
• ALL Grade 4 (life threatening or disabling) Medical Events – Unless 
expected AND specifically listed in protocol as not requiring reporting. 
• ALL Grade 5 (fatal) Events regardless of study phase or attribution 
Note: If subject is in Long Term Follow Up, death is reported at continuing 
review. 
Note: Abnormal laboratory values are not considered medical events, 
unless determined to be causative of SAE by the investigator or grade 5. 
The following table (Table 4.1) outlines the required forms and reporting 
structure for clinical trials. Table 4.2 outlines MCC reportable complications. 
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Table 4.1 Required forms and reporting structure for clinical trials. 
Study 
type 
Expedited 
reporting to 
MCC 
Expedited 
reporting 
to External 
Agency 
Non- 
expedited 
AE 
Form IRB 
IIT where 
MCC 
Investi-
gator 
holds the 
IDE or 
IND 
Grade 3 – 
Unexpected 
AE PLUS 
Possibly, 
Probably or 
Definitely 
Related 
ALL Grade 4 
Unless 
expected 
AND listed in 
protocol as 
not requiring 
reporting. 
ALL Grade 5 
(fatal) 
Events 
FDA: 
Suspected 
AE that is 
serious and 
Unanticipat
ed (not 
listed in IDB 
or consent) 
OnCore 
and 
DSMC 
reporting 
only 
Mandatory 
Medwatch 
3500a for 
Serious 
and 
unanticipat
ed 
OnCore 
for all Aes, 
including 
SAEs 
Yes if it 
meets the 
IRB 
reporting 
require-
ments: 
Unantici-
pated 
Problem 
and/or 
Serious AE 
(use IRB AE 
reporting 
form for all 
correspond-
dence with 
IRB) 
IIT by 
MCC 
Investi-
gator of 
comer-
cially 
available 
agent 
Grade 3 – 
Unexpected 
AE PLUS 
Possibly, 
Probably or 
Definitely 
Related 
ALL Grade 4 
FDA: 
Suspected 
AE that is 
serious and 
Unantici-
pated (not 
listed in IDB 
or consent) 
OnCore 
and 
DSMC 
reporting 
only 
Voluntary 
Medwatch 
3500 for 
Serious 
and 
unantici-
pated 
OnCore 
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(non-IND 
and non- 
IDE) 
Unless 
expected 
AND listed 
in protocol 
as not 
for all Aes, 
including 
SAEs 
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Table 4.2. MCC reportable complications. 
Attribution 
Gr. 2 & 3 
AE 
Expected 
Gr. 2 & 3 
AE 
Unexpected 
Gr. 4 AE 
Expected 
Gr. 4 AE 
Unexpected 
Gr. 5 AE 
Expected or 
Unexpected 
Unrelated 
Unlikely 
Not 
required 
Not 
required 
5 calendar 
days# 
5 calendar 
days 24 hours* 
Possible 
Probable 
Definite 
Not 
required 
5 calendar 
days 
5 calendar 
days# 
5 calendar 
days 24 hours* 
# If listed in protocol as expected and not requiring expedited reporting, event 
does not need to be reported. 
* For participants enrolled and actively participating in the study or for Aes 
occurring 
Protocol-Specific Expedited Adverse Event Reporting Exclusions for 
this protocol only, the Aes/grades listed below do not require expedited reporting 
to the Overall PI or the MCC DSMC, however, they still must be reported 
through the routine reporting mechanism (i.e. case report form). IRB reporting is 
as outlined in IRB SOP: http://www.research.uky.edu/ori/SOPs_Policies/C2-
0350- . 
CTCAE 
SOC 
Adverse 
Event 
Grade Hospitalization 
/ Prolongation of 
Hospitalization 
Attribution Comments 
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Expedited Reporting to External Agencies 
The Overall PI will comply with the policies of all external funding agencies 
and the UK IRB regarding expedited reporting, as per the UK IRB’s SOP: 
http://www.research.uky.edu/ori/SOPs_Policies/C4-0150- . 
Expedited Reporting to the FDA  
The Overall PI, as study sponsor, will be responsible for all 
communications with the FDA. The Overall PI will report to the FDA, regardless 
of the site of occurrence, any serious adverse event that meets the FDA’s criteria 
for expedited reporting following the reporting requirements and timelines set by 
the FDA. 
Expedited Reporting to Hospital Risk Management 
Participating investigators will report to the UK Office of Risk Management 
any participant safety reports or sentinel events that require reporting according 
to institutional policy. 
Routine Adverse Event Reporting 
All Adverse Events must be reported in routine study data submissions to 
the Overall PI on the OnCore case report forms. Aes reported through expedited 
processes (e.g., reported to the IRB, FDA, etc.) must also be reported in routine 
study data submissions 
4.8 Pharmaceutical Information 
Metformin Product description: 
Metformin will be dosed in single 850 mg tablets and dispersed to the 
patients in a blinded fashion by the clinical research technician. The study drug 
will be purchased through the UK-Chandler Pharmacy in Lexington, KY and will 
all be pharmaceutical grade medication acceptable for human use. 
Solution preparation  
The study medication will be prepared in a standard fashion by the UK 
Chandler Pharmacy. Please see package insert for details. 
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Route of administration: 
Patients will take Metformin 850 mg PO two times per day, Q 12 hours. 
We suggest taking medication in an upright position to prevent aspiration and 
staying well hydrated while taking the study drug. Patients taking Glucose 10 mg 
PO two times per day, Q 12 hours will also be encouraged to maintain an upright 
position to prevent aspiration and staying well hydrated while taking the study 
drug. 
Metformin should be taken with meals to reduce gastrointestinal side 
effects. Glucophage can cause lactic acidosis leading to hypoxic states and 
impairment of renal function. Metformin should not be administered in pregnant 
women and breast feeding mothers unless clearly indicated. Metformin tablet 
should be taken as whole without chewing or crushing. Glucophage is not 
recommended in patients with active hepatic disease. It is advised to avoid 
alcohol intake while on Metformin treatment as alcohol potentiates lactic acidosis. 
Agent Ordering: 
We will obtain all study drug materials through the UK-Chandler 
Pharmacy. All study drugs will be de-identified and labeled in such a fashion that 
only the clinical research nurse and the pharmacist will be aware of which study 
drug the patient is given. Patient will be given amount of study drug necessary for 
treatment up until the night before their surgery. Their medication container will 
contain their name, study number, and contact information for the clinical 
research nurse. 
4.9 Biomarker, Correlative, and Special Studies 
Pre-treatment samples will be collected at the colonoscopy suite and 
surgical specimens will be retrieved with the pathologist in the pathology suite. 
The patient samples will be retrieved immediately and cryopreserved with liquid 
nitrogen after diagnostic biopsy during the colonoscopy procedure and the 
surgical procedures, respectively. Another portion of the tissues will be collected 
in cold 10% formalin and prepared for IHC staining. Our lab as well as our 
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collaborator’s lab (Fan) have an extensive background in tissue collection, 
cryopreservation, processing, and storage 
Biomarker Studies 
AMPK analysis by IHC staining 
We plan to analyze both the pre and post treatment specimens to 
determine phosphorylation changes of AMPK in the Metformin treated 
specimens. IHC staining is an established and well characterized technique to 
identify and analyze AMPK in both pre-clinical and clinical studies (71, 127, 128). 
AMPK is an enzyme that plays a role in cellular energy homeostasis. It is also 
acts as an effector of metformin action on glucose uptake in cellular processes 
(129). Since Metformin targets AMPK we intend to use it as a primary biomarker 
in our study. We anticipate that Metformin treated tissues will show increased 
phosphorylation changes in AMPK when compared to specimens not treated 
with Metformin. We plan to prepare and stain these tissues in our laboratory at 
the Markey Cancer Center and have the resources and equipment to carry out 
all procedures (Harris, Gao). We plan to quantify and compare differences in 
AMPK phosphorylation with Aperioscope imaging and quantification. 
 Ki67 analysis by IHC staining 
We plan to analyze both the pre and post treatment specimens to 
determine the proliferative changes present by comparing and quantifying the 
positive staining of Ki67 in the tissues. Ki67 is a nuclear protein that is 
associated with and may be necessary for cellular proliferation, and it is also 
associated with ribosomal RNA protein transcription (130, 131). There are 
multiple pre-clinical and clinical studies supporting the evaluation of Ki67 as a 
proliferative marker in tumor biology studies and that it can be accurately 
quantified and used as a reliable marker (131, 141). We anticipate that tumor 
specimens which have not been exposed to the study drug will have an 
increased observance of the staining of Ki67, thus indicating an increase of 
proliferation in tissues not exposed to Metformin. We plan to stain all tissues for 
this biomarker by the same protocol to maintain consistency and we plan to 
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quantify and compare differences in Ki67 staining with Aperioscope imaging and 
quantification. 
LKB1 analysis by Western blotting 
LKB1 is a primary upstream kinase of AMPK and exerts its growth 
suppressing effects by activating a group of ~14 other kinases, comprising 
AMPK and AMPK- related kinases (48). Activation of AMPK by LKB1 
suppresses growth and proliferation when energy and nutrient levels are scarce. 
Activation of AMPK- related kinases by LKB1 plays vital roles maintaining cell 
polarity thereby inhibiting inappropriate expansion of tumor cells (34). LKB1 
leads to disorganization of cell polarity and facilitates tumor growth under 
energetically unfavorable conditions (132). We plan to analyze both the pre and 
post treatment specimens to determine the presence of LKB1. We anticipate an 
increase in LKB1 in the tissues not exposed to Metformin as this kinase which is 
upstream of the anticipated target biomarker as it is allows tumor growth in 
settings of cellular stress. Western blotting analysis will allow us to study 
qualitative data of protein expression related to LKB1. 
p-mTOR and phospho-S6K analysis by Western blotting 
mTOR and phospho-S6K are both effectors of cell growth and proliferation 
via the regulation of protein synthesis in tumor cell growth and metabolism we 
intend to analyze with Western blotting. mTOR is a phylogenetically conserved 
serine/threonine kinase which is phosphorylated and activated by Akt, but can 
also auto phosphorylate when experiencing metabolic stress (133).  
Pre-clinical studies have shown that metformin potentiates the effects of 
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and 
modulation of the mTOR pathway and clinical studies in human tumor xenografts 
show that Metformin treatment results in a downregulation of mTOR and 
downstream effectors such as pS6K (42, 134). We intend to use Western blotting 
analysis to study qualitative data of protein expression related to the mTOR and 
pS6K inhibition we expect to observe in Metformin treated tissue specimens. 
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ACC analysis by W estern blotting 
is produced during the second step of aerobic cellular respiration, 
pyruvate decarboxylation, which occurs in the matrix of the mitochondria and its 
main function is to convey the carbon atoms within the acetyl group to the citric 
acid cycle to be oxidized for energy production. This metabolic molecule is 
extremely important in the understanding of cellular metabolism and for this 
reason we would like to include it in our qualitative Western blotting analysis 
studies. Preclinical data shows that fatty acid oxidation is increased in the 
presence of Metformin and downstream effectors involved in fatty acid 
metabolism such as ACC and fatty acid synthase (FASN) are increased in 
models of cellular stress (23, 106, 135). We anticipate that the Metformin treated 
tissues will show an increase in the protein expression of acetyl CoA using 
Western blotting analysis. 
Genetic studies of surgical specimens 
Genetic analysis of all tumor specimens is important as we need to 
understand the implications of any genetic differences we find in comparing the 
pre and post treatment specimens. We intend to observe mutations for K-ras, 
PI3KCA, HNPCC, and MMR, all of which are important genetic mutations in 
colon cancer known to effect tumor biology (136-139). It is currently unknown if 
or how Metformin treatment changes expression of any of these genetic profiles. 
Unfortunately adequate tumor biopsy tissue will not be available in quantity or in 
a timely manner in order to stratify patient to a respective treatment arm based 
on genetic information, however a post-hoc analysis to determine if there is a 
relationship between Metformin and any of these mutations will present novel 
and interesting data. 
Metabolomic analysis of specimens with NMR and MS 
Metabolomic analysis is a new and exciting high throughput analysis 
which will allow for rapid progress that will significantly advance the fields of 
colon cancer physiology, endocrinology, and metabolism. Ultimately, our findings 
will provide insight into the specific mechanisms by which Metformin acts on 
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human colon cancer tissues could provide other insights into other novel 
avenues of research for drug development in the treatment and control of this 
devastating disease. This technology has been utilized by other groups to study 
the pharmacokinetics of Metformin and suggest its effect in in vitro studies, but 
has yet to be used to study Metformin and/or colon cancer in human tissue 
studies (100, 106, 140). Fan et al. has shown that human tissue studies in lung 
cancers can be performed using both NMR and MS (92, 94, 97). We anticipate 
that tissues treated with Metformin will show decrease levels of glycolysis and 
downstream effects of tumor metabolism, but these secondary outcomes will 
involve drug and pathway discovery in Metformin and its relationship to colon 
cancer. 
4.10 Study Calendar 
Schedules shown in the Study Calendar (Table 4.3) below are provided as 
an example and should be modified as appropriate. 
Baseline evaluations are to be conducted within 1 week prior to start of 
protocol therapy. Scans and x-rays must be done <4 weeks prior to the start of 
therapy. In the event that the patient’s condition is deteriorating, laboratory 
evaluations should be repeated within 48 hours prior to initiation of the next 
cycle of therapy. 
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Table 4.3. Study calendar. 
 Pre- 
Study 
Wk.  
1 
Wk.  
2 
Wk.  
3 
Off  
Study 
Metformin vs Placebo  A A A  
(if 
indicated) 
 
Informed consent X     
Demographics X     
Medical history X     
Concurrent meds X  
Physical exam X X   X 
Vital signs X X   X 
Height X     
Weight X X  X X 
Performance status  
X 
 
X 
  
X 
 
X 
CBC w/diff, plts X X X X X 
Serum chemistrya X X X X X 
EKG (as indicated) X     
Adverse event 
evaluation 
 X 
Tumor measurements X X 
Radiologic evaluation X X 
B-HCG X
b     
Other tests, as 
appropriate 
     
Other correlative 
studies 
     
 
 125 
4.11 Measurement of Effect 
This is a pilot study of metformin in the preoperative setting and as such, 
is not intended to have a significant cancer therapy effect. 
4.12 Data Reporting / Regulatory Requirements 
Adverse event lists, guidelines, and instructions for AE reporting can be 
found in Section 7.0 (Adverse Events: List and Reporting Requirements). 
Data Reporting 
This study will require data submission and reporting via the OnCore 
Database, which is the official database of the Markey Cancer Center Clinical 
Research and Data Management Shared Resource Facility (CRO). Instructions 
for submitting data is listed in Study-Specific Data Management Plans created by 
CRO staff. 
Responsibility for Data Submission 
Study staff are responsible for submitting study data and/or data forms to 
OnCore as per the Markey Cancer Center CRO SOP’s. This trial will be 
monitored by the MCC Data and Safety Monitoring Committee (DSMC) on a 
schedule determined by the Protocol Review and Monitoring Committee at the 
initial PRMC review. THE CRO staff is responsible for compiling and submitting 
data for all participants and for providing the data to the Principal Investigator for 
review. 
4.13 Statistical Considerations 
Study Design/Endpoints 
Draft Sample Size Calculation: 
Study Design and Sample Size. A (two armed) one-arm trial will be 
employed wherein upregulation of AMPK will be compared from pre to post-
treatment tissues within the same patient. AMPK will be measured using 
standard technique of immunohistochemistry (IHC) tissue staining which is 
routinely performed in our lab (Harris, Gao). Changes in quantitatively measured 
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AMPK IHC score from pre to post-treatment samples will be evaluated. Using 
published data on histoscore of AMPK alpha 2 levels), we will assume that the 
mean increase from pre to post-treatment sample will be equal to 75 (SD of the 
difference = 125), resulting in a moderate effect size equal to 0.60 (128). A 
sample of 26 patients will provide 80% power to detect this effect size based on a 
two-sided, nonparametric Wilcoxon signed ranks test with 5% significance level. 
In order to account for at most a 10% possibility of unpaired pre and post sample 
in a patient, we will enroll a total of 30 patients into the trial. 
A secondary, exploratory goal of the study is to compare high-throughput 
metabolomics parameters between pre and post treated samples. We assume at 
least 3% of metabolites are truly differentially expressed with a 2-fold difference 
between pre versus post treatment samples. The standard deviation of 
metabolite expression is assumed to be 25% of the mean value based on our 
experience. Based on Monte Carlo simulations, a sample of 10 patients (with 
matching pre and post specimens) will provide over 80% power to detect 
metabolite changes at 5% FDR based on a paired t-test. 
Statistical Analysis. Data analysis for quantitative levels of AMPK, Ki-67 
and other biomarkers will involve descriptive summaries and graphical 
presentations of pre, post-treatment and changes from pre to post evaluations. 
Comparisons of changes in biomarker levels will be performed using non-
parametric Wilcoxon signed ranks test (or paired t-test, if appropriate). 
Correlations between biomarkers will be assessed using measures of correlation 
coefficient such as Spearman’s correlation. 
Bioinformatics methods including computational processing and statistical 
analysis for differential analysis will be employed for the metabolomics studies. 
Specifically, before downstream statistical data analysis can begin system 
biochemistry and bioinformatics methods will be employed in collaboration with 
Dr. Fan and her team. Statistical analysis for the processed metabolite 
endpoints will involve pairwise comparisons for each endpoint based on paired t- 
tests as well as general linear and linear mixed models to evaluate kinetics over 
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stratification factors. 
Interim Analyses 
Interim analysis will be performed after 15 patients have been accrued and 
relevant data is reviewed. We will ensure there is a difference in our primary 
endpoint, phosphorylation, and also determine that all tissues specimens are 
being processed and stored appropriately for NMR and MS analysis. 
Data Management. The study statistician and staff from the Biostatistics 
and Bioinformatics Shared Resource Facility (B2SRF) of the Markey Cancer 
Center will work closely with the study PI and the CRO at Markey in the 
development of eCRFs for the study. A draft data collection form has been 
devised as part of the protocol submission. In addition to the standard eCRF 
forms available in Oncore, this draft data collection form will serve as a guide for 
development of additional protocol- specific eCRFs in Oncore. Specifically, the 
statisticians will attend several meetings including the Protocol Initiation Meeting 
(PIM) to address all statistical considerations for this protocol including data 
collection forms and database for quantitative assessments of AMPK, Ki-67 and 
other biomarkers. The OnCore clinical trial management system, managed by 
Markey’s CRO, will be the primary database repository of clinical data from all 
patients enrolled into this trial. Data will be accessed by the study statistician on 
a regularly-scheduled basis to perform statistical programming for conduct of 
data quality control, data management, generation of interim reports and 
statistical analysis. The B2SRF has developed an automated mechanism for 
generating the interim reports of accrual and safety data. In collaboration with 
the study team, procedures will be developed for timelines for data quality 
control, resolution of data queries, and final data analysis. Finally, access of the 
high-throughput metabolomics data and linkage with the clinical data will be 
arranged between the study PI, statistician and Dr. Fan’s study team. 
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CHAPTER FIVE: DISCUSSION 
5.1 Overview of determined mechanisms of action 
The oral anti-diabetic drug metformin is beneficial for at least a subset of 
cancer patients, but there continues to be a staunch debate about whether 
metformin can directly affect tumor metabolism or if it can actually reduce the risk 
of cancer at all (142). The majority of existing data regarding the effect of 
metformin on tumorigenesis has focused on breast and prostate cancer. As the 
literature is currently lacking data specific to the metabolomic effects of 
metformin on combined in vitro, in vivo , and ex vivo data in colon cancers this 
prompted us to systematically determine this agent’s specific effects on tumor 
cells and tissues in these settings. We carefully designed our experiments to first 
evaluate in vitro cellular and molecular mechanisms in multiple and varied colon 
cancer cell lines to determine which phenotypes best respond to metformin. We 
determined that responsive colon cancer cell lines involve the canonical and 
known mechanisms of action involving metformin such as increased 
phosphorylation of AMPK and ACC and downregulation of pS6 indirectly through 
the PI3K/mTOR pathway. However, we determined that “resistant” cancer cell 
lines don’t follow this pattern and participate in adaptive metabolic behaviors to 
evade effects of metformin. Our next step was to follow these experiments with 
studies to determine the metabolic alterations metformin triggers in certain 
cancer cell lines through mitochondrial complex I inhibition. This gave us further 
insight into how more aggressive cancer cell lines such as SW480, KM20, and 
our newly synthesized PDX evade targeted molecular therapies. Using SIRM 
metabolomics and NMR analysis we determined that in cancer cell lines that 
evade metformin as a targeted agent tend to preferentially utilize alanine as an 
seemingly renewable energy substrate. Determining how and where alanine is 
“renewed” is a potential next step with our current hypotheses including that it 
may be recycled through additional pyruvate pools or that a high rate of recycling 
via the pentose cycle suggests that a significant fraction of cellular NADPH is 
generated by the pentose cycle as opposed to generation by the malate-pyruvate 
shuttle and this is the actually “additional” energy substrate (143). 
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5.2 The potential impact of metabolomics on preclinical and clinical data 
Our next step in determining the specific mechanisms of metformin in 
colon cancer was to collect human colon cancer tissues in order to develop truly 
translational in vivo and ex vivo models to specifically evaluate aggressive 
tumors and use metabolomic analyses to determine how we can potentially 
target them. These models maintain their structural and oncogenic integrity 
through multiple generations and are reproducible. This provides a realistic 
canvas to test new molecular inhibitors and anti-oncogenics on human tissues 
without any risk to the patient. Using human tissues in conjunction with SIRM 
offers the best opportunity to create novel research models of human colon 
cancer that are clinically applicable (92, 144). 
Improving our current work with in vitro and in vivo models is paramount to 
producing research that is clinically valid and relevant. Many current animal 
models used to study colon cancer use quite a variety of species, as well as 
methods of oncogenic vector introduction, and even variable doses of drugs with 
and without combinations of other therapies that may or may not be effective 
(145). As translational researchers we must aim to make tedious and expensive 
animal work as clinically relevant as possible (73, 146). However, 
xenotransplantation of human tissue into animals requires ethical training and 
consideration and clinical and translational scientists must agree to take on the 
tremendous responsibility of doing no harm on the bench or at the bedside (147, 
148). Long-standing cancer cell lines are still common sources of scientific data 
when evaluating colon cancer, and although high throughput metabolomics can 
be used for these types of studies, the great power of metabolomic analysis is 
that real, human cancer tissues can literally collected at the bedside, the 
surgeon’s bedside, and processed and stable isotope labeled within minutes. 
Hours to days later scientists, physicians, and surgeons can begin to gather 
valuable data that can potentially lead to better tailored therapies for patients in 
the form of molecular inhibitors and anti- oncogenic immunomodulators. For 
example Jahnke et al. developed a label-free monitoring system to directly 
analyze the chemosensitivity of undissociated tumor tissue. Using a preparation 
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of tumor micro-fragments (TMF) established from melanoma biopsies, we 
characterized the tissue organization and biomarker expression by 
immunocytochemistry. Robust generation of TMF was established successfully 
and demonstrated on a broad range of primary melanoma tumors and tumor 
metastases. Using isolated TMF, sensitivity to six clinically relevant 
chemotherapeutic drugs (dacarbazine, doxorubicin, paclitaxel, cisplatin, 
gemcitabine, and treosulfan) was determined by impedance spectroscopy in 
combination with a unique microcavity array technology we developed. In 
parallel, comparative analyses were performed on monolayer tumor cell cultures. 
Lastly, we determined the efficacy of chemotherapeutic agents on TMF by 
impedance spectroscopy to obtain individual chemosensitivity patterns (149). 
5.3 Clinical and Translational Scientists, Cash, and Clinical Trials 
Some of the major impediments to these valuable studies are funding, 
lack of collaboration between scientists and direct health care providers, and 
difficulty design valid clinical trials that will successfully meet accrual while also 
assessing relevant primary endpoints (150, 151). Unfortunately, The US is 
experiencing a severe shortage of underrepresented biomedical researchers 
(152). Even more discouraging, Hu et al. determined Inflation-adjusted NIH 
funding for surgical research decreased 19% from $270M in 2003 to $219M in 
2013, with a shift from R-awards to U-awards. Proportional funding to outcomes 
research almost tripled, while translational research diminished. Nonsurgical 
departments have increased NIH application volume over the last 10 years; 
however, surgery's application volume has been stagnant. To preserve surgery's 
role in innovative research, new efforts are needed to incentivize an increase in 
application volume (153). Programs like the Center for Clinical and Translational 
Studies and the current T32 grant at the University of Kentucky offer an excellent 
opportunity for residents who intend to pursue a career in academia and need 
the training and guidance to be part of developing projects and trials that will be 
beneficial to patients and cost-effective for funding organizations. 
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5.4 Conclusions and Further Directions 
In conclusion, we embarked on a project to determine the true mechanism 
of action of metformin on colon cancer cells. We determined that metformin 
decreases cell proliferation and protein synthesis through the mTOR pathway, 
and increases metabolic stress points by the activation of p-AMPK and p-ACC in 
certain less aggressive cell lines such as HT29 and HCT116. However, 
determining the specific mechanisms of more aggressive and elusive cell lines 
like SW480, KM20, and PDX required more investigative work through metabolic 
analysis with measurements of OCR and ECAR to determine if and where they 
may be mitochondrial complex stress points that could be targeted. We 
determined that very aggressive cell lines will seek other energy sources to 
continue to grow and live. We used SIRM and 13C-NMR to determine that certain 
aggressive colon cancer cell lines evade the glycolytic inducing stress of 
metformin by seek renewable energy sources available via the Kreb’s cycle and 
potential the pentose phosphate pathway. Also, we determined that metformin 
does anti-proliferative effects on human tissues carried in a PDX treated with and 
without metformin for a two week period. Finally we have performed initial ex vivo 
13C-glucose labeling of human tissues and with and without metformin and intend 
to perform the necessary analysis to determine if the effect in human tissues 
mirrors our findings in two aggressive colon cancer cell lines, one that was 
developed during my training and offers a solid clinical and translational model of 
developing in vitro, in vivo, and ex vivo studies with a single human tissue. 
Finally, I hope that additional future directions lead to a continued career 
as an academic surgeon with active basic science and clinical and translational 
projects throughout my career. 
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APPENDIX A. Institutional Review Board Approval for Gastrointestinal 
Tissue Collection Protocol 
Background 
Gastrointestinal malignancies in the United States are increasing in 
incidence, and Kentucky leads the nation in number of colorectal cancer and 
pancreatic cancer deaths in both men and women in data from 2004-2008 
according to the American Cancer Society. The Center for Disease Control 
evaluated cancer rates in Appalachia and determined that the incidence of 
gastrointestinal malignancies for this population is even higher than other parts of 
the United States. In order to better understand tumor growth and metastasis of 
these diseases, we must evaluate tumor metabolism and microenvironments 
responsible for the aggressive nature of these processes. Biospecimens and 
data collected from cancer patients and people without cancer are paramount to 
understanding the metabolic function of these tumors and developing modalities 
that can impede or halt their growth. We will use de-identified biospecimens 
collected from leftover resected patient tissues for non-human research purposes 
to study molecular pathways and signaling related to cancer growth. We also 
intend to obtain serum and plasma from these patients prior to the initiation of 
their surgical procedure. This protocol describes the methods used to protect 
human subjects for Markey Cancer Center (MCC) sponsored/sanctioned 
research studies that use biospecimens and data collected from such people. It 
details the standard operating procedure we intend to use to consent patients for 
biospecimen collection and collection of these specimens by our honest brokers. 
Fresh tissue including normal and primary tumor is prospectively collected 
in patients already undergoing surgical resection for gastrointestinal malignancy 
and inflammatory bowel diseases. Frozen previously banked specimens are also 
available. We also intend to collect one total milliliter of serum and plasma in the 
pre-operative holding area from the patient prior to surgery. A technician in the 
Markey Cancer Center Biospecimen and Tissue Procurement Shared Resource 
Facility (MCC BSTP SRF) will act as an honest broker and will provide 
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specimens completely de-identified of PHI to Dr. Evers’ lab personnel for non- 
human research purposes. The tissues, serum, and plasma samples collected 
will be analyzed by Markey Cancer Center laboratory staff by methods to analyze 
tumor metabolism and cellular and molecular signaling. While this research will 
not affect the care of the patients providing the samples, their tissues will be used 
to better understand mechanisms that contribute to tumor signaling, growth, and 
metastasis. We intend to develop methods to slow, or potentially inhibit these 
pathways. Better understanding of these pathways and strategies to diminish 
them can result in development of treatment options for future patients suffering 
with malignancies of the gastrointestinal tract. 
Objectives 
To obtain bio specimens from an honest broker to perform non-human 
research using tissues from surgical specimen while protecting the rights of the 
individuals from whom the specimens and information was obtained. Non-human 
research experiments will include protein and biomarker analysis using Western 
blotting, cell culture, molecular signaling pathway analysis and metabolic 
analyses using ELISA (enzyme-linked immunosorbent assay), study of genetic 
polymorphisms using PCR (polymerase chain reaction), and genetic and 
epigenetic testing using DNA microarrays. Only the biospecimens mentioned in 
this protocol will be used for non-human research, and their retrieval will have no 
impact on patient treatment or plan of care. 
Biospecimens 
Tissue including primary tumor and/or nonneoplastic tissue that 
automatically comes with the surgical specimen (e.g. mesenteric fat) is 
prospectively collected in patients already undergoing resection for 
gastrointestinal disease. After the specimen is acquired it will be evaluated by the 
pathology department to determine what tissue is necessary and unnecessary for 
clinical workup and pathologic staging of the tumor. Fresh (unprocessed) tissue 
designated as unnecessary for clinical care will therefore be available for 
research, as it represents material in excess of what is needed for clinical care 
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and, thus, would otherwise be disposed. Tissues will be stored in solution of 
phosphate buffered solution and 20mg/ml fetal bovine serum and deidentified by 
Brent Hallahan, both of whom are honest brokers in the MCC BSTP SRF. This 
sort of approach to fresh tissue processing by the BSTP has already been 
approved by the IRB (protocol 04-0454). The specimens will then be collected by 
Evers lab associates. 
Regarding the use of already-existing archival formalin-fixed paraffin 
embedded material (FFPE) housed in the department of pathology, FFPE tissue 
blocks will be obtained from archival clinical material stored in the pathology 
department. These are cases that have already been processed, evaluated, and 
signed out by an attending pathologist. In most instances, after tissue sections 
are cut from such blocks, the remaining FFPE tissue is no longer needed for 
patient care. Judging when a given FFPE tissue block is no longer needed will be 
the responsibility of Dr. Horbinski, the MCC BSTP SRF Director and a board- 
certified anatomic pathologist. Dana Napier, a histotechnician in the MCC BSTP 
SRF, will act as an honest broker and will provide FFPE specimens completely 
de-identified of PHI to Markey Cancer Center lab personnel for non-human 
research purposes. 
Patients who also consent to providing serum and plasma biospecimens 
under the IRB protocol # 04-0454 will have a blood sample drawn from a 
previously placed intravenous catheter at the same time as specimen retrieval 
specified in IRB protocol #04-0454. These specimens will not be obtained by 
separate venipuncture, fingerstick, heelstick, or earstick. One milliliter of blood 
will be aliquoted from the sample drawn for the IRB protocol # 04-0454 for our 
purposes and poses minimal risk and discomfort to the patient. After retrieval the 
sample will be placed on ice and the honest broker will de-identify the sample 
prior to contacting Markey Cancer Center laboratory personnel for biospecimen 
retrieval. The de-identified specimen will be given a study code or number and 
the laboratory personnel will have no access to patient health information. 
Regarding patients who have already consented to tissue collection using 
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IRB protocol # 04-0454 we are requesting the ability to retrospectively obtain 
plasma and serum samples that are archived in the MCC BSTP SRF. Dana 
Napier a histotechnician in the MCC BSTP SRF, will act as an honest broker and 
will provide these specimens completely de-identified of PHI to Markey Cancer 
Center lab personnel for non-human research purposes. 
Data 
Honest brokers will be responsible for entering, tracking, and maintaining 
the identity of the samples through electronic database tables. For research 
purposes, the honest brokers will assign a unique de-identified study code to 
each sample. The following data will be collected by the MCC BSTP SRF: 
Patient demographics, specimen characteristics, specimen tracking information, 
cancer pathology where applicable, cancer registry information (diagnosis, 
staging, treatment, survival, historical cancer diagnoses, etc.), patient survey 
information, biospecimen analytic results, environmental specimen analytic 
results, etc. The information will be stored in database tables that reside on 
access-restricted servers managed by the MCC Informatics Shared Resource 
Facility (ISRF). Some, but not all database tables may contain PHI. Database 
tables will utilize one or more unique identifiers (such as medical record number) 
with the associated unique de-identified study code to associate records across 
database tables. Database tables may be managed by one or more software 
applications such as caTISSUE and custom applications developed by the ISRF. 
All computer systems and applications will require authentication through unique 
logins and passwords. Computer systems, network, and applications will be 
maintained with due diligence to modern security standards. Servers will reside 
behind appropriately configured firewalls managed by UK Communications and 
monitored by ISRF personnel. Access to patient information will be restricted to 
the honest brokers and clinical research personnel who come into contact with 
patients prior to their operation for consenting purposes. Only de-identified, 
coded or aggregate information will be given to investigators/study personnel by 
the honest brokers, and honest brokers will provide laboratory staff with de- 
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identified tissue, plasma, or serum specimen. As stated above, the honest 
brokers will maintain the identity of the samples through unique identifiers such 
as medical record numbers and each sample will be assigned a unique de- 
identified study code. Study personnel will only obtain samples with the specific, 
de-identified study code. 
Study population 
Biospecimens and data from adult patients of UK Healthcare and MCC 
affiliates will be collected. Patients undergoing surgical resection for 
gastrointestinal malignancy or inflammatory bowel disease in which the treatment 
procedure includes resection of all or portions of visceral fat or mesentery will 
meet inclusion criteria for the study. Any archival FFPE tissue from a cancer 
patient obtained before 2008 is automatically included, as it is likely that the 
individual from whom the tissue was removed is no longer available to give 
specific consent. As this represents a repository for future research, its size is not 
limited. 
Subject recruitment methods and privacy 
BSTP employees identify potential donors by monitoring the UK 
Healthcare data base for patients undergoing surgery for gastrointestinal 
diseases, and who are/will be treated at UK Healthcare or an affiliate health care 
provider. They will be asked to participate and will be asked to sign the general 
banking protocol consent form (already IRB approved, IRB# 04-0454) For the 
use of specimens for existing studies, the possible uses are covered in the 
general banking consent form. This consent includes a discussion of the possible 
uses and risks for their specimens that adequately inform the subject for the 
limited types of existing and future studies of banked specimens that are eligible 
to receive specimens. Privacy will be maintained by not providing the specimen 
to investigators with any unique patient identifiers. 
Informed consent process 
Patients will be consented by BSTP-SRF and clinical research personnel 
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using the general banking combined consent and authorization form from the 
Markey Cancer Center General Specimen Banking Protocol (IRB# 04-0454). A 
waiver of informed consent has been requested for the existing FFPE block data 
base, serum, and plasma specimens and is requested in this application for the 
use of clinical/epidemiologic data. 
Research Procedures 
This protocol involves obtaining biospecimens that will be used for non- 
human research only. Non-human research experiments will include protein and 
biomarker analysis using Western blotting, cell culture, molecular signaling 
pathway analysis and metabolic analyses using ELISA (enzyme-linked 
immunosorbent assay), study of genetic polymorphisms using PCR (polymerase 
chain reaction), and genetic and epigenetic testing using DNA microarrays. 
Molecular pathway inhibitors and modulators of genetic and epigenetic 
expression will be developed in efforts to learn how to slow down and/or inhibit 
the processes that contribute to tumor metabolism and growth. Only leftover 
tissues will be used for non-human research, and will have no impact on patient 
treatment or plan of care. 
Resources 
This protocol will utilize physical resources and established operations 
within the department of pathology and the BSTP. The department of pathology’s 
surgical pathology laboratory will be used to obtain fresh (unprocessed) 
specimens from clinical specimens that are not needed for clinical care. Plasma 
and serum samples will be collected at the same time as plasma and serum 
samples are collected for patients consenting to biospecimen donation using IRB 
protocol # 04-0454. Archival FFPE material as well as archived serum and 
plasma samples will be obtained from material stored in the pathology 
department. 
Storage of the biospecimens will follow established procedures. The 
material obtained from fresh specimens is available for immediate use or can be 
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frozen and stored in the MCC BSTP laboratory for future use. The archival 
clinically derived FFPE material is stored in the department of pathology. 
Once de-identified tissues are received from the honest broker, 
researchers associated with the Evers lab will perform experiments as mentioned 
above. Data will be stored within the MCC ISRF. Database tables may be 
managed by one or more software applications such as caTISSUE and custom 
applications developed by the ISRF. Access to patient information will be 
restricted to authorized study, clinical research personnel, MCC biospecimen 
core personnel, and ISRF personnel. All computer systems and applications will 
require authentication through unique logins and passwords. Computer systems, 
network, and applications will be maintained with due diligence to modern 
security standards. Servers will reside behind appropriately configured firewalls 
managed by UK Communications and monitored by ISRF personnel. Only coded 
or aggregate information will be given to investigators. Information will not be 
provided using personal identifiers. 
Personnel 
All key personnel and the individuals acting as honest brokers will have 
training in human subject protection. Basic science research personnel 
associated with Dr. Evers’ lab will only have contact to the honest broker in order 
to obtain the de-identified tissue. 
Potential risks 
Privacy and confidentiality see data section and request for wavier of 
informed consent. 
Safety precautions 
Use of a unique identifier so that the donor of the specimen/data remains 
anonymous to the user of the specimen. Use of hospital or General consent to 
confirm intent. Tissue will be retrieved from resected specimens who are involved 
in the anticipated surgical specimen with regards to appropriate oncological 
margins. 
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Benefit vs risk 
No direct benefit. Indirect benefit to everyone including subject if 
information that leads to more effective ways to prevent, treat or cure cancer are 
found. No physical risks as specimen/data are collected as part of routine patient 
care. There is a minimal risk of breach or privacy/confidentiality as noted above. 
Available alternatives 
None. 
Research materials 
Existing and to be collected material in conjunction with routine patient 
care. 
Privacy and confidentiality 
As noted above all material stored and distributed to investigators using 
unique (non-patient) identifiers and an “honest broker” system that isolates the 
identity of the source of the material being used for research from the researcher. 
All data stored in limited access and password protected manner. 
Payment 
None 
Cost to subject 
None 
Data and Safety monitoring 
By Markey scientific advisory committee. The ultimate responsibility for 
oversight of data and specimen handling is the Director of Markey Cancer Center 
who is listed as the PI of this application. 
Subject Complaints 
Subjects may address questions or complaints to Craig Horbinski, MD, 
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PhD, The Markey Cancer Center director of research, UK Healthcare customer 
service, the UK Hospital ethics committee or the IRB. 
Research involving non-English speaking subjects  
HIV/AIDS 
Not available. 
PI- sponsored FDA regulated research 
Not available. 
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APPENDIX B: Institutional Animal Care and Use Committee Approval for 
Patient Derived Xenografts for the Implantation of Human Tissues 
USDA Pain Category: D  
Preoperative Evaluation: Animals and occupied animal cages should be 
placed on a preheated circulating water heating pads set to 90-100F to prevent 
hypothermia which can result in slowed metabolism, prolonged induction, and 
extended postsurgical recovery times. 
Preoperative xenografts preparation: All patient tissues will be handled 
with sterile, autoclaved instruments and be processed under a sterile hood. 
Patient tissues will be cleansed with Phosphate buffered solution (Sigma) and 
2% penicillin/streptomycin (Sigma) and fungizone (LifeSciences). Once cleansed 
the tissues will be cut into 5mm pieces and mixed with 100 uL of sterile Matrigel 
(BDBiosciences). This tissue/Matrigel mixture will be placed in sterile 1.5mL 
microcentrifuge tubes and placed in an opaque container with ice for transport to 
the animal facility. 
Type of surgery to be performed: Surgical Implantation: Patient derived 
xenografts, colon, pancreatic 
Is this a Recovery or Non-recovery Type of Surgery: Recovery 
Duration of anesthesia/surgery: 15-30 min 
Describe pre-op health assessment: Animals will be visually examined 
to ensure they are healthy and normally active. Individual animal body weights 
will be determined and noted on the pink DLAR Surgery Cards. 
Describe use of pre-anesthetic medications: Buprenorphine 0.05-0.1 
mg/kg SC (only when using Isoflurane anesthesia). 
Operative Anesthesia: Isoflurane (1-4% in O2, inhaled-nosecone) 
How will anesthetic depth be measured? Adequate depth of anesthesia 
will be assessed by presence of regular steady respirations and absence of a 
withdrawal reflex (toe or tail pinch) or corneal reflexes. 
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Surgical table, incision site and surgeon preparation: Surgical table, 
incision site and surgeon preparation. Standard procedures for rodent survival 
surgery will be followed as described in the IACUC Policies, Procedures and 
Guidelines on Rodent Surgery. Procedures will be performed in a designated 
area of the laboratory specifically prepared in advance for that purpose. 
Following induction of anesthesia an artificial tear or ophthalmic ointment is 
applied to both eyes. The skin will then be shaved and scrubbed thoroughly with 
Povidone iodine or Chlorhexidine solution. The animal’s body temperature will 
be maintained with heating pads or lamps, as necessary. The surgeon will wear 
a mask and sterile gloves. Instruments will be steam autoclaved prior to use and 
sterilized with a glass bead sterilizer between animals. Assurance is made that 
the temperature of instruments from the hot bead sterilizer are normalized 
before use. The pump will be prepared aseptically. 
Support equipment: Isoflurane vaporizer with gas scavenging (if using 
isoflurane), recirculating water heating pad(s), and glass bead sterilizer. 
Describe surgical procedure Prior to surgery mice will be assessed for 
normal activity, inquisitiveness, condition of hair coat, eating, drinking, 
defecation, urination, appearance of eyes, breathing rate, gait and bodyweight. If 
any abnormal condition is observed, the animal will not be used and the PI or one 
of the co-investigators will consult with a DLAR veterinarian. 
Adequate anesthesia will be assessed by checking eye blinking, response 
to toe pinch, palpebral reflex muscle relaxation, lack of response to incision, 
respiratory rate and depth. 
If animals respond to any of these, they are not adequately anesthesized 
and anesthesia will continue until these signs are absent. Additional isoflurane 
will be administered through inhalation for isoflurane (via cone placed over the 
animal’s nose and connected via a hose to isoflurane vaporizer) as necessary. 
At all times, sterile techniques will be followed. Instruments will be initially 
steam sterilized. Between animals, instruments will be rinsed with sterile saline 
and heat sterilized (glass bead sterilizer). Two sets of instruments will be used 
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alternately in the event that surgery is being performed on >4 animals per day. 
Persons performing the surgery will scrub their hands with bactericidal 
scrub and wear a clean lab coat, sterile surgical gloves, and a surgical mask. 
The surgical table will be disinfected and covered with sterile drapes. 
The surgical site(s) (abdominal fossa located caudal to the margin of the 
ribcage and ventral to the transverse spinous processes of the lumbar vertebra) 
will be shaved in case of SCID mice. The surgical sites will be cleaned with a 
Betadine swab stick from the center of the incision to the periphery. This process 
will be repeated with 70% alcohol prep pads. Scrubbing will be alternated 
between the Betadine and alcohol and repeated at least three times, ending with 
the Betadine. The surgical sites will be draped with sterile drapes. 
Once the surgical sites have been prepared, disinfected and covered with 
a sterile drape, small flank incision just inferior to the scapula will be made using 
an 11” blade scalpel. The subcutaneous tissues will be bluntly dissected using a 
hemostat. The PDX/matrigel mixture prepared under sterile conditions in the lab 
with by introduced into the subcutaneous pocket using sterile large opening 
micropipette tips to deposit the PDX. Once the PDX has been deposited the 
incision will be closed with a subcuticular 5-0 Vicryl (Ethicon) suture, or wound 
clips. The wound will be cleaned with alcohol wipe. Drapes will be removed and 
the animal will be allowed to recover from anesthesia. 
Reference article for the caecal injection of CRC cells: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557075/ 
Post-surgery/anesthetic recovery monitoring plan: Postoperatively, 
animals will be placed on warm heating pads and monitored for signs of 
recovery, including signs of pain or discomfort (lethargy, hunched position). The 
animals’ progress will be monitored daily by members of the Mark Evers lab. 
Post- operative animals, will be given buprenorphine (opioid) analgesia 0.1mg/kg 
by IP every 12 hours for 48 hours. 
As part of our standard post-operative care, mice will be monitored for 
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normal grooming behavior, clean coat, clear eyes and normal locomotion and 
inquisitiveness. The incisions will be checked for swelling and redness. If the 
animals do not appear normal or if problems occur with the incisions, a DLAR 
veterinarian will be asked to examine the animal and recommend treatment (or 
euthanasia if needed). 
Wound Closure: Surgical wounds will be closed with 5.0 Vicryl (Ethicon) 
absorbable sutures, or wound clips. 
Will post-operative analgesics be administered? Yes 
Indicate Post-Operative Medications and Describe Postop Care: 
1. Post-operative animals, will be given buprenorphine (opioid) analgesia 
0.1mg/kg by IP every 12 hours for 48 hours. 
2. A pink DLAR Surgery Card with the date the procedure was performed will be 
used to mark cages after surgery. Animals that have had surgery will be 
observed daily (5-7 days) by the PI, or a member of the research team, and 
the results of observations recorded (e.g. back of pink card). The animals will 
be observed with regard to normal activity, inquisitiveness, condition of hair 
coat, eating, drinking, defecation, urination, appearance of eyes, breathing 
rate, gait, and body condition. The animals will also be evaluated for 
vocalization, dehydration, and appearance of the surgical wound (e.g. red 
edges, swelling, or exudates), and suture/wound clip displacement. The 
cards will be removed after suture/staple removal. 
3. Mice will be observed twice weekly for tumor growth and size. Endpoints 
requiring sacrifice include decreased range of motion, poor oral intake, 
tumors > 2 cm, lethargy, or signs of animal discomfort. Tumors greater than 
10% animal body weight will require humane euthanasia. 
4. If abnormal conditions are observed, the PI or a co-investigator will consult 
with a DLAR veterinarian. 
When will sutures/staples be removed? Absorbable sutures. Not 
applicable. 10-14 days for wound. 
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APPENDIX C: Center for Clinical and Translational Sciences Seed Grant 
The metabolomic effects of Metformin on colon cancer in human colon 
tissues 
Applicant: 
Jennifer W. Harris, MD 
741 S. Limestone Street, BBSRB  
Lexington, KY 40505 
Post-doctoral Fellow, Markey Cancer Center 
University of Kentucky College of Medicine 
(859) 330-0777 
jenn.whittington@uky.edu 
 
Immediate Supervisor: 
B. Mark Evers, MD  
 
Primary Mentor:  
Tianyan Gao, PhD 
741 S. Limestone Street 
B367 BBSRB  
Lexington, KY 40505 
Core Support, Markey Cancer Center 
University of Kentucky, Department of Molecular and Cellular Biochemistry 
(859) 323-3454 
Tianyan.gao@uky.edu 
 
Amount requested: 
$5,000 
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Budget and Budget Justification 
Metfomin Metabolomic Study Budget 
Incubation and Laboratory Supplies Cost Total cost 
Laboratory computer for research nurse $700  
13C labeled media and supplies $500  
Tissue analysis fees   
NMR/MS analysis $2,640  
Computational fees $600  
Medication costs   
Metformin Hydrochloride $560 $5,000 
 
Overview: 
Funding for this project is requested for 1) equipment to assist in the 
record keeping for the clinical research nurse and supplies for tissue 
preparation, 2) partial cost of nuclear magnetic resonance imaging (NMR) and 
mass spectrometry (MS) for tissue analysis and 3) study drug purchase. This 
project will continue enrollment until a maximum of 33 subjects complete one 
experiment. 
Incubation and Laboratory Supplies: 
We are requesting a laptop PC ($700) for the clinical research nurse to 
keep all data with patient health information in a secure, password protected 
location. We anticipate one year lab costs for basic supplies including 13C 
labeled media and tissue preparation supplies to cost ($500). This will result in 
$1,200 in cost. 
These supplies will be necessary to process tissues collected from the 
subjects in our study. The PC will be a one-time purchase and the cost of the 
supplies from our current providers has remained static for the past three years. 
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Tissue analysis fees: 
NMR and MS sample analysis costs forty dollars per hour of sample 
analysis. The pair based approach of tissue incubation will result in sixty six total 
samples from thirty three patients will result in a cost of $2,640 dollars. 
Computational data analysis will cost an additional $600, resulting in a total cost 
of $3,240. 
Medication costs: The Markey Cancer Center laboratory will purchase all 
study medications from a United States retailer, and study medication will be of 
pharmaceutical grade and quality as defined by the FDA. Cost of Metformin for 
tissue incubation is $76 for 100 gram. We anticipate medication costs for patient 
sample incubation to be approximately $560 over the course of the study for 
thirty three patients. 
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Abstract: 
Colon cancer is the third leading cause of cancer mortality worldwide and 
is associated with obesity and Type II diabetes (110) (111). Metformin is an FDA 
approved oral antidiabetic drug which has also been shown to have anti-cancer 
effects (11, 18). The primary anti-tumor molecular target of Metformin is AMP- 
activated protein kinase (AMPK), a serine/threonine protein kinase (113). AMPK 
plays a crucial role in monitoring systemic and cellular energy status and crucial 
cellular functions under energy-restricted conditions such as metabolic stress, i.e. 
tumor development . Specific downstream mechanisms proposed to be affected 
by Metformin’s action on AMPK in colon cancers are i)protein metabolism by the 
mammalian target of rapamycin (mTOR) pathway and ii) acetyl co-enzyme A 
(ACC) pathway in lipid metabolism (45, 114). Previous studies have shown the 
anti-tumor effects of Metformin in breast, prostate, gastric, and pancreatic 
cancers (83, 124-126). However, a trial studying the specific metabolic effects of 
Metformin in colon cancer has yet to be performed. We propose a novel, 
innovative approach studying the metabolic effects of Metformin in colon 
cancer tissues using a prospective patient matched tissue pilot study. Our 
proposed project is fundamentally different from previous studies using 
Metformin since we will use human tissues as opposed to in vitro cell lines or 
animal tissues to examine this drug’s anti-oncogenic effects. Furthermore, we will 
determine the specific metabolic effects of the drug which contribute to its ability 
to target colon cancer cells. This innovative study will provide insight into further 
understanding of colon cancer metabolism and novel strategies for targeted 
therapies. 
Study Personnel: 
Jennifer W. Harris, M.D., Principal Investigator, is currently a post-
doctoral fellow recipient of a T32 training grant and general surgery resident at 
the University of Kentucky. Dr. Harris has considerable experience in human 
tissue collection and tissue processing and analysis, as well as treatment of 
clinical diseases such as metabolic syndrome and colon and rectal cancers. The 
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proposed project is an extension of metabolic studies performed at the University 
of Kentucky Markey Cancer Center exploring tumor microenvironment and 
signaling in human colon cancers. Dr. Harris’ responsibilities will be to 
coordinate clinical study and perform metabolic studies in collaboration with Dr. 
Gao and Dr. Fan. 
Mark Evers, M.D., Consultant, is currently the director of the Markey 
Cancer Center and surgeon at the University of Kentucky. Dr. Evers has an 
extensive background in conducting clinical trials and is an expert in cancers of 
the gastrointestinal tract. He will serve as a mentor and provide guidance to 
assist in coordinating the progression of the study and collaboration of the group 
as a whole. 
Tianyan Gao, PhD, Co-Investigator, is currently an Associate Professor 
in the Department of Cellular and Molecular Biology at the University of 
Kentucky. Dr. Gao has an extensive background in conducting protein and 
ribonucleic acid analysis which will be necessary for the analysis of patient 
samples and cellular data collection. Dr. Gao will assist with specimen analysis 
and data interpretation. 
Tersea Fan, PhD, Co-Investigator, has a longstanding history in quality 
human tissue collection and analysis, and is considering an expert in the field of 
isotope labeling of human tissues for metabolic study using nuclear magnetic 
resonance imaging and mass spectrometry. Dr. Fan will share her expertise in 
our proposed study by assisting us with the use of this state of the art technology 
and interpretation of data and results. 
Clinical Research Nurse, R.N, B.S.N. required, will be responsible for 
ethical registering and consenting patients for the study, obtaining and labeling 
study medications for the patients, being on call for patient questions, blinding 
the treatment arms to the care providers and patients, and collecting clinical data 
on study patients. We plan to interview several clinical research nurses all of 
whom have a strong background in human trials at the University of Kentucky for 
this position which will offer a stipend to their additional pay. 
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Heidi Weiss, PhD, Consultant, is a Professor of Biostatistics at the 
University of Kentucky. Dr. Weiss will conduct the data analysis with her 
statistical expertise both during and at the conclusion of our proposed study. 
Resources and Environment: 
Utilizing a multidisciplinary approach with significant surgical and clinical 
experience from the Colorectal Surgery Division of General Surgery at University 
of Kentucky (Beck, Hourigan, Patel), metabolism and obesity (Fan, Lane, 
Higashi), colon cancer treatment/study design (Gao, Evers), and 
biostatistics/computational biology (Weiss/Moseley) we plan to develop a patient 
matched tissue human pilot study using Metformin as a metabolic 
chemotherapeutic agent against colon cancer. Comparing patient matched 
samples incubated with and without Metformin we will determine the short-term 
effects of Metformin treatment by comparing protein expression of effectors 
involved in protein synthesis, tumor cell migration, and tumor metabolism. We will 
also use isotope labeling to determine protein and fatty acid metabolism 
differences between the pre-treatment and post-treatment samples. 
The Markey Cancer Center at the University of Kentucky Medical Center 
is a NCI (National Cancer Institute) designated center that provides cutting edge 
surgical and medical cancer care to Kentucky and surrounding states. The 
endoscopy and surgical services provided at this center have the expertise and 
surgical volume to support this trial. A clinical research nurse will be designated 
to enroll patients and organize and record of data to ensure the success of this 
trial. We have worked closely with the Markey Cancer Center Biospecimen Core 
to collect gastrointestinal tissues from surgical patients. Over the past six months 
we have enrolled over seventy five percent of patients from whom we requested 
consent for tissue collection. We do plan to financially compensate participants 
as we are requesting that patients in this study reliably take a study drug for two 
weeks. Plasma samples to confirm Metformin use will be drawn in the 
preoperative area to ensure usage of drug and study cooperation. 
Our laboratory is located in the Biomedical/Biological Sciences Research 
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Building and has all of the necessary equipment and supplies we need for tissue 
storage, culture, and preparation. We have spent the last year refining our tissue 
collection and preparation techniques with assistance from the Markey Cancer 
Center Biospecimen Core and lab personnel from the Fan lab to ensure the 
appropriate protocol is followed and those samples are ready for metabolomics 
analysis. We will work with the Fan lab using state of the art metabolomics 
analysis to perform 1D nuclear magnetic resonance (NMR) and gas 
chromatography mass spectrometry (GC-MS) to assess the difference between 
patient matched samples collected from our study population. 
Finally, we plan to work closely with our biostatistician colleagues Heidi 
Weiss, PhD and Hunter Moseley, PhD to analyze and interpret the data we 
collect for our outlined experiments. Dr. Weiss has an extensive background in 
development and data analysis of clinical trials, and Dr. Moseley is an expert in 
the analysis and interpretation of metabolomics data. 
Specific Aims: Metformin is a safe, low cost, FDA approved drug for the 
treatment of type II diabetes mellitus, but has also been shown to have potential 
anti-cancer effects (11, 18). Epidemiologic data in human colon cancers 
suggests patients taking Metformin for the treatment of diabetes have better 
outcomes than their non-diabetic counterparts, which seems counterintuitive as 
these patients often have other comorbidities such as obesity which contribute to 
less optimal outcomes (67, 121). Both in vitro and in vivo animal data in colon 
cancer also suggest Metformin does have an anti-tumor effect, but the direct 
metabolic implications of the drug have yet to be determined (122, 123). Thus far 
the only human clinical trials have been performed on patients with benign colon 
diseases and not colon cancer (154). We are proposing a novel human tissue 
pilot study to determine the underlying metabolic effects of Metformin in colon 
cancer. 
Our central hypothesis is that the predominant role of Metformin in colon 
cancer cells is to activate AMPK which has downstream impacts on decreasing 
protein metabolism through its effect on Akt/mTOR pathway, and decreasing 
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fatty acid metabolism through decreasing ACC and its targeted impact on fatty 
acid metabolism. Moreover, we speculate that Metformin’s impact on these 
molecular growth factors will inhibit colon cancer cell growth and proliferation, 
and may even offer a therapeutic option for patients whom cannot tolerate 
aggressive traditional chemotherapy agents. To examine our hypothesis and 
achiever our long term goal of better defining the metabolic impact of Metformin 
in human colon cancers, we have planned experiments with the following. 
Aim 1: To determine the role of Metformin on protein metabolism and 
tumor cell proliferation in colon cancer tissues. 
Hypothesis: Patient colon cancer tissues treated with Metformin will have 
decreased expression of markers indicative of protein metabolism and tumor cell 
proliferation compared to samples treated with the placebo condition. 
Approach: Surgically resected patient colon cancer tissues will be treated 
ex vivo with Metformin. We will use the well-established techniques of Western 
blotting and immunohistochemistry staining to evaluate protein metabolism 
markers AMPK, Akt, mTOR, and phosphor-S6 ribosomal protein and cell 
proliferation marker Ki-67 and markers of fatty acid metabolism such as fatty 
acid synthase (FASN). 
Impact: This study will establish that tumors in patient tissue samples 
treated with Metformin have less growth potential due to a decrease in protein 
metabolism and ability to grow and proliferate secondary to the targeted 
molecular effects of Metformin. 
Aim 2: To delineate the effect of Metformin on cellular metabolism in 
human colon cancer tissues.  
Hypothesis: Patient tissues treated with Metformin will have altered 
cellular metabolism and particularly decreased fatty acid synthesis in evaluated 
colon cancer tissues compared to patients treated with the placebo condition. 
Approach: We will utilize state of the art metabolomic techniques 13C- 
labeled NMR and GC-MS to study specific metabolic pathways in patient derived 
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colon cancer tissues. 
Impact: This patient matched human tissue study will establish that tumors 
in patients treated with Metformin are indeed less metabolically active compared 
to tissues of patient tissues incubated without Metformin. 
To achieve our aims, we have assembled a multidisciplinary team with 
significant expertise in colon cancer physiology and function (Harris, Evers, 
Gao), metabolism and obesity (Evers, Fan), and biostatistics/computational 
biology (Weiss, Moseley). Our highly collaborative team has the requisite 
expertise, novel model systems and state-of-the art technology to make rapid 
progress that will significantly advance the fields of colon cancer physiology, 
endocrinology, and metabolism. Ultimately, our findings will provide insight into 
the specific mechanisms by which Metformin acts on human colon cancer 
tissues could provide other insights into other novel avenues of research for drug 
development in the treatment and control of this devastating disease. 
Research Strategy 
Significance: Colon cancer is the third leading cause of cancer mortality 
worldwide has become increasingly prevalent in Western populations (111). This 
devastating disease was the second leading cause of cancer mortality in the 
United States in 2008, and is projected to increase in prevalence given its 
association a sedentary lifestyle and a high/ low fiber diet (155-157). Obesity and 
its associated comorbid conditions have become an increasingly difficult 
challenge for healthcare providers worldwide, and in the U.S. adult obesity rates 
rose from 14% in 1978 to over 30% in 2000 with over 50% of Americans 
projected to be obese in 2030 (158). Obesity and its associated comorbid 
conditions, namely Type II diabetes mellitus, are suggested as culprits for 
increasing the risk of developing colon cancer, as well as increasing both the 
morbidity and mortality of patients who fall victim to this disease (41, 159, 160). 
Metformin is an oral antidiabetic drug in the biguanide class and is FDA 
approved as the first line drug of choice for the treatment of DMII, but has also 
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be shown to have an anti-tumor effect on colon cancer cells in in vitro and animal 
studies (123, 161, 162). 
Metformin acts through both insulin dependent and insulin independent 
pathways and this makes it an attractive option for targeted molecular therapy as 
it has the potential to inhibit multiple pathways involved in cancer cell metabolism 
(40) The consensus of the published literature agrees that the main effect of 
Metformin on tumorigenic cells occurs at the convergence of multiple metabolic 
pathways, namely at the molecular activator AMPK which is of paramount 
importance as it plays a significant role in how cells respond under metabolic 
stress conditions (36, 70, 163, 164). AMPK acts on protein metabolism through 
the Akt/mTOR pathway and on fatty acid metabolism through mechanisms 
involving ACC (47, 135). Little is known regarding the effect of Metformin on the 
nuclear and mitochondrial changes which occur downstream from these 
molecular pathways. 
Our proposal is significant as we intend to discover these downstream 
mechanisms which profoundly affect tumor growth and cancer cell proliferation. 
Innovation: Our innovative approach to determine the metabolic impact of 
Metformin will involve the analysis of patient tissues using state-of-the-art 
approaches. This system combines the use of stable isotope tracers with mass 
spectrometry (MS) and nuclear magnetic resonance imaging (NMR) analyses, to 
enable robust and global mapping of Metformin’s impact on fatty acid 
metabolism, lipid absorption, metabolism, and storage. All of these factors 
contribute to a cancer cell’s ability to acquire nutrition and survive under 
metabolic stress conditions. 
Another novel and innovative detail to our proposal is the design of our 
study. Patients will undergo surgical resection of all or part of their colon. 
Multiple tissue samples of the tumor will be collected and a portion of the sample 
will be incubated in growth media with Metformin while another portion of the 
sample will be incubated in growth media without Metformin. We will be able to 
create a human tissue pilot study using Metformin in which we compare the 
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metabolic effects of the drug on patient matched samples. This approach offers 
an innovative qualitative as well as quantitative analysis of the differences in both 
patient matched samples as well as samples from patient tissues receiving the 
two different study conditions. 
Approach: Our work on the in vitro effects of Metformin on colon cancer 
cell lines was initially funded by the T32 funding mechanism (Trainee Grant 
5T32CA160003-03). We found that there is a considerable difference in the 
cellular growth and metabolism of colon cancer cell lines HT29, HCT116, 
SW480, and KM20, all of which are colon cancer cell lines derived from human 
colon cancers. We also successfully submitted a human gastrointestinal tissue 
collection protocol to the University of Kentucky IRB which aims to collect colon 
cancer tissues from human patients (IRB# 13-0753-P2H). We were strongly 
advised to seek additional funding to explore performing protein analysis and 
metabolomic studies on tissues acquired from patients who have colon cancer. 
Human tissue pilot study design: Patients seeking treatment at the Markey 
Cancer Center who have been recently diagnosed with Stage I- Stage IV colon 
cancer will discuss study involvement with the clinical research nurse designated 
to the study. Pre-clinical data will be reviewed to determine if the patient has any 
of the excluding criteria that would make them ineligible for the study. Exclusion 
criteria for the study include the following: 
• Ages < 21 or > 90 years old 
• Stage 0 (carcinoma in situ) 
• Metformin treatment within the past 6 months for any other condition 
• BMI < 18 or > 40 
• Previous malignancies treated with chemotherapy or radiation 
• Surgical intervention at another institution for treatment of colorectal 
cancer prior to being treated at University of Kentucky 
• Current pregnancy or breast feeding. If patient becomes pregnant during 
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their time in the study they will be removed from the study. 
The patient will be enrolled in the study if they agree to informed consent 
to provide tissues for analysis. After surgical resection, the patient samples will 
be retrieved immediately and either cultured under different conditions ex vivo in 
medium or cryopreserved directly in liquid nitrogen. Our lab as well as our 
collaborators lab (Fan), have an extensive background in tissue collection, 
cryopreservation, processing, and storage (92, 94, 97). According to our power 
analysis we need to have a total of thirty three patients in order to adequately be 
able to ascertain statistical significance, if any, between the patient matched 
samples. The specific analysis of these tissues and the approaches in which we 
will successfully complete our proposed aims are discussed in further detail 
below. 
Specific Aim 1: To determine the role of Metformin on protein metabolism 
and tumor cell proliferation in colon cancer tissues. 
Metformin acts through insulin dependent mechanisms mainly in the liver, 
and this contributes to increased systemic glucose by means of 
gluconeogenesis in the liver which releases glucose into the blood stream 
(Figure A.1). This effect increases the amount of circulating insulin and 
subsequent binding of insulin the insulin receptors on cells in the body. This 
cellular stimulation results in increased cellular catabolism and downstream 
protein synthesis and cell growth. However, the insulin independent mechanism 
of Metformin acts intracellularly and increases the effects of AMPK. 
Intracellularly AMPK decreases the cells ability to participate in protein synthesis 
in two ways: i) it increases the activity of TSC2 which is a tumor suppressor of 
the mTOR complex, and also directly decreases the activity of the mTOR 
complex. Increased AMPK activity also decreases the activity of ACC which is 
the first gateway of the cell to participate in fatty acid metabolism. 
Metformin acts on this pathway in an insulin dependent manner and 
results in decreased fatty acid production and subsequent storage. Our intended 
experiments after collection of surgical specimen human tissues will use  
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Figure A.1. Metformin is an oral antihypoglycemic drug that plays an 
important role in regulating cellular metabolism via AMPK and mTOR. 
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biochemical and immunological techniques to measure protein expression of 
protein synthesis and fatty acid metabolism. Freshly collected tissues will be 
incubated in Metformin containing or control medium and cellular lysis will be 
performed to isolate protein samples for Western blotting. After cell lysate and 
protein isolation, Western blotting will be performed and we will probe for 
markers for cell energy utilization such as AMPK, protein synthesis including 
mTOR and phospho-S6, as well as markers of fatty acid metabolism such as 
ACC and fatty acid synthase (FASN) (44, 165). Alternatively, the treated tissues 
can be fixed and prepared as paraffin-embedded tissue blocks. To measure cell 
proliferation we will use the standard technique of immunohistochemistry (IHC) 
tissue staining which is routinely performed in our lab (Harris, Gao). We will only 
evaluate the surgical specimens with IHC as the biopsy samples will not provide 
enough tissue to perform the paraffin preparation step required for IHC. We will 
probe for a well-known marker of cell proliferation Ki-67, as well as FASN (43). 
Statistical considerations for the endpoints of protein metabolism will include 
comparisons of pre- and post-treatment tissues, and also comparison of tissues 
from patients in the different treatment conditions using both descriptive and 
graphical presentations. Similar comparisons comparing qualitative data for IHC 
will include a comparison of patient tissues after different treatment conditions to 
asses for changes in markers indicating decreased cell proliferation. We will 
quantify the number of cells stained with the respective markers and perform a 
two tailed t-test comparing the expression of cell proliferation markers in the two 
groups (Weiss). 
Anticipated results, potential problems, and alternative solutions: 
There will be a decrease in protein synthesis and fatty acid metabolism 
markers in the Metformin treated tissues compared to those not treated with 
Metformin. 
Potential problems could include loss of sample due to inappropriate 
tissue preparation or errors in performing Western blotting. To prevent either of 
these problems we will only allow experience technicians to process samples 
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and perform Western blotting. We anticipate IHC staining results will show that 
post treatment samples will have a decreased expression of Ki67 and FASN. 
One potential limitation is that the surgically resected tissues may undergo 
apoptosis during the ex vivo treatment period. We will monitor the level of 
apoptosis by analyzing the expression of apoptosis markers such as cleaved 
caspase 3 to make sure that tissues are mostly viable after the control treatment. 
We are currently conducting pilot experiments using mouse colon tissues to 
determine the optimal incubation time needed. Our experiments with human 
tissues will be adjusted accordingly. 
Specific Aim 2: To delineate the effect of Metformin on cellular metabolism 
in human colon cancer tissues. 
It is well established in the colon cancer literature that an increase in fatty 
acid metabolism and fatty acid production promotes the growth of colon cancer 
cells by increasing the activity of ACC and its downstream effectors (166-168). 
Previous authors have also shown Metformin impacts fatty acid 
metabolism in vitro and in animal models, but the literature lacks evidence of 
these effects actually being present in humans and there have only been 
analyses to evaluate protein and nuclear markers (23, 50, 169). We are also 
interested in detecting any global alteration in cellular metabolism (e.g. Increased 
TCA cycle activity) upon Metformin treatment. Our intended experiments after 
collection of the surgical specimen human tissues will use similar techniques to 
measure protein expression of protein synthesis and fatty acid metabolism. To 
label freshly collected tissues, mucosal slices will be incubated with 13C-glucose 
containing medium for 24 hours and processed as described previously. SIRM 
analysis will be performed by a combination of NMR, Gas chromatography-mass 
spectrometry (GC-MS), and Fourier transform mass spectrometry (FT-MS) (92). 
Our co-investigator has over twenty years of experience with this technique and 
equipment (Fan). The extent of 13C-labeling lipid precursors in both treatment 
groups of patient matched samples, including glycerol-3-phosphate and citrate, 
will be obtained from GS-MS analysis while intact triglycerides, phospholipids, 
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and fatty acids will be acquired from FT-MS analysis (Figure A.2). Based on 
these 13C-labeled enrichment patterns of lipids in Metformin treated and non-
treated human patient matched colon cancer samples and their precursors, the 
dynamics of colon cancer cells and their de novo fatty acid and lipid synthesis 
pathways in the two treatment groups will be compared, thus delineating if 
Metformin treatment does indeed affect de novo fatty acid and lipid synthesis. 
Labeling the tissues and using this advanced technology will tell us exactly when 
and where in the Krebs cycle these metabolic changes are taking place. 
Statistical analysis will include using two sample t-tests with Hochberg’s p-
value adjustment due to the simultaneous testing of multiple metabolites. 
Software simulation will be performed 1000 times to determine the sample size 
that will provide adequate statistical power to detect the hypothesized difference 
between treatment groups with control of family-wise error rate. Statistical 
analysis for the processed endpoints from the fatty acid synthesis and fatty acid 
oxidation studies will involve pairwise comparisons for each treatment condition, 
each pair matched sample, and time points of software analysis. Linear and 
mixed models to evaluate metabolic kinetics will be measured. Multivariate 
statistical analyses will be used for the discovery of non-targeted metabolic 
changes. 
Anticipated results, potential problems, and alternative solutions: 
We anticipate that there will be a decrease in fatty acid synthesis in 
Metformin treated patient tissues compared to their matched non-treated 
specimens. In addition, we expect to detect various metabolic alterations 
associated with metformin treatment. We do not anticipate problems with tissue 
collection or processing, nor do we anticipate problems with profiling the lipid 
and polar metabolites including their 13C-labeling patterns using in-house tools 
established in the metabolomics center at the University of Kentucky through 
collaboration with Dr. Fan. Dr. Weiss, our biostatistics collaborator will perform 
multivariate statistical analysis for discerning non-targeted metabolic changes  
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Figure A.2. NMR and GC-MS analyses.  
(A) NMR analysis. Expected 13C-positional isotopomer patterns of glycolytic and 
Krebs cycle metabolites synthesized from [U-13C]-Glc by mammalian cells (Fan 
et al.); (B) GC-MS analysis. Each 1H peak arose from protons directly attached 
to 13C and the peak assignment denotes the 13C-carbon. Thus, the peak intensity 
reflects 13C abundance of the attached carbon (Fan et al.). 
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from the very large metabolomics datasets for any unexpected but meaningful 
metabolic signature associated with AMPK or ACC manipulation. This is the 
value of the metabolomics approach for discovery of new functional links for 
signaling pathways. 
Training Plan: 
1. Training expectations associated with research 
The funds we are requesting through the CCTS Seed grant will be applied 
to this study by providing materials for data collection and analysis, as well as 
tissue sample analysis and study medication. These funds will specifically cover 
the expenses of the most translational aspects of this novel and innovative 
study. As post-doctoral fellow/surgical resident who is interested in oncology this 
project literally takes a novel idea from the bench to the bedside, involves patient 
intervention in the clinical, pre-operative, and surgical setting, and brings the 
tissues they generously provide for bedside to bench research. This approach 
embodies the heart of clinical and translational science and the use of NMR and 
GC-MS metabolomics analysis is an elegant method of elucidating information 
that will significant advance this topic in the surgical and oncology literature. 
2. Plan for meeting these expectations 
We will obtain both IRB approval as well as approval from the Markey 
Cancer Center Clinical Trial Board to conduct this project. We anticipate starting 
patient enrollment and tissue collection in October 2014 and concluding 
enrollment and tissue collection in April 2015. Funds provided by the CCTS 
Seed grant will be applied to the project as outlined in the proposal by funding 
supplies for tissue collection and preparation, a computer for the clinical 
research nurse, and human patient sample analysis. We plan to complete tissue 
and data analysis in May 2015 and begin work on our findings and a manuscript 
in June 2015. 
3. Objective criteria for meeting these criteria 
The data and safety monitoring board will meet monthly and discuss data 
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collection, monitoring, and any adverse events. At these bi-monthly meetings the 
board will confirm the following criteria: 
• patient enrollment is meeting its proposed trajectory and is documented 
correctly 
• patient data is satisfactorily being collected and protected by the clinical 
research nurse 
• tissues are being collected in a timely manner and being appropriately 
prepared for analysis 
• data and data analysis is shared with the board as it is collected at each 
meeting 
4. Schedule of meetings with applicant and primary mentor 
The applicant already has scheduled weekly meetings with the primary 
mentor, Dr. Gao and scheduled bi-weekly meetings with the immediate 
supervisor, Dr. Evers. These meetings can be recorded and all parties can sign 
a document that can be copied and recorded for the records of the data and 
safety monitoring board, as well as the CCTS. 
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